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targeted  in  patients  presenting with  osteolytic  lesions  by  addition  of  anti‐resorptive 
agents  (bisphosphonates)  to  standard  neoplastic  therapy.  In  addition  to  the  bone 
sparing effects, bisphosphonates have been shown to exert anti‐tumour effects in vitro 
and  in  vivo.  The  main  aim  of  this  thesis  was  to  identify  bone  cell‐tumour  cell 
interactions  during  disease  progression,  including  stages  prior  to  bone  destruction. 
Furthermore,  the  anti‐cancer  effects  of  early  sequence‐  and  schedule‐dependent 
combination therapy with doxorubicin followed by zoledronic acid were assessed, with 
particular  focus  on  the  bone  microenvironment.  In  addition,  the  frequently  asked 
question whether bisphosphonates are actively internalised by peripheral tumour cells 
(i.e. outside the skeleton) was investigated in vivo. 
This  thesis  contributes  important  information  to  the  field  of  bone  metastases  by 
showing for the first time that osseous tumour growth in vivo dramatically alters bone 
cell  distribution  depending  on  cell  type,  proximity  to  the  tumour  and  disease  stage. 
Treatment studies provided strong evidence that early administration of a single dose 
of  combination  treatment  is  effective  in  bone  protection  and  in  the  inhibition  of 
osseous  tumour  growth.  It  was  furthermore  shown  for  the  first  time  that  a  small 
subset  of  peripheral  breast  cancer  cells  internalise  fluorescently  labelled 
bisphosphonate,  suggesting  a  potential  direct  effect  of  the  compounds  on  extra‐
skeletal tumour cells in vivo. 
Collectively,  the work presented  in  this  thesis has provided  strong evidence  that  the 
presence of  tumour  cells  initiates  significant  changes  to  the bone microenvironment 
prior  to  the  development  of  lesions.  Treatment  should  therefore  be  initiated  at  an 
earlier  stage  of  advanced  disease.  In  addition,  anti‐tumour  effects  of  combination 
therapy  were  found  to  be  in  part  mediated  through  alterations  to  the  bone 
microenvironment.  It was  furthermore  shown  that  bisphosphonate  treatment might 










































































































































































































































































































































































































































1.1 Breast cancer and the metastatic process 
Among  women,  breast  cancer  is  the  most  common malignancy  and  represents  the 
second  leading  cause  of  the  high mortality  rate  for  cancer  patients.  At  least  70% of 
breast  cancer patients with advanced disease develop bone metastases and death  is 
often  due  to  the  formation  and  progression  of  metastatic  lesions  (Coleman,  2001). 
Over the past decades there has been great progress in the treatment of early breast 
cancer,  but  the  current  inability  to  cure metastatic  disease emphasises  the need  for 
new  treatment  strategies  for  advanced  cancer  patients.  The  investigation  of  bone 
metastases in humans is greatly impeded due to the lack of available biopsies. Hence 
translational  research  using  preclinical models  plays  an  important  role  in  identifying 
new treatment targets.  
The process of metastasis, the dispersion of tumour cells through blood or  lymphatic 
fluid  and  establishment  at  a  new  site,  is  comprised  of  a  coordinated  sequence  of 
events. Most studies investigating the metastatic process have focussed on the cancer 
cells,  however, more  recent  research  is  pointing  out  the  significance  of  the  tumour 
microenvironment for the metastatic process (Joyce and Pollard, 2009). Stephen Paget 
was  the  first  to  report  that metastatic patterns of human cancers  follow a preferred 
distribution to certain sites with close associations between the seed (tumour) and soil 
(microenvironment), an  interaction that  is now investigated frequently (Paget, 1889). 
Some  cancer  cells  within  the  primary  tumour  alter  their  interactions  with  the 
surrounding extracellular matrix, which provides the cells with the potential to detach 
and enter  the circulation but  it  still  remains unclear what  triggers  these processes  in 
detail. One important step in the release of tumour cells from the primary mass is the 
epithelial  to  mesenchymal  transition  (EMT  or  oncogenic  EMT).  In  this  reversible 
process,  the  polarised,  sessile  epithelial  cells  undergo  several  changes  to  become 
mesenchymal  like cells with characteristics such as enhanced migration,  invasion and 
protection  from  apoptosis  (Kalluri  and  Weinberg,  2009).  The  EMT  transition  is 
therefore connected to increased tumourigenicity and increased cell survival and it has 
furthermore been  shown  that  EMT  is  linked  to  expression of  stem  cell  like markers. 
Once  in  the  circulation,  tumour  cells  are  thought  to bypass  the  immune  system and 
mechanic  forces  through  the  formation of microthrombi with platelets  (Jurasz et  al., 




the new site  in order  to  initiate  tumour cell progression and blood vessel  formation. 
Although  the presence of disseminated breast  tumour  cells  in  the bone marrow has 
been  associated with  poor  prognosis  (Gebauer  et  al.,  2001),  not  all  of  these  cancer 
cells will develop into tumour colonies. Hence it is thought that only some specialised 
cancer cells, possibly those with stem like properties, are able to form metastatic foci. 
In  addition,  the  complex  interactions  with  the  cells  of  the  bone  marrow  is  further 
highlighted by recent reports showing that cancer cells colonise to specialised sites in 
bone, the putative metastatic niches. The latter could help to explain the occasionally 
long  period  of  time  between  primary  tumour  presentation  and  bone  metastases 
development, a process that can last several years.  
1.2 Tumour-induced bone disease 




secreted  by mesenchymal  derived  osteoblasts.  Progenitor  cells  of  the mesenchymal 
lineage interact with hormones, TGF‐ß (transforming growth factor β) and BMPs (bone 
morphogenic  proteins)  leading  to  the  activation  of  the  canonical  Wnt/ß‐catenin 
pathway. Furthermore, expression of Runx2 (Runt‐related transcription factor 2) (Ducy 
et al., 1999) and the downstream expression of osterix (Nakashima et al., 2002) were 
linked  to  the  differentiation  into  pre‐osteoblasts.  Active  osteoblasts  then  secrete 
collagen type I and alkaline phosphatase, both essential for the formation of osteoid, 
as  well  as  factors  involved  in  bone  remodelling  such  as  osteonectin,  osteocalcin, 
osteopontin,  SDF‐1  (CXCL12),  macrophage  colony  stimulating  factor  (M‐CSF), 
osteoprotegerin (OPG) and receptor activator of nuclear factor kappa‐B ligand (RANKL) 
(Harada  and  Rodan,  2003).  The  latter  three  molecules  play  a  major  role  in  the 
regulation of osteoclast differentiation, activation and survival and form together with 
RANK the main pathway of osteoclastogenesis  (Boyle et al., 2003). On completion of 
bone  formation  the osteoblasts  undergo  apoptosis,  develop  into bone  lining  cells  or 
become  embedded  in  the  osteoid,  thus  giving  rise  to  osteocytes.  An  important 
negative  regulator  of  osteoblast  formation  is  the  inhibition  of  the  canonical  Wnt 
18 
 
signalling  pathway  through  antagonists  like  DKK1  (dickkopf  1)  and  sclerostin 
(expressed  by  osteocytes  and  osteoblasts)  (Niehrs,  2006; Mendoza‐Villanueva  et  al., 
2011). 
In  contrast  to  the  bone matrix  secreting  osteoblasts,  the  osteoclasts  carry  out  bone 
resorption.  Osteoclast  precursors  derive  from  haematopoietic  stem  cells  of  the 




Together  with  OPG  (osteoprotegerin),  the  soluble  decoy  receptor  to  RANK  and 
therefore an inhibitor of the RANKL/RANK interaction, a system is generated to control 
formation  and  activity  of  mature  osteoclasts  (Lacey  et  al.,  1998).  The  controlled 
interactions between osteoblast and osteoclast differentiation and activity are called 







Pre‐osteoclasts  interact  with  RANKL  and  M‐CSF,  which  is  followed  by  fusion  of  several 
precursors.  The  polykaryon  is  then  attached  to  the  bone  matrix  through  αvß3  integrin 
interactions.  Mature  osteoclasts  form  a  ruffled  border  and  release  acid  and  proteolytic 
enzymes  onto  the  calcified  matrix  triggering  bone  degradation  and  the  formation  of  a 
resorption  pit.  During  this  process,  TGF‐ß,  Ca2+  and  other  molecules  are  released  from  the 
matrix.  Several  of  these  factors  then  interact  with  osteoblast  precursors  resulting  in  the 
expression  of  Runx2  and  osterix  and  thus  the  development  into mature  osteoblasts.  During 
osteoid  formation,  osteoblasts  also  release  RANKL,  OPG  and M‐CSF,  which  in  turn  regulate 





In  a  healthy  human  approximately  5‐10%  of  the  bone  matrix  is  replaced  per  year 
resulting  in perpetual bone  turnover. One cycle of  trabecular bone  remodelling  lasts 
approximately 200 days in which around one quarter of this time is attributed to bone 
resorption and three quarters to bone formation. The process is closely regulated by a 






and  blood  vessels.  During  remodelling  the  osteoclasts  adhere  to  the  bone  matrix 
through αvβ3 integrin, osteopontin and sialoprotein mediated interactions (Reinholt et 
al., 1990; Ross et al., 1993). The intimate contact between the ruffled border and the 
bone  surface  leads  to  the  secretion  of  acid  and  proteolytic  enzymes  onto  the  bone 
matrix.  During  this  process,  collagen  and  stored  growth  factors  (TGF‐β,  Ca2+)  are 
released,  which  is  followed  by  osteoblast  migration  to  the  site  of  bone  resorption. 
Osteoclast activity  is  terminated and osteoblast maturation commences before  fresh 
osteoid  is  secreted  (Boyle  et  al.,  2003;  Teitelbaum,  2000)  (Fig.  1.2).  This  fine  tuned 
process  of  bone  remodelling  is  normally  perfectly  balanced  in  time  and  space but  it 
may  be  disrupted  in  pathological  conditions.  Thus,  bone  remodelling  can  also  carry 
risks:  control‐errors  can  cause  either  excessive  bone  resorption  or  formation. 











Different  types  of  solid  tumours  show  a  predilection  of  metastases  to  bone,  with 
breast, prostate and lung cancer being the most common types. Tumour cells in bone 
result  in  the development of  osteolytic,  osteoblastic  or mixed  lesions,  depending on 
the  type  of  primary  cancer.  The  associated  skeletal  morbidity  is  high,  with  a 
pathophysiology  of  bone  fractures,  hypercalcemia  of  malignancy  and  spinal  cord 
compression. 
Studies  investigating metastatic  tumour growth  in bone have mainly  focused on end 




also abundant  in bone  localised breast  cancer  cells  and  it  is  therefore  likely  that  the 
integrin,  in addition to other factors, assists towards the adherence of cancer cells to 
bone  (Liapis  et  al.,  1996).  Once  tumour  cells  have  formed  established  colonies  they 
disturb  the  normal  bone  remodelling  through  several  factors,  such  as  PTHrP 
(Parathyroid  Hormone‐related  Protein),  thus  inducing  osteoblasts  to  mediate 
osteoclast formation and activity through RANK/RANKL interactions (Roodman, 2001). 
In  addition,  tumour  cells  have  been  reported  to  express  RANK  and OPG,  suggesting 
that  the  cells  may  actively  alter  the  most  relevant  pathway  of  osteoclastogenesis 
(Thomas  et  al.,  1999).  RANK  expressing  tumour  cells  were  furthermore  shown  to 
colonise  tissues with high  levels of RANKL, as was  shown by  tumour growth  in bone 




the BMP  inhibitor  noggin  are  selectively  expressed  in  ostoelytic  but  not  osteoblastic 
cell  lines  (Schwaninger  et  al.,  2007).  Furthermore,  intraosseous  PC3  xenografts 
(osteolytic prostate  cancer) were  shown  to  reduce bone  formation  in  vivo,  an effect 
that could be reversed after silencing noggin (Secondini et al., 2011). Tumour cells may 




bone  resorption,  TGF‐β  and  Ca2+  ions  are  released  from  the  bone  matrix  causing 
increased  PTHrP  secretion  by  breast  cancer  cells.  This  finally  results  in  increased 
osteoclast  formation  connected  with  bone  resorption  and  a  vicious  cycle  of  bone 
destruction  and  tumour  cell  growth  is  generated.  However,  before  this 
microenvironment‐independent stage of  tumour growth  is  reached,  the  tumour cells 
firstly need to adapt and survive at the new site in order to initiate proliferation. The 
latter  requires  several  interactions  between  the  cancer  cell  and  the  bone 
microenvironment and will be discussed in the following section. 
1.2.4 The bone marrow– a safe place for cancer cells? 
Bone  marrow  contains  mesenchymal  stem  cells  (MSCs),  haematopoietic  stem  cells 
(HSCs)  and endothelial  stem cells  (EnSCs). MSCs have  the ability  to  regenerate bone 
cells  (osteoblasts,  chondrocytes)  and  marrow  stromal  cells  (fibroblasts,  adipocytes) 
while HSCs  regenerate cells of  the  lymphoid  (Β‐, Natural Killer‐, T‐cells and  lymphoid 
dendritic  cells)  and  blood  lineage  (erythrocytes,  platelets,  granylocytes,  monocytes, 
myeloid dendritic cells). The bone marrow is thus comprised of a high heterogeneity of 
cell  types  and  several  of  them  have  been  shown  to  have  implications  in  tumour 
growth.  For  instance,  bone marrow  derived  cells  like  hematopoietic  progenitor  cells 
are  involved  in  the  formation of  the pre‐metastatic niche  (Kaplan et  al.,  2005) while 
monocytes  and macrophages  are  recruited  by  the  tumour  due  to  their  secretion  of 
tumourigenic chemokines and MMPs (Rogers and Holen, 2011). The osteoclasts, which 
also  derive  from  the  hematopoietic  lineage,  are  heavily  involved  in  osseous  breast 
tumour  growth  due  to  the  involvement  in  the  vicious  cycle.  Finally,  mesenchymal 
derived cells, like fibroblasts are crucial components in the tumour stroma (Kalluri and 
Zeisberg,  2006),  while  osteoblasts  have  only  recently  been  associated  with  breast 
tumour growth in bone as will be shown in the following section. 
1.2.5 Interaction of tumour cells with cells of the bone marrow  
Our  understanding  of  the  initiating  stages  of  metastatic  tumour  growth  in  bone 
including  homing,  engraftment  and  the  switch  from  micro‐  to  macro‐metastatic 








be  a  similar  process  to  that  of  HSC  homing  and  retention,  including  factors  like 




express  CXCL12  (SDF‐1) while  some breast  cancer  cells  have  been  shown  to  express 
the receptor CXCR4 (Muller et al., 2001). In addition, the osteoblast derived adhesion 
molecule osteopontin was  suggested  to  interact with αvß3  integrin expressing cancer 
cells (Takayama et al., 2005). A recent study by Shiozawa et al. (2011) was the first to 
show  that  disseminated  prostate  cancer  cells  directly  compete  with  HSCs  for 
engraftment  into  the  osteoblastic  niche  at  endosteal  surfaces  of  an  in  vivo  prostate 
cancer  model.  It  was  furthermore  shown  that  experimental  expansion  and 
compression of the HSC niche was associated with increased or decreased numbers of 
disseminated cancer cells  in  the bone marrow. The spatial and temporal  interactions 
between  cancer  cells  and  osteoblasts  during  tumour  progression  require  further 
comprehensive  in  vivo  studies  in  order  to  fully  understand  the  complex  cellular 
interactions.  One  important  concept  of  the  occupancy  of  the  HSC  niche  by 
disseminated tumour cells may be the associated potential to induce a dormant state, 
thus  enabling  these  cancer  cells  to  escape  cytotoxic  challenges.  In  this  respect,  the 
study mentioned above has proposed a novel way of  targeting these quiescent cells. 














eventually  leading  to  the  establishment  of  new  vasculature  and microenvironment‐
independent  growth.  Although  angiogenesis  is  crucial  for  tumour  progression,  this 
process  is  not  frequently  studied because of  difficulties  in  reproducible,  quantitative 
analysis of (tumour associated) blood vessels in bone. The osteoclast is furthermore a 
cell type that is greatly involved in metastatic breast tumour growth in bone due to the 





bone marrow and  the  tumour are of high  complexity  and  require  further  analysis  in 
order  to  develop  new  therapeutics  for  these  crucial  early  stages  of  tumour 
progression.  Especially  the events  involved  in  tumour  cell  engraftment,  the  initiating 
processes  of  tumour  progression  leading  to  bone  destruction  and  the  transition  of 
micro‐ to macro‐metastatic growth requires further investigation (Fig. 1.3). While the 
importance of the osteoblast in breast cancer has been shown for cancer cell homing 
to  bone,  the  role  of  these  cells  at  other  stages  of  breast  tumour  growth  remains 
greatly  unknown.  The  osteoblast,  in  connection  with  the  osteoclast,  may  be  a  key 









The  cartoon  emphasises  the  lack  of  available  treatment  options  for  early  stage  disease  and 
highlights  the  focus  of  preclinical  studies  on  end  stage  disease.  In  order  to  develop  new 
therapeutic  strategies, more  research  has  to  be  carried  out  at  the  earlier  stages  of  tumour 
growth  including  homing,  engraftment  and  the  switch  from  micro‐  to  macro‐metastatic 
growth. BP=bisphosphonate, HSC=hematopoietic stem cell. 
 
1.3 Treatment of cancer-induced bone disease 
As  shown  above,  bone  homing  tumour  cells  may  interact  with  the  bone 
microenvironment and use  it  to  their  favour,  resulting  in  tumour growth progression 
and  induction  of  the  vicious  cycle.  Cancer‐induced  bone  disease  is  generally  treated 
with  an  anti‐neoplastic  and  a  palliative  regimen,  the  latter  including  radiotherapy, 
administration of analgesia and occasionally orthopaedic surgery to improve quality of 





Breast  cancer  patients  with  recurrent  disease  can  be  separated  into  two  groups,  a 
high‐risk and a low‐risk group, based on clinical  information regarding the probability 
of  aggressive  tumour  progression.  Low  risk  patients, with  long  disease‐free  survival, 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confined  metastatic  sites  and  often  ER+  (oestrogen  receptor  positive)  tumours  are 
most susceptible to hormone therapy. However, therapy resistance is not uncommon, 
thus  necessitating  the  need  for  alternative  treatments  (chemotherapy)  in  this 
subgroup  of  patients.  In  addition,  high‐risk  patients  with  multiple  metastases  and 
aggressive  ER‐  (oestrogen  receptor  negative)  tumours  and  patients  requiring 
neoadjuvant  therapy  will  be  treated  with  a  cytotoxic  regimen.  Due  to  the  high 
heterogeneity  of  fast  proliferating  tumour  cells,  combination  treatment with  two  or 
more of a variety of cytotoxic agents and/or other targeted compounds is common in 
clinical  practice.  While  a  number  of  chemotherapeutic  agents  are  licensed  for  the 
treatment of breast cancer, the vast majority of patients will receive an anthracycline 
based  treatment  (for  example  doxorubicin  or  epirubicin)  during  the  course  of  their 
disease, either as neoadjuvant/adjuvant or metastatic therapy.  
1.3.1.1 Doxorubicin –mechanism of action  
Doxorubicin is an anthracycline antibiotic produced by Streptomyces peucetius varians 
caesius. The planar structure of  the tetracyclic  ring system enables the compound to 
intercalate  with  the  DNA  double  helix  resulting  in  impairment  of  DNA‐  and  RNA‐
polymerase  activity  and  therefore  leads  to  inhibition  of  DNA  replication  and 
transcription (Fornari et al., 1994). Apart from this, it was shown that doxorubicin can 
form DNA structures with topoisomerase II possibly causing the frequently found DNA 
strand  breaks  and  it  is  thought  that  this  mechanism  is  the main  contributor  to  the 
drugs  cytotoxicity  (Silber et al.,  1987). Doxorubicin has also been  reported  to  induce 
the formation of hydroxyl free radicals (HO⋅) eventually leading to irreversible damage 
(Doroshow,  1983).  As  a  result  of  the mechanisms  described  above  cells  exposed  to 
doxorubicin eventually undergo apoptosis.  
1.3.1.2 Doxorubicin in clinical practice 
Because  chemotherapeutic  agents  generally  target  fast  proliferating  cells,  not  only 
tumour  cells  but  also  hair  follicle  and  cells  lining  the  intestine  etc.  are  affected, 
resulting  in  a  number  of  side  effects  associated with  cytotoxic  drugs.  In  the  case  of 





The drug  is most  commonly  administered  in  intervals  of  21‐days  as monotherapy  at 
60‐75mg/m2 and in combination at 40‐60mg/m2 via a single intravenous injection. The 






1.3.2.1 Chemical properties of bisphosphonates 











chain R1,  usually  ‐OH,  ‐H or  ‐Cl,  enhances  this  effect.  The R2  side  chain  is more  variable  and 
enhances the anti‐resorptive potency of the bisphosphonate. 
 
1.3.2.2 Simple bisphosphonates and nitrogen-containing bisphosphonates 
The  varying  chemical  structure within  the  bisphosphonate  group  has  been  found  to 
affect  their  anti‐resorptive  activity  and  the  underlying  mechanisms  of  action.  This 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divides  the  compounds  into  two  classes:  the  simple  bisphosphonates  and  the more 













1.3.2.3 Mechanism of action of nitrogen-containing bisphosphonates 





diphosphate  (FPP)  synthase,  which  is  responsible  for  conversion  of  IPP  (isopentenyl 
diphosphate)  to  FPP  (Fig.  1.6)  (Martin  et  al.,  1999).  The  lack  of  the  downstream 
products  FPP  (farnesyl  diphosphate)  and  GGPP  (geranylgeranyl  diphosphate) 
consequently leads to lack of substrates required for protein isoprenylation (Luckman 
et  al.,  1998).  The main  group  of  prenylated  proteins  is  comprised  of  small  GTPases, 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such as Ras, Rho and Rac, and correct  intracellular  localisation and  function of  these 
proteins  is dependent on the post‐translational modification.  It has been shown that 
the  members  of  these  protein  families  are  essential  for  a  variety  of  functions, 
especially in osteoclast activity and viability (Rogers et al., 2000). The drugs therefore 
inhibit  osteoclastic  bone  resorption  efficiently  and  thus  find  broad  application  in 
diseases of the bone. In addition, other prenylated proteins are likely to be affected by 
the  drug.  For  example,  the  zoledronic  acid‐induced  inhibition  of  prenylation  was 
shown  to  cause  delocalisation  of  the  centromere  protein  F  (Cenp‐F)  from  the 


















likely  reflected  in  their  endocytic  activity  (Thompson  et  al.,  2006),  suggesting  that 
cancer  cells may  also  be  affected.  Indeed,  the  latter  has  been  true  for  a  number  of 
cancer cell  types  in  in vitro experiments showing a reduction  in cell proliferation and 
induction  of  apoptosis  (Fromigue  et  al.,  2000;  Clyburn  et  al.,  2010).  Whether  the 
compound can also reach tumour cells in vivo and if the concentration is high enough 
to induce cytotoxic effects remains to be established.  
1.3.2.4 Clinical use of bisphosphonates 
Bisphosphonates are commonly used to treat breast cancer‐induced bone disease, but 
also find application in other bone related malignancies to reduce the risk of skeletal 
related  events  (SREs)  such  as  hypercalcemia,  bone  pain,  pathological  fractures  and 
spinal  cord  compression.  In  an  advanced  cancer  setting,  zoledronic  acid  is  currently 





Chemotherapy  in  pre‐menopausal  women  can  induce  menopause,  ovarian  function 
can be suppressed by therapies (e.g. goserelin) and aromatase  inhibitors can cause a 
reduction in oestrogen levels resulting in bone reduction. The treatment‐induced bone 











suggested  induction  of  apoptosis,  inhibition  of  proliferation,  invasion  and  adhesion 
being  involved  in  the molecular mechanisms  (Neville‐Webbe  et  al.,  2002;  Clezardin, 
2005).  For  example,  zoledronic  acid,  pamidronate  and  ibandronate  treatment  were 
shown to have anti‐proliferative and pro‐apoptotic effects on several breast cancer cell 






coated bone slices  reduce the growth of primary rat osteoblasts,  suggesting that  the 
drugs may also interact directly with the bone forming cells (Cornish et al., 2011). The 
relevance of these data in an in vivo setting remains to be established. In addition, the 





times  resulting  in drug  levels  that  are not  achievable  in  vivo.  This  is  due  to  the high 
affinity of  the drugs  to bone and  thus bisphosphonates are  rapidly  cleared  from  the 
circulation  effectively  reducing  the  compounds  availability  in  soft  tissues.  In  clinical 
practice, zoledronic acid is administered as an infusion of 4mg over 15 minutes every 
3‐4  weeks.  After  intravenous  administration,  the  majority  of  the  drug  (up  to  60%) 
rapidly binds to bone resulting in a short serum half‐life of about 1 hour (Chen et al., 
2002;  Brown  et  al.,  2007).  Hence,  zoledronic  acid  peak  plasma  levels  reach  only 
concentrations  of  1‐2M  and  decline  to  approximately  1%  after  24  hours.  In  bone, 




resorbing osteoclasts  (Sato et  al.,  1991),  a  level  that may  induce  cytotoxic  effects.  It 
has  therefore  been  proposed  that  tumour  cells  within  bone  could  be  exposed  to  a 
potentially  cytotoxic  concentration  of  bisphosphonates,  compared  to  cancer  cells 
localised in peripheral soft tissues. The difference in drug distribution between tissues 
consequently  leads  to  the  question whether  bisphosphonate  concentrations  outside 
bone  ever  reach  cytotoxic  levels.  In  addition,  the  exact  cellular  and  molecular 
mechanisms involved in the proposed anti‐tumour activity of bisphosphonates remain 








of  a  range  of  prenylated  proteins,  γδT‐cells,  tumour‐associated  macrophages  and 
effects on angiogenesis.   
1.4.1.1 Prenylated proteins 













the  anti‐tumour  effects  of  NBPs  are  attributable  to  the  in  vivo  accumulation  of 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unprenylated  proteins.  However,  an  indirect measurement  through  the  detection  of 
unprenylated Rap1A in tissue samples can be used as an indicator of the drug’s effects 
on the MVA‐pathway. It is noteworthy that there are about 300 prenylated proteins in 
the  human  proteome  (Sebti,  2005),  suggesting  that  there  may  be  several  proteins 









of  a MVA‐pathway metabolite  (IPP),  which  is  known  to  accumulate  in  tumour  cells, 
after  NBP  exposure  (Gober  et  al.,  2003).  Thus,  the  drug‐induced  accumulation  of 
mevalonate metabolites results in tumour cell recognition by γδT‐cells and triggers an 
immune  response  against  cancer  cells.  In  this  respect,  lymphocytes  expressing  the 
Vγ9Vδ2T‐cell  receptor have been shown to recognise and kill  tumour cells previously 
exposed  to  zoledronic  acid,  including  breast,  myeloma  and  lymphoma  cells  in  vitro 
(Kunzmann et  al.,  2000; Gober et  al.,  2003).  The  relevance of  these data  in  vivo  has 
recently been assessed by Benzaid et al.  (2011). NOD‐SCID mice bearing T47D breast 
tumour  xenografts  were  injected  with  human  peripheral  blood  mononuclear  cells, 
which  trigger  in  vivo  expansion  of  human  Vγ9Vδ2T‐cells.  Animals  with  human 
Vγ9Vδ2T‐cell and zoledronic acid +  IL‐2  (30μg/kg every 2 days  for a total of 2 weeks) 
treatment  were  shown  to  have  significantly  reduced  tumour  growth  and  increased 
Vγ9Vδ2T‐cell  numbers  compared  to  control  mice.  The  data  suggest  that  zoledronic 
acid  treatment  induced  a  significant  anti‐tumour  effect  mediated  through 
phosphoantigen recognition by human Vγ9Vδ2T‐cells. 
1.4.1.3 Macrophages and tumour-associated macrophages (TAMs) 
The role of macrophages in tumour growth and metastasis has become a growing field 
of  interest with  several  studies  showing  an  association  of  a  variety  of  tumours with 




the  body  but  also  in  tumour  progression.  M2  polarised  macrophages  have  been 
associated with pro‐tumourigenic characteristics as they are shown to support tumour 
growth,  migration,  invasion  and  angiogenesis.  Hypoxic  tumour  areas  are  known  to 
release  chemokines  and  cytokines  such  as  IL‐8,  MMP‐9,  fibroblast  growth  factor  2 
(FGF‐2), VEGF and LOX (lysyl oxidase) to recruit TAMs in order to assist  in new vessel 
formation  (Murdoch  et  al.,  2004)  and  metastatic  growth  (Erler  et  al.,  2009). 
Importantly,  it was shown that the primary tumour  influences the polarisation of the 
recruited  macrophages  to  its  favour  with  most  TAMS  exhibiting  pro‐tumourigenic 
properties  (Allavena  et  al.,  2008).  NBPs  have  been  shown  to  inhibit  macrophage 
proliferation  and  induce  apoptosis  via  the mevalonate  pathway  in  vitro  (Luckman et 
al.,  1998).  The  first  in  vivo  study  to  report  that  TAMs  are  directly  affected  by 
bisphosphonate  treatment was  carried  out  by  Coscia  et  al.  (2010).  The  group  could 
show  that  zoledronic  acid  treatment  (100μg/kg/week  zoledronic  acid  or  PBS  for  4 
weeks followed by 3 weeks drug free interval, repeated cycles) reduced spontaneous 
mammary  fat pad  tumour growth  in BALΒ‐neuT mice as well as TAM  infiltration and 
angiogenesis.  Interestingly,  the  bisphosphonate  induced  a  switch  in  macrophage 
phenotype  from  the  pro‐tumourigenic  M2  to  the  tumouricidal  M1  type.  Taken 
together  these  studies  suggest  that  the  NBP‐induced  effects  on macrophages  could 
contribute to the reported anti‐tumour effects.  
1.4.1.4 Angiogenesis 
The  induction  of  new  vessel  formation  is  an  essential  step  within  the  complicated 
sequence  of  metastatic  tumour  growth  and  there  is  a  growing  body  of  evidence 
suggesting  that  nitrogen‐containing  bisphosphonates  may  exhibit  part  of  their  anti‐
tumour effects through anti‐angiogenic effects. Solid tumours with a diameter of less 
than  2mm  are  sufficiently  supplied  with  nutrients  through  diffusion  but  tumour 
progression  beyond  this  point  requires  additional  blood  supply.  Zoledronic  acid  has 
been  reported  to  inhibit  neo‐angiogenesis  in  vivo  and  in  vitro  (Wood  et  al.,  2002), 
possibly mediated through inhibition of protein prenylation. In a clinical setting, Santini 
et  al.  (2003)  could  show  that  4mg  zoledronic  acid  administration  to  patients  with 




of  low‐dose, high‐frequent administration of  zoledronic  acid  (1mg/week  for 4 weeks 
followed by 3 cycles of 4mg every 28 days) confirmed the anti‐angiogenic findings with 
reduced  serum  VEGF  levels  from  seven  to  up  to  eighty‐four  days  after  the  first 
treatment  (Santini  et  al.,  2007).  Although  these  clinical  studies  suggest  a 
bisphosphonate‐induced anti‐angiogenic effect, the involved cell type(s) remain to be 
established.  
Taken  together,  NBPs  may  have  a  number  of  targets  in  vivo  and  it  is  likely  that  a 
combination  of  several mechanisms  contribute  to  the  reported  anti‐tumour  effects. 
Several  preclinical  studies  investigating  these  effects  in  models  of  breast  cancer 
metastases  to  bone  have  been  published  and  will  be  discussed  in  the  following 
sections. 
1.4.2 Potential anti‐tumour activity of NBPs reported in in vivo studies 
There  is  increasing  preclinical  evidence  of  anti‐cancer  effects  of  bisphosphonates  in 
bone,  reducing  the  extent  of  bone  lesions  as  well  as  osseous  tumour  burden.  In 
contrast,  reports  of  the  ability  of  bisphosphonates  to  affect  tumours  that  have 
progressed  to  colonise  bone‐associated  soft  tissue  and  peripheral  tumours  are  less 
consistent. 
1.4.2.1 Bisphosphonate-induced effects on tumours in bone 
As previously mentioned, bisphosphonates are commonly used to treat patients with 
confirmed  metastatic  bone  disease  and  over  the  years,  a  growing  number  of 
publications  report  a  potential  anti‐tumour  activity  of  these  compounds  (Neville‐
Webbe et al., 2002; Clezardin, 2005; Caraglia et al., 2006; Winter et al., 2008). A range 
of  tumour  types  that  spread  to bone,  including breast, prostate and  lung have been 
subject  to  investigation  in  vivo.  The  main  body  of  studies  has  applied  therapeutic 
protocols to assess the effects on established bone metastases. The drug‐induced anti‐









The  effects  of  zoledronic  acid  or  clodronate  on  tumours  derived  from  the  human 
breast  cancer  cells  B02/GFP.2  in  female  balb/c  athymic mice were  investigated  in  a 
recent study  (Daubine et al., 2007). The drugs were administered as daily, weekly or 




zoledronic  acid  treatment  being  superior  to  clodronate.  Bisphosphonate 
administration  in  adjuvant  breast  cancer  therapy  could  therefore  reduce 
cancer‐induced  bone  disease  and  may  be  most  effective  at  the  early  stages  when 
tumour  growth  and  expansion  is  still  dependent  on  the microenvironment.  A  study 
investing  the effects of  ibandronate on  intrafemural MDA‐MΒ‐231  tumour growth  in 
athymic rats found that therapeutic ibandronate (10μg/kg/day) reduced progression of 
osteolytic  lesions  and metastases. However,  complete elimination of  tumour  growth 
was not achieved, with bigger lesions staying unaffected (Neudert et al., 2003). When 
treatment  was  initiated  prior  to  cancer  cell  injection,  formation  of  new  osteolytic 
lesions was decreased  and  animals  had  reduced  incidence of metastases. A possible 
explanation  of  this  differential  effect  could  be  that  small  metastatic  foci  consist  of 
microenvironment‐dependent  cells  and  were  therefore  more  sensitive  towards  the 
bisphosphonate‐induced  changes  whereas  larger  tumours  may  achieve  autocrine 
(microenvironment‐independent)  growth.  In  addition,  treatment‐induced  alterations 
to  the metastatic  site may  impede  cancer  cell  engraftment  to  bone  suggesting  that 
adjuvant  bisphosphonate  treatment  may  be  able  to  prevent  bone  metastases 
development.  
A study underlining the suggestion that BPs do not exert their anti‐tumour effects by 
direct mechanisms used  the MDA‐231‐B/luc+ breast  cancer model  to  investigate  the 
effect of olpadronate on cancer‐induced bone metastases (van der Pluijm et al., 2005). 
When  olpadronate  was  given  in  a  preventive  way  (s.c.  1.6µmol/kg/day),  before 




have  significant  impact  on  osseous  tumour  cell  growth  although  a  reduction  in 
osteolysis  was  seen.  In  an  intraosseous  model,  pamidronate  (16µmol/kg/day)  or 
olpadronate  (1.6µmol/kg/day)  were  given  daily  following  cancer  cell  implantation. 
Treatment reduced intraosseous colonies significantly but did not affect total tumour 
burden.  The  authors  concluded  that  cancer  cell  growth was merely  redirected  from 
intra‐  to  extraosseous  sites  due  to  space  limitations  caused  by  the  drug‐induced 
inhibition of bone resorption. 
As  shown above, a number of  studies have  reported  that bisphosphonate  treatment 
caused  a  reduction  of  skeletal  tumour  burden  and  inhibited  osteolysis.  However,  in 
those  studies  investigating  soft  tissue  tumour  burden,  no  anti‐tumour  effect  was 




In  contrast  to  the  reports  described  in  the  previous  section,  a  few  studies  have 
detected an  increase of  tumour mass  in  the  soft  tissue adjacent  to affected bone  in 
bisphosphonate  treated  animals.  Sasaki  and  colleagues  found  that  risedronate 
treatment increased soft tissue MDA‐MΒ‐231 human breast tumour burden in female 
balb/c‐nu/nu  mice,  although  there  was  a  reduction  in  skeletal  tumour  colonisation 







and  area  of  osteolytic  lesions  and  decreased  osseous  tumour  volume  in  a  dose‐
dependent  manner.  However,  daily  administration  of  0.2  or  2μg  YH529/mouse 
increased  tumour  volume  in  soft  tissues  surrounding  bone while  the  higher  dose  of 
20μg/mouse/day reduced it when compared to control. These results indicate that, in 
a  clinical  setting,  prophylactic  treatment  with  a  low  dose  and  continuous 
administration  could benefit  cancer patients with high  risk of  skeletal metastases by 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reducing  the  incidence  of  bone  metastases.  The  detection  of  increased  bone‐
associated soft tissue tumour burden after bisphosphonate treatment requires further 
preclinical investigation.  
Taken  together,  the majority  of  published  data  support  that  bisphosphonates  exert 
their anti‐tumour effects through inhibition of bone resorption, and that the drugs do 
not exhibit direct activity at non‐osseous sites. However, most of  these studies were 
not  primarily  designed  to  investigate  the  effects  on  soft  tissue  tumours,  or  in many 
cases  the  occurrence  of  extra‐skeletal  disease  was  not  evaluated.  In  addition, 
preclinical  studies  reporting  anti‐tumour  effects  of  bisphosphonates  have  frequently 
used high dosing regimens resulting in accumulated concentrations well beyond those 
used  in  clinic.  However,  frequent  administration  in  a  preventive  schedule  has  been 
shown  to  be  the  most  effective  at  protecting  bone  from  metastatic  breast  cancer 
(Sasaki et al., 1995; Sasaki et al., 1998; Neudert et al., 2003; van der Pluijm et al., 2005; 
Daubine  et  al.,  2007).  Currently,  clinical  treatment  with  bisphosphonates  alone  will 
only  be  initiated  once  bone  metastases  are  confirmed,  although  preclinical  studies 
suggest  that  the best  results would be obtained with  an earlier  treatment  schedule. 
Despite  the  beneficial  effects  of  a  preventive  treatment  regimen,  it  is  important  to 
note  that  none of  the  studies  could  report  a  complete  inhibition  of  tumour  growth, 
suggesting  that  additional  therapy  with  other  anticancer  agents  is  required.  An 














practice,  treatment  of  cancer‐induced  bone  disease  commonly  comprises  the 
administration of cytotoxic drugs in combination with the palliative treatment offered 
by  bisphosphonates.  In  vitro  studies  have  shown  that  the  combination  of  potent 
bisphosphonates,  such  as  zoledronic  acid,  with  other  cytotoxic  agents  results  in 
enhanced anti‐tumour effects (Jagdev et al., 2001; Neville‐Webbe et al., 2005; Neville‐
Webbe et al., 2006; Clyburn et al., 2010). These have been followed by in vivo studies 



















































































































bisphosphonates,  showing  increased  anti‐tumour  effects  compared  to  single  agent 
therapy  (Hiraga  et  al.,  2003;  Duivenvoorden  et  al.,  2007;  van  Beek  et  al.,  2008; 
Ottewell et al., 2008a; Ottewell et al., 2008b). The cellular and molecular mechanisms 
underlying the  increased anti‐tumour effects caused by combined treatments remain 
to  be  identified.  A  number  of  studies  using  breast  cancer  models  have  reported 





combined  treatment  regimen  was  reported  to  be  superior  in  the  reduction  of 
metastatic bone areas but tumour burden at the orthotopic site (mammary fat pads) 
was not affected. The  increased anti‐tumour effects  in bone support  the  theory  that 
combined  therapy  might  be  more  effective  in  clinical  practice  compared  to  single 
treatments.  However,  very  high  doses  of  zoledronic  acid  were  used  in  this  study, 






zoledronic  acid  alone  resulted  in  a  93%  reduction  of  tumour  area  in  the  soft  tissue 
adjacent  to  the affected bones but only  in 73%  in  total  tumour burden, suggesting a 
direct  effect  of  the  drug  on  tumour  cells  outside  the  bone  microenvironment.  The 
combination  of  zoledronic  acid  and  doxycycline  may  therefore  be  a  possible 
therapeutic strategy for patients with advanced breast cancer.  
In a study investigating early combination treatment, female balb/c nu/nu mice were 
inoculated  intratibially with MDA‐231‐B/luc+  cells  and  treatment  commenced 2 days 
later  with  zoledronic  acid  (i.p.,  37.5,  75  or  150μg/kg,  5x/week)  or  risedronate  (i.p., 
150μg/kg,  5x/week),  docetaxel  (i.p.,  2,  4,  or  8 mg/kg,  2x/week)  or  a  combination  of 




and  the  combination  schedule  prevented  osteolytic  bone  destruction,  but  docetaxel 
alone  had  no  effect  when  compared  to  control.  After  combination  treatment,  no 
tumour  growth  in  bone  was  detected  in  6  out  of  7  mice,  while  treatment  with 
docetaxel  alone  prevented  tumour  growth  in  only  2  out  of  7  mice  and  risedronate 




tumours growing  in bone, and  it  is  therefore not possible  to determine whether  the 
reported  anti‐tumour  effects  are  induced  directly,  indirectly  or  as  a  combination  of 
both mechanisms. When using in vivo models, a separation of these effects is possible 
by e.g.  subcutaneous  implantation of  tumour  cells, which allows  the  investigation of 
the effects on cancer cells without bone involvement. Ottewell et al. (2008b) assessed 
the effects of doxorubicin (dox) and zoledronic acid (zol) on established subcutaneous 
tumours  derived  from  MDA‐G8  (MDA‐MB‐436‐GFP)  human  breast  cancer  cells,  to 
determine  whether  sequential  and  combined  treatment  can  significantly  inhibit 
subcutaneous tumour growth. Sequential treatment with dox followed 24 hours later 
by  zol  (once  per  week  for  a  duration  of  six  weeks)  was  shown  to  cause  almost 
complete  abolition  of  peripheral  tumour  growth  and  was  reported  to  be  the  most 
effective  of  all  treatment  regimens  tested.  Pathway‐specific  gene  array  analysis 
performed  to elucidate  changes  in gene expression  induced by  sequential  treatment 
showed  that  30  genes  involved  in  cell  cycle  regulation  and  apoptosis  had  been 
changed  in  the  subcutaneous  tumour  cells.  Zoledronic  acid  (100μg/kg  weekly  for  6 
weeks)  alone  had  no  effect  on  peripheral  tumours,  therefore  not  supporting  the 
proposed  direct  anti‐tumour  activity  of  zoledronic  acid  monotherapy.  The  authors 
concluded  that  sequence‐specific  combination  treatment  might  be  beneficial  to 
patients with early‐stage breast cancer even  in the absence of bone metastases. The 
effects  of  zoledronic  acid  combined  with  standard  neoadjuvant  chemotherapy  on 
pathological response of the primary tumour were investigated in a subset of patients 
of the recent AZURE trial  (Coleman et al., 2010). The addition of the bisphosphonate 
was  shown  to  significantly  reduce  residual  invasive  breast  tumour  size  compared  to 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women  receiving  standard  therapy  alone,  supporting  the  proposed  anti‐tumour 
activity of doxorubicin and zoledronic acid outside the skeleton.   
The  effects  of  clinically  relevant  doses  of  zoledronic  acid  and  doxorubicin  on 
established  extra‐  and  intraosseous  tumours  was  investigated  using  female  balb/c 
nu/nu mice injected i.v. with B02 human breast cancer cells, which are known to home 






microenvironment  and  the  local  drug  concentration  in different parts of  the  tumour 
could  influence  the  response  to  treatment.  The  authors  concluded  that  sequential 
administration  of  doxorubicin  followed  by  zoledronic  acid  may  be  used  in  the 
treatment of advanced breast cancer patients, particularly for those with smaller bone 
metastases confined to the marrow space. Although significant synergistic anti‐tumour 
effects  could  be  detected  when  using  the  combination  treatment,  the  study  by 
Ottewell et al. (2008a) investigated advanced disease stages and used repeated dosing 
regimens.  In  addition,  the  effects  of  the  treatment  on  the  bone  microenvironment 
were not addressed.  
As  shown  above,  several  combination  studies  have  been  performed with  zoledronic 
acid in combination with UFT (Hiraga et al., 2003), doxycycline (Duivenvoorden et al., 
2007)  and  doxorubicin  (Ottewell  et  al.,  2008a;  Ottewell  et  al.,  2008b). Most  studies 
investigated  late  stage  bone  disease  and  reported  a  significant  reduction  in  osseous 
tumour burden following combination therapy, compared to using the single agents. In 
addition,  therapeutic  treatment  regimens  rather  than  preventive  ones  were  used 
predominantly.  The  reported  effects  on  visceral  tumours  or  cancer  cells  in  bone‐
associated  soft  tissue  are more  conflicting, with  some  studies  showing  no  beneficial 
effects of drug combinations. The effects of  treatment on metastatic prevention and 




1.4.2.3 Bisphosphonates alone vs. in combination – summary of findings 
There is strong evidence that bisphosphonate treatment does reduce tumour growth 
in bone and inhibits the associated bone disease in a range of different cancer types in 
vivo  (Brown  and  Holen,  2009).  The  effects  on  tumours  spreading  from  the  bone 
marrow cavity to the surrounding soft tissue, and effects on visceral tumours, are less 




resulting  high  cumulative  dose.  Also,  the  need  for  repeated  dosing  indicates  that 






1.5 Clinical application of bisphosphonates in adjuvant breast 
cancer therapy 
Bisphosphonates  are  currently  gold  standard  of  care  for  patients  with  advanced 
disease  and  established  bone  metastases.  Regarding  the  potential  use  of 
bisphosphonate  in  the  adjuvant  setting,  the  main  areas  of  investigation  include 
metastasis  prevention  and  treatment‐induced  bone  loss.  The  latter  has  been 
extensively  investigated  in  breast  cancer  and much  data  is  available  supporting  the 
administration of bisphosphonates  to prevent/treat  SREs  in  affected women  (Wilson 
and Coleman, 2011). The use of the bone sparing agents in a preventive setting is less 
well established and is currently under investigation in a number of clinical trials. 
The  recent  ABCSG‐12  trial  (n=1800)  reported  a  significant  increase  in  disease‐free 
survival  (DFS)  in  pre‐menopausal women  receiving  endocrine  therapy  (goserelin  and 
tamoxifen/anastrozole) and 4mg zoledronic acid once every 6 months for a duration of 
3  years  (Gnant  et  al.,  2009).  Interestingly,  a  reduction  in  loco‐regional  and  extra‐
skeletal  events  was  also  reported.  However,  the  survival  benefit  was  confined  to 
women  >40  years  of  age, who would  be  expected  to  have  complete  suppression  of 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ovarian  function with goserelin.  The  results  suggest a beneficial  effect of addition of 
bisphosphonate  treatment  to  adjuvant  endocrine  therapy  in  this  sub‐population  of 
patients.  
A number of  studies have  investigated  the adjuvant administration of clodronate  for 
prevention  of metastases  in mixed  cohorts  of  pre  and  postmenopausal women  and 
have  reported  conflicting  results.  Direct  anti‐tumour  effects  on  visceral  tumours  as 
well as reduction of tumour burden in bone and prolonged survival has been reported 
in  a  study  investigating  the  effects  of  adjuvant  oral  clodronate  administration  in 
patients with early breast cancer and with confirmed disseminated tumour cells in the 
bone marrow (Diel et al., 2008). In contrast, Saarto et al. (2004) reported no decrease 
in skeletal  tumour burden but an  increase  in visceral  tumours, which was associated 
with  reduced  disease  free  survival  (placebo  58%  vs.  clodronate  45%)  after  10  years 
when  administering  oral  clodronate  in  an  adjuvant  setting.  The  most  recent,  large 
NSABP‐34 trial  (n=3400)  investigated the effects of daily oral clodronate (1600mg) or 
placebo in addition to standard therapy in stage I‐II breast cancer patients (Paterson et 
al.,  2011).  The  primary  endpoint was  disease  free  survival  and  secondary  endpoints 
included  incidence  of  metastases  and  overall  survival.  Subset  analysis  showed  that 
addition  of  oral  clodronate  in  women  of  50  years  or  more  significantly  reduced 
metastatic disease including bone metastases. 
The  potential  of  combination  therapy  in  prevention  of  bone  metastases  was  also 








group analysis depending on menopausal  status was  carried out  after  completion of 
the  trial, postmenopausal women  (>5 years)  receiving zol were  found to have a 25% 








reproductive  hormones  in  bone  remodelling.  In  summary,  the  AZURE  trial  together 
with  evidence  from  the  ABCSG‐12  and  NSABP‐34  trials,  suggest  that  reproductive 
hormone  levels  play  a  role  in  the  observed  anti‐tumour  effects  of  bisphosphonates, 
and  should be  investigated  in more detail.  Furthermore,  the NSABP‐34  trial  suggests 
that the anti‐tumour effects are not limited to nitrogen‐containing bisphosphonates. 
Several  other  clinical  breast  cancer  trials  of  adjuvant  bisphosphonate  treatment  are 





1.6 Outstanding questions  
The  data  from  the  clinical  trials  reflect  the  variable  responses  reported  in  in  vivo 
studies,  with  the  majority  of  reports  observing  anti‐tumour  effects  and  others 
reporting either no effect or increased cancer cell growth. The reported effects appear 
to be highly dependent on tumour type, treatment protocol and model system used. 
While most of  the studies have  reported  the  involvement of bone  in  the anti‐cancer 
activity  of  bisphosphonates,  there  are  some  studies  reporting  evidence  of  direct 
effects using  tumour models  independent of bone. Despite  this, more detailed  trials 
are required to elucidate whether bisphosphonates exert their anti‐cancer activity via 
direct,  indirect  or  both  mechanisms,  and  it  remains  to  be  established  whether 
bisphosphonates are able to be internalised into cancer cells in vivo. 
A greater effect of early compared to late bisphosphonate treatment was shown by a 
number of  the preclinical  studies.  This  is  in  agreement with  the  recently  highlighted 
importance of early stages of tumour growth in bone. However, to date only very little 









• To  determine  whether  the  cellular  composition  of  bone metastases  changes 
with disease progression. 





• To  investigate  the  treatment‐induced  effects  of  a  single  dose  of  doxorubicin 
followed  by  zoledronic  acid  administered  at  an  early  stage  (day  2)  on  bone‐
tumour cell interactions. 
• To determine whether cells in subcutaneous breast tumour xenografts and host 







































































































































































































































The  oestrogen  and  progesterone  receptor  negative  human  breast  cancer  cell  line 
MDA‐MB‐231  was  transfected  by  Dr  PD  Ottewell  to  stably  express  the  green‐
fluorescent protein (GFP). A bone homing subclone of the MDA‐MB‐231 cells, the B02 
cell  line, was used  for  some experiments. B02  cells,  stably expressing GFP and beta‐
galactosidase  (β‐Gal), were kindly provided by Dr P Clezardin  (INSERM, Lyon, France) 





in  a  37°C water  bath  before  addition  of  9ml  of  RPMI‐1640  +  10%  foetal  calf  serum 
(FCS). After centrifugation at 800rpm for 5 minutes the cell pellet was resuspended in 
10ml of fresh medium and plated into a T75 flask. To freeze, cells were washed twice 
with PBS before  trypsinising and dislodging  from  the bottom of  the  flask. Cells were 






Cells  were  grown  in  T75  flasks  in  RPMI‐1640 medium  supplemented with  10%  heat 
inactivated  foetal  calf  serum  and were  incubated  at  37°C  and  5%  CO2.  Subculturing 









was  discarded  and  the  cell  pellet was  gently  resuspended  in  10ml  of  fresh medium 
prior  to  plating  the  cells  at  the  required  concentration  into  a  sterile  T75  flask  and 
incubation  at  37°C  and  5%  CO2.  In  some  cases  5%  penicillin  and  streptomycin  was 
added  to  the  medium  to  prevent  infection.  For  in  vivo  experiments,  antibiotic‐
containing medium was replaced with RPMI‐1640 + 10% FCS for 24 hours prior to use. 






for  four primary  squares was divided by 4 and  the  resembling number multiplied by 
the original  volume  from which  the  cell  sample was  removed.  The  resulting number 





In  order  to  assess  the  percentage  of  GFP  positive  cells  a  confluent  cell  layer  was 
washed  twice  with  PBS  before  trypsinising  and  resuspending  cells  in  PBS  to  give  a 
concentration  of  1x106  cells/ml  as  described  above.  The  cell  suspension  (0.5ml) was 
transferred through a 100μm cell strainer into a FACS tube. The same procedure was 
carried  out  for  a  corresponding  GFP  negative  cell  line  as  negative  control.  Samples 
were  analysed using  a  flow  cytometer  and Cell QuestTM  software.  Samples  from  cell 
passages  with  75%  or  lower  GFP  positive  cells  were  sorted  as  described  in  the 
following section prior to use in in vivo experiments. 
2.2.6 Cell sort 
Cells  of  a  confluent  T75  flask  were  washed  with  PBS  and  trypsinised  as  described 
earlier before resuspending  the cell pellet  in 0.5ml of PBS. Cells were sorted  for GFP 








To  specify  tumour  cell  size  for  identification  of  tumour  cells  by  multiphoton 
microscopy,  an  in  vitro  experiment  was  carried  out measuring  the  diameter  of  B02 
breast cancer cells. B02 human breast cancer cells were seeded at a density of 2x104 
cells/ml  into  6‐well‐plates.  Cells  were  left  to  settle  over  night  at  37°C  and  5%  CO2 
before  capturing  images  of  randomly  chosen  fields  using  an  inverted  widefield 
fluorescence microscope  and  a  40x  dry  objective.  Images  were  then  analysed  using 
Volocity software. The diameter of thirty‐seven GFP positive cells was measured twice. 
An  image showing  the measurement of  the cells  is depicted  in Figure 2.1. The mean 







2.2.8.1 Ethics and animals 
Animals were housed  in  the University of Sheffield Biological  Service  to  the  required 
guidelines.  All  experiments  were  conducted  according  to  the  institutional  ethical 
guidelines and under the Home Office project licence 40/2972. 
Figure  2.17Measurement 
of  cancer  cell  size  using 
Volocity software 
GFP  expressing  breast  cancer 
cells  were  seeded  into  a  6‐








as  indicated  in  the  experiments.  Animals were  ordered  at  an  age  of  4‐5 weeks  and 
were no older  than 6‐7 weeks at day of  tumour  inoculation  for  the  intravenous and 
intracardiac models. For subcutaneous tumour models, animals were approximately 8 
weeks of age at initiation of the experiment. 
2.2.8.2 Preparation of injectables and in vivo procedures 
2.2.8.2.1 Anaesthetic 
Anaesthetic  used  for  tumour  cell  injections  was  prepared  by  mixing  ketamine  with 
xylazine  in  autoclaved H2O or  sterile NaCl  and was  administered  intraperitoneally  at 
the either 116.0mg/kg ketamine, 7.3mg/kg  xylazine,  in NaCl or 56.5mg/kg ketamine, 
5.5mg/kg  xylazine,  in  H2O.  The  solution  was  filter  sterilised  using  filter  and  a  5ml 
syringe directly before use. Animals used for in vivo live imaging using the IVIS® Lumina 
II system were anaesthetised by isoflurane.  
2.2.8.2.2 B02 cancer cell injection  
On day of injection, GFP positive B02 cells were trypsinised, re‐suspended in medium 
to  inactivate  the  enzyme,  spun  down,  re‐suspended  in  sterile  PBS  to make  a  1x106 







surface  disinfectant)  before  0.1ml  of  the  1x106cells/ml  suspension  (1x105  cells  per 
mouse) were slowly injected using a 1ml insulin syringe with a 27‐gauge fitted needle. 
Clearing of the blood from the artery during injection and subsequent minor bleeding 
from  the  injection  site  were  indications  of  successful  administration.  Animals  were 
monitored closely and were placed back  into the  incubator to recover. Note that the 





2.2.8.2.3 MDA-MB-231-GFP intracardiac injection 
On day of injection, a 1x106 cells/ml suspension of GFP positive MDA‐MB‐231‐GFP cells 
was prepared as described for B02 cells and 6 week old balb/c nude female mice were 
anaesthetised  using  56.5mg/kg  ketamine  and  5.5mg/kg  xylazine.  Complete 
anaesthesia was  assessed  by  pinch  reflex  and  the  procedure was  only  carried  out  if 
animals  did  not  withdraw  the  paw.  Anaesthetised  mice  were  slowly  injected  with 
0.1ml  of  the  cell  suspension  (1x105cells/mouse)  directly  into  the  left  heart  ventricle 
using  a  1ml  insulin  syringe  with  a  27‐gauge  fitted  needle.  Successful  administration 
was judged by the bright red colour of oxygenated blood drawn into the syringe bevel 
prior  to  injection of  the cells. Animals were monitored closely and were placed back 
into the incubator to recover. 
2.2.8.2.4 MDA-MB-231-GFP and MDA-G8 subcutaneous injection 
GFP  positive  MDA‐MB‐231‐GFP  or  MDA‐G8  (GFP  expressing  clone  of  MDA‐MB‐436) 
cells were used for preparation of a 5x106 cells/ml suspension in sterile PBS. The cells 
were  placed  on  ice  and  female  balb/c  nude  mice  (8  weeks)  were  injected 
subcutaneously with  0.1ml of  the  cell  suspension  resulting  in  5x105  cells  per mouse. 
Animals were monitored  closely  post  injection  and  tumour  size was measured  once 
weekly  using  callipers.  Tumour  volume  was  then  calculated  from  the  mean  of  two 
measured  diameters  (mm)  per  tumour  using  the  following  formula: ¾  x  π  x  r3, with 
r=mean diameter/2. 






2.2.8.2.6 Zoledronic acid injection 
A  10mM  stock  solution  of  zoledronic  acid  ([1‐hydroxy‐2‐(1H‐imidazol‐1‐
yl)ethylidene]bisphosphonic  acid),  supplied  as  the  hydrated  disodium  salt  was 




the  solution,  0.1ml was  injected  subcutaneously using  a 1ml  syringe and a 25‐gauge 
needle.   
2.2.8.2.7 PBS injection 
PBS  was  injected  to  function  as  vehicle  control.  0.1ml  sterile  PBS  or  filter  sterilised 
(32mm and 0.45μm membrane) PBS was  injected by the appropriate route using a 1ml 
syringe and a 25‐gauge needle. 
2.2.8.2.8 BrdU injection 
BrdU  (5‐Bromo‐2’‐deoxyuridine) was  dissolved  in  2.6% DMSO  in  PBS;  filter  sterilised 
and  was  used  at  a  final  concentration  of  400mg/kg.  The  solution  was  injected 
intraperitoneally three hours prior to sacrifice with 1ml syringe and a 25‐gauge needle.  
2.2.8.2.9 AlexaFluor-647 (AF647) and AF647-Risedronate (AF647-RIS) injection 
A 400μg/kg  solution AF647‐RIS  (kindly  supplied by Professor M Rogers, University of 
Aberdeen, UK) and AF647 were prepared in sterile PBS prior to subcutaneous injection. 
AF647 has an excitation wavelength of 652nm and emission of 668 nm.  
2.2.8.3 Exsanguination from the heart 
Blood was collected at consistent time points for the course of each study and blood 
was  removed  after  removal  of  food.  Animals  were  injected  intraperitoneally  with 
0.5ml  pentabarbiturate.  Each  animal  was  monitored  after  injection  and  deep 
anaesthesia was confirmed by using the pinch reflex. A fresh 1ml syringe and 25‐gauge 
needle was  used  to  retrieve  blood  from  the  heart  before  cervical  dislocation.  Blood 
was  immediately  placed  into  a  1.5ml  Eppendorf  tube  after  removing  the  needle  to 
reduce sheer stress. Blood was left to clot at ambient temperature and was stored on 
ice until further processing (section 2.2.9.1). 





2.2.8.5 In vivo imaging 
An Illumatool Lighting System was used to visualise GFP positive tumours  in the hind 
legs.  On  day  of  sacrifice,  hind  legs  were  excised  and  stripped  of  muscle  before 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visualisation  of  the  tumour  using  a  Retiga  EX‐B  camera  with  QCapture  software 
(Version 2.70.0) and an exposure time of 104ms. 
In some experiments the  IVIS® Lumina  II system and Living  Image software was used 
for non‐invasive in vivo imaging. Anaesthetised (isoflurane) animals were placed into a 
darkbox imaging chamber with a 12.5cm field of view (shelf position D) and focus on 
subject  height.  Gray‐scale  images  were  taken  and  animals  were  imaged  for  GFP 
(excitation  filter:  465nm)  and  AF647  (excitation  filter  640)  using  the  auto‐exposure 
setting of the software. For analysis, PBS injected mice were used as negative controls 
to  adjust  for  background  fluorescence.  The  relative  fluorescence was  visualised  and 
overlaid  with  the  gray‐scale  photographs  using  pseudo  colours  and  Living  Image 
software. 
2.2.9 Sample processing 
2.2.9.1 Blood samples 
Blood  samples  were  centrifuged  at  10  000  rpm  for  10  minutes  at  4°C  to  separate 
serum  and  cellular  components.  The  clear  serum  was  then  carefully  removed  and 
placed into fresh 1.5ml Eppendorf tubes. Serum samples were stored at ‐80°C.  






2.2.9.3 Bone samples 
2.2.9.3.1 Histology 
Excised and stripped hind legs were placed in 4% PFA in PBS at 4°C and rotation for 48‐
72  hours.  In  some  cases  μCT  was  performed  during  this  time.  After  fixation,  the 
solution was exchanged  to decalcifying  solution  (0.5% PFA, 0.5M EDTA  in PBS, pH8), 
which was changed every two days for two weeks. Bone specimens were placed into 
histological cassettes and washed in PBS three times for 1 hour before being infiltrated 
with  wax  (carried  out  by  the  Bone  Analysis  Laboratory,  University  of  Sheffield  UK). 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Processed  bone  specimens  were  embedded  in  paraffin  wax  and  sectioned  at  a 
thickness of 3µm.  
2.2.9.3.2 µCT and X-ray 
Excised  hind  legs  that  were  not  used  for  histology  were  placed  into  10%  buffered 
formalin, and stored at ambient temperature until further use for either X‐Ray or μCT 
analysis. Formalin solution was changed after a maximum of 3 months to 70% EtOH. 
2.2.9.3.3 Multiphoton microscopy 
On day of sacrifice 










left  to  cool. Moulds were  filled with OCT  embedding medium,  placed  on  top  of  the 




















carried  out  at  a  voltage  of  50kV  and  a  currency  of  200µA  with  a  medium  camera 




trabecular bone. The  reference  line was defined as  the break  in  the  first bridge  (Fig. 
2.3). The offset for trabecular bone was set to 0.5mm away from the reference point. 















of  bone  derived  tumour  growth  on  the  skeleton.  The  electron  dense  bone  matrix 
absorbs photons generated by the X‐ray beam allowing analysis of bone integrity on a 
radiographic film. X‐ray images were taken with a Faxitron‐cabinet‐X‐Ray system and a 
mammography  film.  Tube  voltage  was  set  to  32kV  and  an  exposure  of  1  minute. 
Radiographs were then developed using a Curix60 developer and were scanned using 






A  range  of  staining  procedures  was  used  to  identify  cells  and  cell  components  on 
histological  bone  sections.  Staining was  carried out on a minimum of  two non‐serial 
bone sections (3μm) using the methods described below. 
2.2.12.1 Dewaxing and dehydrating of paraffin embedded sections 
Prior  to  use  of  paraffin  embedded  sections  for  staining  procedures,  slides  were 
dewaxed in xylene (2x 5 min) and then taken through 99%, 99%, 95% and 70% ethanol 
(5 min each) to tap water. For dehydration prior to mounting of the stained samples, 
the  slides were  taken  through  70%  (10  sec)  95%  (10  sec)  99%,  99%  ethanol  (30  sec 
each) and 2x xylene (1 and 3 minutes). 
2.2.12.2 Haematoxylin and eosin staining (H&E) 
H&E staining  is widely used in histology, based on its ability to clearly demonstrate a 
number of different  tissue structures. Haematoxylin  stains cell nuclei blue with good 
intranuclear  detail, while  the  eosin  stains  cell  cytoplasm and most  connective  tissue 
fibres in various shades and intensities of pink, orange and red. 
Slides  were  dewaxed  before  incubation  in  Gill’s  II  haematoxylin  for  90  seconds 
followed  by  washes  in  tap  water  for  5  minutes.  Next,  slides  were  incubated  for  5 
minutes in 1% aqueous eosin with 1% calcium carbonate, washed in tap water for 30 
seconds and dehydrated before mounting.  








to  ensure  optimal  conditions  for  the  enzyme.  Sections  were  dewaxed,  placed  in  a 
coplin  jar with warmed acetate‐tartrate buffer  and  incubated at  37°C  for  5 minutes. 
Next, sections were incubated in solution A for 30 minutes at 37°C (Solution A: 0.02g 






nitrite  solution  to hexazotise  the pararosaniline and was  left  to  stand  for 5 minutes. 
Just  before  use,  2.5ml  of  this  solution  was  added  to  50ml  of  pre‐warmed  acetate‐
tartrate buffer. Sections were then incubated in solution B for 15 minutes at 37°C and 
rinsed  twice  in  running  tap  water  before  being  counterstained  for  20  seconds  in 
haematoxylin and washes in running tap water, dehydration and mounting. 
2.2.12.4 BrdU staining 
BrdU  is an analogue of  thymidine and  is often used  for  identification of proliferating 
cells  in  living tissues. The synthetic nucleoside  is  incorporated  into newly synthesised 
DNA of every replicating cell exposed to BrdU. It is therefore possible to investigate the 
effects of treatment regimens on the growth of a wide range of cell types.  
Slides  were  dewaxed  before  placing  into  PBS.  Endogenous  peroxidase  was  blocked 
with  3% H2O2  in methanol  for  15min  at  ambient  temperature  before washing  slides 
twice in PBS‐T (PBS + 0.1% Tween 20) for 5 minutes. For antigen retrieval, slides were 
either microwaved at a high setting for 5 minutes in 10mM citric acid buffer (pH6) or 
using  the  pre‐treatment  antigen  retrieval  bath  (Dako).  Sections  were  then  carefully 
washed  in  PBS‐T  (2x  5min)  before  blocking  unspecific  binding  sites  with  a  1:10 
casein/PBS  solution  for  30min  at  ambient  temperature  in  a  moist  chamber.  The 
primary antibody (mouse anti BrdU) was added at 1:175 in 5% casein in PBS and left to 
incubate over night at 4°C  in a moist  chamber.  The next day,  slides were washed  in 
PBS‐T  (2x  5min)  prior  to  adding  the  secondary  antibody  (anti‐mouse  biotin)  at  a 
dilution  of  1:200  made  up  in  5%  casein  and  incubation  for  30  minutes  at  ambient 
temperature in a moist chamber. After washing in PBS‐T (2x for 5 min) sections were 
incubated  for  30  minutes  at  ambient  temperature  with  ABC  solution  (avidin:biotin 
enzyme  complex;  the  solution was made  up  at  least  30 minutes  prior  to  usage  and 
according  to  manufacturer’s  description).  Following  two  wash  steps  in  PBS‐T  for  5 
minutes, sections were incubated in DAB for approximately 5 minutes and transferred 
into water. Counterstaining of nuclei was performed by incubation in haematoxylin for 




2.2.12.5 GFP staining  
Apart  from exciting GFP by using the  in vivo  imaging tool or by microscopy, anti‐GFP 




minutes.  Subsequently  slides  were  washed  trice  in  distilled  H20  for  1  minute  each 
before  another wash  step was  carried  out  in  1x  PBS  (3x,  2 minutes  each).  To  block 
unspecific  binding,  slides  were  incubated  in  10%  normal  goat  serum  in  PBS  for  30 
minutes. The primary antibody or isotype control was added at a 1:600 dilution in 5% 
normal goat serum (NGS) and  incubated at 4°C over night. On the next day, sections 








2.2.12.6 ß-Galactosidase staining  
Dr Alyson Gartland (University of Sheffield, UK) kindly provided an optimised protocol 
for  ß‐Gal  immunohistochemistry.  Paraffin  bone  sections  were  dewaxed  before 
blocking endogenous peroxidase in 1% H2O2 in methanol for 30 minutes. After 3 wash 
steps  in dH2O  (5 min each) and 3 wash  steps  in TBS  (0.5M TRIS and 9% NaCl, 5 min 
each) unspecific binding sites were blocked by adding 5% normal goat serum diluted in 
TBS for 30 minutes. Primary antibody (rabbit anti‐mouse ß‐galactosidase) was added at 
a  dilution  of  1:1000  and  slides were  incubated  over  night  at  4°C.  The  following  day 
excess  antibody was  removed by 3 washes  in  TBS  (5 min each) before  incubation  in 
secondary antibody (1:200, biotinylated goat anti‐rabbit) for 30 minutes. Subsequently 





2.2.12.7 Immunohistochemistry staining for the human cytokeratin Cam5.2  




using the PT  (pre‐treatment) module and  low pH retrieval solution  for 20 minutes at 
97°C. After dewaxing  and antigen  retrieval,  slides were washed  in Dako wash buffer 




In  the manual protocol  the primary antibody was used at a serial dilution  to  test  for 
the  best  staining/background  results.  Briefly,  sections were  incubated  in  3% H2O2  in 
methanol before antigen  retrieval  in  trisodium citrate buffer  (pH6.5)  for 10 minutes. 
After blocking in horse serum the primary antibody was added for 1 hour at ambient 




Immunohistochemistry  for  the  cell  proliferation  antigen  Ki67  was  carried  out  as 
previously  described  (Ottewell  et  al.,  2008a)  using  a  mouse  monoclonal  antibody 
specific for human Ki67, which is expressed by actively proliferating cells.   
Slides  were  dewaxed  prior  to  blocking  endogenous  peroxidase  with  3%  H2O2  in 
methanol  for 10 minutes at ambient  temperature  followed by washes  in PBS‐T  (PBS‐
and 0.1% Tween, 2x for 5 minutes). Antigens were retrieved by microwave (high for 5 
minutes; low for 5 minutes) in 10mM Citric acid buffer (pH 6) and slides were washed 
in PBS‐T  (2x  for 5 minutes). Unspecific binding sites were blocked  in 1:10 casein/PBS 
for  30  minutes  at  ambient  temperature  followed  by  overnight  incubation  at  4°C  in 
primary antibody (mouse anti‐human Ki67) at a 1:125 dilution made up in 5% casein. 
Sections  were  then  washed  in  PBS‐T  (2x  for  5  minutes)  before  incubation  for  30 
minutes  at  ambient  temperature  in  secondary  antibody  (anti mouse‐biotin)  at  1:200 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made  up  in  5%  casein.  Slides  were  washed  in  PBS‐T  (2x  for  5  minutes)  prior  to 
incubation in ABC solution (made up 30 minutes prior to use (2 drops of A; 2 drops of 
B;  5ml  PBS))  for  30  minutes  at  ambient  temperature  and  further  washes  and 
incubation  in DAB  for  3 minutes.  Finally,  slides were washed  in H2O,  counterstained 
with haematoxylin for 30 seconds and dehydrated before mounting in DEPEX.  
2.2.12.9 Caspase-3 immunohistochemistry 
Immunohistochemistry for caspase‐3 was carried out as previously described (Ottewell 
et  al.,  2008a)  using  the  polyclonal  anti‐active  caspase‐3  antibody  specific  for  human 
cleaved caspase‐3.  




minutes).  Unspecific  binding  sites  were  then  blocked  with  1:10  casein/PBS  for  30 
minutes at ambient temperature. Next, slides were incubated overnight at 4°C in the 
primary antibody (rabbit anti‐human active caspase‐3) at a dilution of 1:750 made up 






H2O,  counterstained  with  haematoxylin  for  30  seconds  and  dehydrated  before 
mounting in DEPEX.  
2.2.12.10 Goldner’s trichrome staining  
The Goldner’s trichrome method highlights specific structures like collagen and muscle 
in addition to allowing identification of bone marrow and tumour colonies. The basis of 
the  staining  is  the  difference  in  molecular  size  of  the  dyes  used.  Smaller  particles 
penetrate  the  exposed  tissue  rapidly  while  larger  ones  require  more  time  and  can 
replace  smaller  molecules  from  the  stained  areas.  Characteristics  are:  nuclei: 
blue/black, red blood cells: red, muscle and fibrin: pink, collagen: green. Staining was 
performed  using  a  Masson‐Goldner  trichrome  staining  kit  to  the  manufacturer’s 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instructions.  Briefly,  sections  were  dewaxed  prior  to  adding Weigert’s  haematoxylin 
solution for 5 minutes and washing in running tap water 5 minutes. Sections were then 
rinsed  in  1%  acetic  acid  (30  seconds)  before  adding  azophloxine  solution  for  10 
minutes. After  rinsing with 1% acetic acid,  tungstophosphoric acid orange G  solution 
was added for 2, 3, 4 or 5 minutes depending on the individual slides and rinsed with 










or Oc  (Fig. 2.4). Further details  for criteria of osteoblast and osteoclast  identification 
are described in Chapter 3, section 3.4.3.  
For  measurements  of  osteoclast  size,  Osteomeasure  software  and  a  Leica  BMRB 











colonies  within  the  chosen  model  system.  However,  because  processing  for 
histomorphometric  analysis  of  tumours  within  bone  requires  various  steps  and 
sectioning of the bone, important information may be lost during these procedures. In 
addition, 2‐D analysis of a 3‐D object may not provide the best possible data in respect 
to  location  of  single  cells  or  colonies  and  their  adjacent  tissues.  Multiphoton 










analyses  with  a  20x  objective  (plan‐apochromat  20x/0.8).  The  area  of  interest  was 
found  using  the  transmitted  light  setting  on  the  microscope  and  tile  scans  were 
performed  using  the  multiphoton  chameleon  laser  at  900nm  to  detect  collagen  by 
second harmonic generation at 435‐485nm and GFP at 525nm. In some cases GFP was 





soluble  proteins  in  less  than  50μl  serum.  Each  bead  is  labelled  with  a  unique 
fluorescent  intensity and  is coated with the antibody of  interest. The beads can then 
be clustered depending on their fluorescent signal and concentration of the protein of 
interest  is  calculated according  to a  standard curve generated  for each bead. Mouse 
Flex  Sets  for  IL‐1α,  IL‐1β,  IL‐6,  KC  (murine  IL‐8)  and  MCP‐1  were  run  to  the 





on  the  night  prior  to  sacrifice  and  blood  was  collected  at  a  consistent  time  point 
(between 10 and 12am). All samples were stored at ‐80˚C until use.  
2.2.16.1 Measurement of CTX in mouse serum 
CTX, degradation products of the C‐terminal telopeptides of type‐I collagen which are 
released  during  bone  matrix  degradation,  is  commonly  used  as  a  bone  resorption 
marker.  The  RatLaps™  EIA  is  an  enzyme‐linked  immunosorbent  assay  for  CTX 
quantification in mouse serum and was performed to the manufacturer’s instructions. 
Briefly, 100μl of the biotinylated RatLaps antigen (biotinylated peptide, EKSQDGGR, a 
sequence  specific  to  a  part  of  rat  type‐I  collagen)  was  added  to  the  streptavidine 
coated microtitre  wells  and  incubated  at  ambient  temperature  for  30 minutes.  The 











2.2.16.2 Measurement of the bone formation marker PINP in serum 
Bone formation requires the synthesis of  type  I collagen, a major organic part of  the 
bone  matrix.  During  collagen  synthesis,  amino‐  and  carboxyterminal  parts  of 
propeptides are secreted into the circulation making them available for quantification 
in serum. The N‐terminal propeptide of type  I procollagen (PINP) was therefore used 
for  determination  of  bone  formation  in  mouse  serum.  The  competitive 
enzymeimmunoassay  (EIA)  kit  for  mouse/rat  PINP  was  used  to  the  manufacturer’s 
instructions. Briefly, 50μl of each calibrator or control were added in duplicate to the 
appropriate  wells  of  the  antibody  coated  96‐well‐plate  (polyclonal  rabbit  anti‐PINP 
antibody). Next, 5μl of each  sample and 45μl of  Sample Diluent  (BSA, 0.05% sodium 




linked horseradish peroxidase  in PBS) was pipette  into all wells before  incubation at 
ambient temperature for 30 minutes followed by washing as described before. Finally, 










2.2.16.3 Human sclerostin ELISA 
Sclerostin  is a negative regulator of  the Wnt pathway and has been shown to  inhibit 
osteoblastogenesis. The Sclerostin ELISA procedure was carried out as follows. 150µl of 
provided  assay  buffer was  added  into  each well  of  the  96‐well  plate  (coated with  a 
polyclonal goat anti human Sclerostin antibody) before pipetting 20µl of the supplied 
standard and control solution as well as the experimental samples in duplicate into the 
assigned  wells.  Some  wells  were  assigned  as  blank  measurements.  Next,  50μl 
biotinylated  anti  Sclerostin  antibody  was  added  into  each  well  and  the  plate  was 
incubated over night  at  ambient  temperature  in  the dark. On  the  following day,  the 





absorbance  was  measured  immediately  at  450nm  with  a  reference  wavelength  of 
630nm  using  a  plate  reader.  Sclerostin  concentrations  were  extrapolated  from  the 
standard curve and data were expressed in pmol/l. 
2.2.16.4 Mouse RANKL ELISA  
The  RANKL  immunoassay  was  performed  by  Alyson  Evans.  Briefly,  50ml  of  Assay 
Diluent was added  to each well of  the microplate  coated with a polyclonal  antibody 
specific for mouse RANKL followed by addition of 50mL of the supplied Standard and 
Control  solution and  the experimental  samples  and gentle  tapping  to mix.  The plate 
was  incubated for 2 hours at ambient temperature and was then washed with Wash 
Buffer  (400ml/well).  Next,  100ml  of  the  Mouse  TRANCEConjugate  (polyclonal  anti‐
mouse RANKL antibody conjugated to horseradish peroxidase) was pipetted into each 
well  and  incubation  for  2  hours  at  ambient  temperature.  After  washing  the  plate, 
100mL  of  Substrate  Solution  (tetramethylbenzidine  and  were  added  to  each  well, 
incubated  for  30 minutes  at  ambient  temperature  in  the  dark  before  adding  100mL 
Stop Solution (equal volumes of hydrogen peroxide and hydrochloric acid solution) and 
mixing (gentle tap). Finally, a plate reader was used to read the optical density of each 






2.2.17.1 Tumour tissue 
For preparation of single cell  suspensions of subcutaneous  tumour  tissue was placed 
into ice cold PBS in a sterile petri dish prior to cutting the tissue into small pieces using 
a scalpel. Next, the tissue was washed twice  in PBS before addition of 1ml of trypsin 
and  incubation at 4°C  for 1 hour  followed by 1 hour at ambient  temperature and 20 
minutes  at  37°C.  2ml  of  cell  culture medium  containing  10%  FCS was  added  to  the 
suspension  to  inhibit  the  enzyme.  Cells  were  washed  twice  in  PBS  and  were 
resuspended  in  1%  FCS  in  PBS  before  passing  the  suspension  through  a  70μm  cell 
strainer  into  a  Flow  Cytometer  tube.  200μl  of  same  cell  suspension  was  used  for 
preparation of cytospins (section 2.2.25).  
2.2.17.2 Bone marrow 
Hind  legs  were  excised  and  placed  into  ice  cold  PBS  before  flushing  out  the  bone 
marrow  using  a  25‐gauge  needle  and  a  1ml  syringe.  Cell  suspensions  were  washed 
twice  in PBS before  resuspension  in 1% FCS  in PBS and passing  through a 70μm cell 
strainer  into  a  Flow  Cytometer  tube.  200μl  of  same  cell  suspension  was  used  for 
preparation of cytospins (section 2.2.25). 






Total RNA  isolation  from cell culture or  in vivo  samples was performed using  the TRI 
REAGENTTM  method,  a  single  step  extraction  technique  using  an  acid  guanidinium 
thiocyanate‐phenol‐chloroform  mixture.  Cells  were  lysed  by  adding  1ml  TRI 
REAGENTTM  and  passing  the  cell  lysate  several  times  through  a  pipette  followed  by 
incubation for 5min at ambient temperature. For in vivo tissue samples, RNAlater was 
removed  and  the  tissue  was  washed  twice  using  sterile  PBS  before  adding  1ml  TRI 
REAGENTTM and homogenising  the  tissue using a Bio Vortex. Next,  0.2ml  chloroform 
was added to the solution which was manually inverted for 15sec prior to incubation at 
ambient  temperature  for 5min. This was  followed by centrifugation of  the sample at 
12000rpm for 15min at 4°C in a bench top centrifuge. After centrifugation, two phases 
could  be  distinguished  in  the  solution,  with  RNA  remaining  exclusively  in  the  upper 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aqueous  phase.  In  order  to  precipitate  the  RNA,  the  upper  aqueous  phase  was 
transferred  to  a  fresh  RNA‐free  Eppendorf  tube  followed  by  addition  of  0.5ml  2‐
propanol  and  manual  inverting.  The  sample  was  then  incubated  at  ambient 
temperature  for 5‐10min and centrifuged once more at 12000rpm  for 15min at 4°C. 
Once  the  supernatant  had  been  removed  carefully,  the  RNA  pellet  was  washed  by 
adding 1ml of 100%  ice cold ethanol and mixing and centrifugation at 12000rpm  for 
5min at 4°C. Two more wash steps were carried out using freshly prepared 80% EtOH 
and  centrifugation  at  7500rpm  for  5min  at  4°C.  In  order  to  obtain  the  RNA,  the 
supernatant  was  removed  and  the  pellet  was  air‐dried  for  10min  at  ambient 
temperature. Finally, the RNA was dissolved in 30μl RNase‐free DEPC‐treated (diethyl 








15  seconds  at  10  000rpm  and  flow‐through  was  discarded.  Next,  500μl  RPF  buffer 
were added before centrifugation as  in the previous step and discarding of  the flow‐
through.  The wash  step was  repeated,  the  columns were  centrifuged  for  2 minutes, 
the  flow‐through  was  discarded  and  the  empty  column  was  spun  once  more  for  1 
















diluted  to  a  concentration  of  <500ng/μl  in  Depec  H2O  and  were  analysed  on  a 
NanoChip  by  Dr  P  Heath  from  the  Microarray  Core  Facility  at  the  University  of 
Sheffield, UK. Typical RIN (RNA Intergrity Number) values were between 9.9 and 7.3 for 







prime  cDNA  synthesis,  1µg  of  purified  RNA were mixed with  1μl  (50µM)  oligo(dT)20 
primers, 1μl Annealing buffer and RNase‐free (DEPC‐treated) H2O in a final volume of 
8µl prior to incubation at 65˚C for 5 minutes followed by cooling at on ice for at least 1 
minute.  Next,  10μl  of  the  2x  First‐Strand  Reaction  Mix  and  2µl  SuperScript 
III/RNaseOUTTM Enzyme Mix were added on ice before mixing and brief centrifugation. 
The mix was then incubated at 50°C for 50 minutes in order for cDNA synthesis to take 
place.  The  reaction  was  terminated  by  incubating  the  sample  at  85˚C  for  5min  and 





specific TaqMan® assays were used  for analysis of  selected genes. The specificity  (all 
TaqMan® assays used were designed  to detect human genes)  and efficiency of each 
primer set had been previously assessed in the laboratory (see page 51). For each gene 




loaded  in  duplicate.  The  tubes  were mixed  by  centrifugation  before  loading  onto  a 
384‐well  PCR  plate  and  analysing  using  the  ABI  7900HT  platform  and  SDS  2.2.1 
software. Exactly the same procedure as above, with the exception of the addition of 
cDNA (replaced by DEPC water) was followed for a sample used as a negative control. 
For  every  sample  the  house‐keeping  gene  GapdH  was  run  on  the  same  plate  for 
subsequent  analysis  of  relative  gene  expression.  After  completion  of  the  run,  ΔCT 









remove genomic DNA)  at  1:100 and homogenising  the  tissue.  The  lysis  reaction was 
mixed  by  pipetting  up  and  down  five  times  followed  by  incubation  at  ambient 
temperature  for  5 minutes.  Next,  5μl  of  Stop  Solution was  added  directly  into  each 

























  Stage   Repeats  Temperature  Time 
Enzyme activation (hold)  1  1  95°C  10min 
PCR (cycle)  2  14  95°C  15sec 




cytospin  preparations.  200μl  of  each  cell  suspension  was  added  to  the  assembled 
cytospin  slide  (glass  microscope  slide,  filter  paper,  funnel  and  metal  holder)  and 















In  vivo models  of metastatic  breast  cancer  are  frequently  used  in  preclinical  studies 
and several techniques have been published using xenograft models of human cancer 
cells implanted in immunocompromised mice. The introduction of human cancer cells 
to  bone  via  the  systemic  route  are  commonly  applied  in  preclinical  investigation  of 
tumour  growth  and  treatment.  Once  the  in  vivo  experiment  has  been  performed, 
comprehensive analysis of the bone and the tumour is possible by several techniques. 
A  vast  number  of  reports  have  been  published  assessing  tumour  growth  in  murine 
bone,  however most  studies  have  focussed  on  large  tumour  colonies  and  thus  only 
little published  information  is available on how to analyse small  (<1mm  in diameter) 
tumours  and  surrounding  bone  cells  appropriately.  Osseous  tumour  growth  is 
frequently measured by histology; but the majority of the published studies have been 
on end stage disease with large tumours filling almost the whole bone marrow cavity. 
Although  these  stages  allow  studies  of  the  tumour,  analysis  of  the  bone 
microenvironment is greatly impeded due to the loss of bone, associated bone cells as 
well as the bone marrow.  
This  chapter  summarises  the  establishment  of  two mouse models  of  human  breast 
cancer growth in bone and the development of measurement of small cancer colonies 






and  outcome  is  generally  poor.  Clinical  samples  of  metastatic  breast  foci  are  not 
obtained  easily  leading  to  a  lack  of  studies  investigating  human  metastatic  bone 
disease.  Animal  models  therefore  enable  preclinical  studies  to  assess  the  different 




transplanted orthotopically  into  the mammary  fat pads  followed by dissemination  to 
visceral and osseous sites  (Hoffman et al., 1999), or  implanted directly  into the bone 
marrow cavity of  long bones of  immunocompromised mice. The latter method is  less 
representative  of  the metastatic  process  since  the  cells  are  directly  placed  into  the 
metastatic  site  (bone),  but  can  be  used  to  study  the  late  stages  of  the  metastatic 
cascade. Moreover,  the  implantation  requires  surgical  intervention  in order  to  inject 
tumour  cells  directly  into  the  medullary  cavity  of  long  bones.  The  technique  may 




(1988)  first  described  the  formation  of  osseous  tumours  after  B16  melanoma  cell 
injection  into  the  left  cardiac  ventricle  of  C57BL/6 mice.  It was  subsequently  shown 
that intracardiac injection of the oestrogen receptor negative human breast cancer cell 
line MDA‐MB‐231  into  nude mice  resulted  in  aggressive  tumour  growth with  a  high 
preference to localise to bone (Yoneda et al., 1999). Although a large number of cells 
(1x105 to 5x105 per mouse) are introduced into the circulation, only about 0.01% of the 
injected  tumour  cells  have  the  potential  to  survive  and  form  metastatic  foci.  The 
selectivity of the metastatic site (bone)  is thought to depend on the site of  injection, 






The observed organ  selectivity of  cancer  cells  post  intracardiac  injection was  further 
used  to  generate  bone  homing  breast  cancer  cell  lines.  In  summary,  human  breast 
carcinoma cells were introduced via the left heart ventricle and the resulting osseous 











the  posterior  part  of  the  skeleton. When  comparing  cancer‐induced  osteolytic  bone 
disease  in mice  injected with B02  cells or  the parental  cell  line MDA‐MB‐231,  it was 
shown  that  B02  tumours  caused  an  increase  in  osteolytic  lesion  number  and  area 
(Pecheur et al., 2002), underlining the bone specific properties of this cell line.  
The described  in  vivo models are  commonly used  to  study  the processes  involved  in 
osseous tumour growth, as well as the effects of treatment, and several techniques are 
available  for  downstream  analysis.  Table  3.1  gives  an  overview  of  the  published 
methods  used  to  determine  breast  tumour  burden  in  bone.  Although  the  literature 
summarised  in  the  table  is  by  far  not  exhaustive,  it  demonstrates  the  variability  of 
methods  used  between  laboratories,  and  emphasises  the  high  number  of  studies 
investigating  end  stage  disease.  Measurement  of  tumour  burden  in  bone  is  often 
performed  on  histological  sections  but  more  recent  imaging  techniques 
(bioluminescence,  PET  (positron  emission  tomography),  MRI  (magnetic  resonance 
imaging),  PET  μCT,  optical  μCT)  are  now  commonly  used.  Bioluminescence,  for 
example,  has  a  great  advantage  over  histological  analysis  because  it  is  non‐invasive 
and  allows  monitoring  of  tumour  growth  in  vivo.  Although  the  histomorphometric 
assessment  of  tumour  size  in  bone  is  technically  challenging  and  can  only  be 




microenvironment  in  a  2‐D  relationship  and  provides  the  possibility  to  stain  for  a 
number of different molecules (tumour or host) on sections of the same sample. 
Several, usually non‐serial sections, should be analysed to get a good representation of 
a  solid  3‐D  tumour,  however,  the  number  of  sections  analysed  and  whether  these 


































































































Detection  of  the  tumour  in  bone  is  possible  due  to  the  morphological  differences 
between human and host bone marrow cells. Solid tumour colonies can therefore be 
identified  on  for  example  haematoxylin  and  eosin  stained  sections.  Difficulties  can 
arise when analysing small tumour colonies because they are easily missed during the 
sectioning process  and often only  little material  is  available  for  subsequent  analysis. 
The  use  of  specific  tumour  cell  markers  should  be  considered  in  order  to  reliably 
identify colonies of less than about 100 cells and single cancer cells. Small numbers of 




The  increased  understanding  of  the  relevance  of  the  bone  microenvironment  in 
metastatic  breast  tumour  growth  lead  to  the  decision  to  carry  out  detailed 
quantification  of  the  static  remodelling  parameters  like  osteoblast  and  osteoclast 
number per mm bone surface in tumour bearing bones. A literature search of studies 




were  studied.  Importantly,  the  lack  of  published  studies  assessing  effects  of  tumour 
growth on bone cells other than at late stage disease highlighted the need to develop a 
protocol for the analysis of early (prior to development of extensive osteolysis) tumour 
growth  in  bone  and  the  associated microenvironment  during my  PhD project.  Apart 
from  osteoblasts  and  osteoclasts,  several  other  factors  may  play  a  role  in  the 
microenvironment‐tumour  cell  interactions,  including  different  cell  types,  soluble 
factors like cytokines and extracellular matrix proteins (Holen and Coleman, 2010). 












































































































i.v.=intravenous,  i.c.  intracardiac,  TRAP=tartrate  resistant  acid  phosphatase,  OC=osteoclast, 





• To  establish  a  suitable  in  vivo model  of  metastatic  breast  cancer  growth  to 
bone  for  analysis  of  different  stages  of  tumour  growth  and  the  effects  of 
treatment. 
• To  develop methodology  for  reproducible  analysis  of  bone  cells  (osteoblasts 
and osteoclasts) in tumour bearing and non‐tumour bearing bones.  
































































3.4 Method development and results 
3.4.1 Establishment of in vivo models of human breast tumour growth in 
bone 
All  in vivo experiments were carried out  in accordance with  local guidelines and with 
Home  Office  approval  under  project  license  40/2972  held  by  Professor  N.J.  Brown, 
University of Sheffield, United Kingdom. 
3.4.1.1 The intravenous model using B02 cells 
The  bone  homing  B02  cell  line  (Peyruchaud  et  al.,  2001),  derived  from  the  parental 
human breast cancer cell  line MDA‐MB‐231, was  initially used  to establish an  in vivo 
model  of  human  bone  metastases.  An  experiment  undertaken  by  Dr  Ottewell 
(University of Sheffield, UK) in collaboration with and in the laboratory of Dr Philippe 
Clezardin  (INSERM,  Lyon,  France)  was  successful  in  inducing  osseous  B02  tumour 
growth  in  balb/c  nude  mice  (Ottewell  et  al.,  2008a).  Because  the  model  had  been 
shown to be effective (80‐100% tumour take rate) the technique was used for initial in 
vivo experiments  in this PhD project. B02‐GFP/β‐Gal  (B02) cells  (kindly received from 
Dr  Clezardin)  expressing  green  fluorescent  protein  (GFP),  luciferase  and  beta‐
galactosidase (β‐Gal) were cultured in 1640‐RPMI supplemented with 10% FCS at 37˚C 
and 5% CO2. Because  it was not possible  to perform bioluminescence  imaging at  the 
University of Sheffield animal facilities, monitoring tumour growth in vivo relied on GFP 
imaging. In vivo detection of a fluorochrome signal through the dense bone matrix and 
several  layers  of  soft  tissue  require  the  tumour  to  reach  a  detectable  size 
(approximately 2 weeks post injection of B02 cells (Peyruchaud et al., 2001) and a high 
number  of  GFP  positive  tumour  cells  on  day  of  injection  should  be  used.  The 
percentage of GFP positive B02 cells was therefore analysed by flow cytometry prior to 
allocation  of  the  cell  batch  for  in  vivo  use.  B02  cells  and  MDA‐MB‐231  cells  (GFP 
negative) were analysed for GFP expression using the FACS Calibur flow cytometer. Cell 
suspensions  suitable  for  in  vivo  experiments  were  defined  as  a  GFP  positive  cell 







A)  The MDA‐MB‐231  cell  line  and  B)  B02  cells  were  analysed  for  GFP  (FL1‐H)  on  the  FACS 
Calibur  system. B02  cells with  a  value of  >85% were used  for  in  vivo  experiments while  cell 
batches below were sorted for GFP before injection.  
 
3.4.1.1.1 B02 injection procedure 
All  steps  in  the  initial  experiment,  including  cell  and  anaesthetic  preparation,  were 
carried out by me while Dr Ottewell injected the cells as described earlier (Ottewell et 
al.,  2008a).  Home  office  regulations  require  specialised  training  of  the  investigator 
prior to performing in vivo procedures, thus I was unable to perform the injections of 
the first experiment myself. Note that suppliers and further details  to this procedure 
can  be  found  in  the  general  materials  and  methods  section  2.2.8.2.2.  On  day  of 
injection,  a  1x106  cells/ml  suspension  of  GFP  positive  B02 was  prepared.  Cells were 
placed on  ice and used  for  injection within approximately 1‐hour post  trypsinisation. 
Female,  6  week  old  balb/c  nude  mice  (Charles  River,  UK)  were  injected  with 
89 
 
ketamine/xylazine  (56.5mg/kg  ketamine  and  5.5mg/kg  xylazine)  into  the  peritoneal 
cavity and placed into an incubator (33°C) to maintain body temperature and to ensure 




27‐gauge  fitted  needle.  Animals  were  monitored  closely  directly  post  injection  and 
then weekly by GFP imaging to assess tumour growth. Despite adopting the protocol 
of the original article (Ottewell et al., 2008a) and being performed or supervised by Dr 
Ottewell,  experiments  performed  using  the  described  method  and  the  cell  batch 


























































histology  and  a  selection  of  samples  was  serial  sectioned,  stained  for  H&E  and 
assessed  for  presence  of  tumour  colonies.  X‐ray  and  histological  investigation 
confirmed the  lack of osseous tumour growth; no bone  lesions were detected  in any 
animal. 
3.4.1.1.3 Investigation of needle gauge size on B02 cell viability 
Because of concerns that the injection process itself could impair B02 cell viability; an 
in vitro experiment was performed  investigating  the effects of  the needle gauge size 
on tumour cell growth. Briefly, 1ml/well of a 2x104 B02 cells/ml suspension was seeded 
in  triplicates  into  a  6‐well‐plate  using  either  a  1ml  syringe  with  a  27‐gauge  fitted 
needle,  a  1ml  syringe  with  a  25‐gauge  needle  or  a  1ml  pipette  tip.  To  mimic  the 
injection process, the cells were passed through the syringe in 0.1ml steps. Cells were 
left  to  grow  for  96  hours  at  37˚C  and  5%  CO2.  Next,  the medium  of  each well  was 
carefully collected to assess non‐viable cell numbers in the supernatant and the viable, 
adherent cells were trypsinised before resuspending in medium. Cell supernatants and 
















plate  before  quantification  of  floating  (supernatant,  non‐viable)  and  adherent  (viable)  cells 
after  96 hours.  Results  are expressed as  cells/ml.   Mean ±  SEM  from  triplicate  samples  in  a 
single experiment. 
 
3.4.1.1.4 Investigation of B02 tumour take rate after use of selection medium and 
injection of increased cell number 
A literature search revealed that B02 cell numbers per mouse varied between studies 
with  some  using  5x105  cells  per  mouse  (Pecheur  et  al.,  2002;  Garcia  et  al.,  2008) 
compared to 1x105 (Peyruchaud et al., 2001; Ottewell et al., 2008a).  In addition, two 
types of B02 selection media were prepared  to select  for GFP  (RPMI‐1640, 10% FCS, 
1mg/ml Geneticin) and for GFP, luciferase and β‐Gal guided by the recommendation of 
Mrs  Deux  B  (RPMI‐1640,  10%  FCS,  1µg/ml  puromycine,  500µg/µl  hygromycine, 
800µg/µl G418, email communication between Dr Ottewell PD, University of Sheffield 
and Mrs Deux B, INSERM, Lyon). B02 cells were grown either in selection media or the 
medium  used  in  the  previous  experiments  (RPMI‐1640,  10%  FCS).  To  ensure  that 
predominantly  GFP  positive  cells  were  injected  under  all  three  conditions,  the  cells 
grown in antibiotic‐free medium were sorted for GFP prior to injection.  
Firstly  it  was  investigated  whether  increased  cell  number  (5x105  vs.  1x105)  and 




River,  (UK)  to Harlan  (UK)  for subsequent experiments. Anaesthesia, preparation and 
injection of  the cells were carried out as described  in section 3.4.1.1.1. Furthermore, 
two mice  were  injected  s.c.  with  1x106  B02  cells,  in  order  to  assess  if  the  cells  are 
capable of growing in vivo at a peripheral site. GFP images and x‐rays taken at the end 
of  the  experiment  (day  43)  did  not  show  GFP  positive  tumour  growth  in  bone  or 
osteolytic bone disease under either condition. However, the s.c. tumour of the mouse 
injected with  cells  grown  in  the  antibiotic  free medium was  palpable  approximately 
one week prior to sacrifice (day 43), suggesting that the cells grow, although slowly, at 
the  subcutaneous  site. Next,  a new batch of  cells  (arrived November 2009)  that had 
kindly been provided on request by the laboratory of Dr Clezardin in Lyon was tested 
for in vivo growth characteristics. In addition, the selection medium recommended by 
the  Lyon  team  (RPMI‐1640,  10%  FCS,  1µg/ml  puromycine,  500µg/µl  hygromycine, 
800µg/µl  G418)  in  combination  with  the  higher  cell  number  (5x105)  was  used  for 
tumour growth in 4 animals (Harlan, UK). Anaesthesia, preparation and injection of the 
cells were carried out as described in section 3.4.1.1.1. GFP images and x‐rays taken at 
the  end  of  the  experiment  (day  55)  did  not  show  GFP  positive  tumour  growth  or 
osteolytic bone disease.  
Collectively  the data  from  the experiments described here  suggest  that  a higher  cell 
number, addition of antibiotics and use if a new cell batch did not result in increased 
osseous  tumour  take  rate.  However,  the  cells  did  grow  at  the  subcutaneous  site  in 
animals  received  from Harlan  (UK)  resulting  in  the decision  that  further experiments 
will be carried out using mice from this supplier.  
3.4.1.1.5 Modification of B02 injection procedure  
As I was unable to generate tumour growth in bone by using the described alterations 
to  the  original  protocol,  I  arranged  a  visit  to  a  collaboration  laboratory  (Galapagos 
SASU, Paris, France) that routinely and effectively uses the B02 model. I therefore was 




























































animals  used  in  Dr  Holen’s  laboratory  in  Sheffield,  UK  and  at  Dr  Pujuguet’s  laboratory  at 
Galapagos SASU, Paris, France. Pen/strep = penicillin and streptomycin. 
 
In  addition  to  providing  the  opportunity  to  monitor  the  B02  model  procedure,  my 
injection  technique  was  monitored  and  approved  by  Dr  Pujuguets’  experienced 
technical  staff  and  a  vial  of  B02  cells  used  at  Galapagos  was  sent  to  Sheffield.  On 
arrival, the cells were thawed and cultured in 1640‐RPMI supplemented with 10% FCS 




dose  than  used  previously  (116.0mg/kg  ketamine,  7.3mg/kg  xylazine,  in  NaCl 
compared  to  56.5mg/kg  ketamine,  5.5mg/kg  xylazine,  in  H2O)  and  animals  were 
injected with B02 cells as described earlier. All animals were monitored weekly by non‐
invasive GFP  imaging. Two weeks post  injection,  the  first animals  showed detectable 
tumour  growth  in  the  hind  legs.  The  experiment was  terminated  once  first  signs  of 










Collectively,  the  in  vivo  experiments  carried  out  to  optimise  the  B02 model  showed 
that the cell number, anaesthesia and possibly the cell batch and animal supplier were 
important  for  successful  tumour  take.  Since  I  was  able  to  optimise  the  B02  model 
successfully,  further  experiments  in  our  unit  will  be  using  the  method  described  in 
section  3.4.1.1.5.  Table  3.5  summarises  the  different  conditions  and  results  of 
experiments undertaken during the optimisation process. The material collected from 
all  B02  experiments  was  used  either  for  analysis  (Chapter  4)  and/or  for  the 
familiarisation  and  optimisation  of  analysis  techniques  such  as  tissue  fixation, 





































































The  table  summarises  the origin of  the  cell  batch,  the number of  cells  used per mouse,  the 
medium used to grow the cells in vitro, the anaesthesia used and the resulting take rate.  
 
3.4.1.2 The intracardiac model using MDA-MB-231-GFP cells 
After  having  performed  several  experiments with  very  low  tumour  take  rate,  it was 
decided  that  a different  tumour model  should be used  in  the PhD project  to ensure 
tumour  growth.  MDA‐MB‐231  cells  had  been  previously  transfected  with  GFP 




Female  balb/c  nude  mice  (6  weeks  of  age  at  day  of  injection,  Harlan,  UK)  were 
anaesthetised with 56.5mg/kg ketamine, 5.5mg/kg  xylazine,  in H2O and 0.1ml of  the 
cell  suspension was  injected  into  the  left  heart  ventricle.  Successful  injections were 
judged by  the bright  red  colour of  the oxygenated blood, which was drawn  into  the 
bevel  of  the  needle  prior  to  injection.  Dr  PD  Ottewell  performed  the  intracardiac 
injections  in  the  first  experiment.  A  44%  (n=30)  take  rate  was  achieved  in  this 
experiment and thus all further bone metastasis studies shown in this PhD thesis were 




the take rate  increased during the course of my PhD up to 88%. Weekly  live  imaging 
showed that tumours were visible by GFP from 2 weeks post injection or from 10 days 
when imaging muscle free hind legs on day of sacrifice.  
In  summary,  the  intracardiac  model  using  MDA‐MB‐231  cells  was  successful  in 
generating  osseous  tumour  growth  in  the  first  performed  experiment  and  was 




One  of  the  aims  of  the  PhD  project  was  to  analyse  small  (<1mm  diameter)  breast 





protocol,  between GFP  positive  osseous  tumour  colonies were  visible when  imaging 
hind  legs  on  day  of  sacrifice.  Small  colonies were  therefore  defined  as  GFP  positive 




3.4.2.1 Histological detection and identification of small breast tumour colonies in bone 
In order to detect tumour colonies of approximately 1mm in diameter, a method had 
to be developed  to  localise  and  identify  the  cancer  focus on histological  sections.  In 
addition,  several  techniques  were  tested  for  tumour  cell  identification  in  bone, 






3.4.2.1.1 Localisation of the tumour in the bone specimen 
Histological  analysis  of  bone  specimens  is  currently  irreplaceable  in  gaining  detailed 
information  of  the  complex  cellular  components  of  the  bone.  However,  in  order  to 
comprehensively  analyse  small  tumour  colonies  and  the  directly  surrounding  cells, 
histological detection of the tumour  is  required. To my knowledge,  there  is currently 
no  standard  protocol  available  on  how  to  process  and  section  histological  bone 
specimens with small tumour colonies. Indeed, this was proven to be challenging since 
small  colonies  were  often  missed  during  the  sectioning  process.  Although  tumour 
colonies  were  detectable  by  GFP  imaging,  tumours  could  not  be  identified  on 
histological sections 10 days and sometimes even 15 days post tumour cell  injection. 
This  was  further  shown  to  be  partly  due  to  the  orientation  of  the  bone  during 
embedding.  For  standard  bone  histology,  all  bone  specimens  in  one  study  are 
orientated  in the same way to ensure the analysis of comparable areas. Because the 
location  of  small  tumour  colonies  was  shown  to  be  highly  variable  within  the 




including posterior, anterior, medial and  lateral view of  the hind  legs  (Fig. 3.4A). The 














The  block  was  sectioned  until  tissue  (bone  associated  soft  tissue  and/or  bone)  was 




had  to  be  performed,  ultimately  saving  time  as  well  as  increasing  the  number  of 
detected tumours. The gap in between different tumour levels was kept at a minimal 
depth  for  the  detection  of  small  tumours.  The  actual  size  of  the  gap was  therefore 
partly dependent on the person using the microtome (sections used in this PhD were 
either  cut  by  Mrs  A  Evans  or  staff  of  the  Bone  Analysis  Laboratory,  University  of 
Sheffield). For medium to  large tumour colonies, a similar process was carried out as 
described  above  with  the  alteration  that  defined  gaps  (>20µm)  were  cut  in  before 









specific  staining method  to aid  identification.  Several markers were  therefore  tested 









and C)  tibia  illustrating  the necessity of  repeated  sectioning and  staining  to  locate a  tumour 
colony. Both tibia and femur show tumour colonies 15 days post tumour cell inoculation. Note 
that  no  tumour  cells  are  visible  in  level  1  or  2.  White  dotted  line=tumour  circumference, 






3.4.2.1.2 Assessment of GFP, β-Gal or cytokeratin staining for tumour cell 
identification in bone 
The use of GFP expressing human breast cancer cells provides the opportunity to track 
small cancer colonies by histological means. GFP and β‐Gal staining was performed on 
B02  tumour‐bearing  bone  sections  (kindly  provided  by  Dr  Ottewell,  University  of 
Sheffield)  as  well  as  tumour‐free  sections  to  assess  background  staining.  Negative 
controls  (isotype  control)  were  added  to  each  staining  run.  Optimised 
immunohistochemistry protocols were kindly provided by Dr Shelly Lawson (GFP) and 
Dr  Alyson  Gartland  (β‐Gal),  University  of  Sheffield. When  analysing  the  GFP  stained 
sections,  it  was  noticed  that  only  a  fraction  of  the  tumour  cells  were  GFP  positive 
suggesting that a number of B02 cells have lost their GFP expression in vivo (Fig. 3.6A), 
while β‐Gal  staining appeared  to detect more B02 cells when compared  to GFP  (Fig. 
3.6B). However not all cancer cells were stained and tumour‐free sections used as an 
additional negative control showed background staining of murine bone cells.  
Although β‐Gal  staining showed promising  results,  it  could not be carried out on  the 











Figure 3.616Comparison of GFP and β-Gal immunohistochemistry (page 101) 
Histological  bone  sections with  B02  tumour  colonies were  stained  for  A)  GFP  and  B) β‐Gal. 




GP=growth  plate,  solid  arrowhead=positive  tumour  cells.  Scale  bar=100µm,  left  panel:  10x 
objective, right panel: 40x objective. 
 
Immunohistochemical  analysis  following  staining  with  antibodies  specific  for  the 
human cytokeratin Cam5.2 were also tested for identification of human breast cancer 












Figure 3.717Cam5.2 staining of osseous bone tumours 
A)  B02  tumour  bearing  sections  were  stained  for  Cam5.2  using  an  automated  stainer.  B) 
Cam5.2  staining  on MDA‐MB‐231  cells  in  bone  using  a manual  staining  procedure  (primary 
antibody  at  1:2).  Tumour‐free  bone  sections  were  used  to  test  for  staining  of  bone  cells. 
T=tumour, BM=bone marrow, B=bone, open arrowhead=background  staining  in  tumour‐free 
bone, solid arrowhead=positive tumour cells. Scale bar=50µm, 20x objective. 
 











visualisation  of  bone  specimens  up  to  a  depth  of  500μm  in  a  3‐D  manner.  The 
technique is therefore useful for detection of small tumour colonies and single tumour 
cells within the bone marrow cavity.  
Appropriately  processed  bone  specimens  (Materials  and Methods  section  2.2.9.3.3) 
were  imaged using a Multiphoton Confocal Microscope (Zeiss LSM510 NLO Inverted). 
Tile  scans of  the metaphysis area were performed using  the multiphoton chameleon 




analysed  using  the  same  protocol  in  order  to  assess  the  detection  of  single  tumour 
cells.  Areas  showing  GFP  positive  objects  were  chosen  to  perform  z‐stack  scans  for 
further analysis. The detection of  single GFP‐positive  tumour cells  (identified by size, 
Fig. 3.8B) and a green object, which was characterised as background staining is shown 






















One  aim of  the  histological  analysis  in  this  PhD project was  to  analyse  the  effect  of 
tumour presence and anti‐cancer therapy on the bone microenvironment, in particular 
the osteoclast and osteoblast populations. Most studies carried out in our unit have so 
far  either  analysed  non‐tumour  bearing  bones  or  samples with  large  tumours  filling 
most of the marrow cavity. Since initial analysis of H&E stained samples showed that 
most  tumours  around  15  days  post  tumour  cell  injection  are  localised  around 
trabecular  spicules,  it  was  decided  to  focus  on  this  area  for  bone  cell  analysis,  and 
cortical  bone  surfaces  were  excluded.  It  was  necessary  to  address  a  number  of 
questions prior to scoring the study material. 
• Which  parameters  should  be  set  for  analysis  of  osteoclast  and  osteoblast 
identification? Due to the lack of published studies investigating osteoblasts in 









3.4.3.1 Criteria for osteoblast and osteoclast identification 
Bone histomorphometry and analysis of bone cells has been performed frequently and 
guidelines  and  nomenclature  have  been  published  by  Parfitt  et  al.  (1988).  Tartrate‐
resistant  acid  phosphatase  (TRAP)  staining  of  histological  sections  enables  the 
identification of osteoclasts as TRAP positive cells in direct contact with bone surfaces 
(Fig.  3.9).  The  identification  of  osteoblasts  is,  however,  more  difficult.  The  use  of 
undecalcified, plastic (methyl‐methacrylate) embedded sections stained for Goldner’s 
trichrome is often used for the detection of osteoid and thus the cells adjacent to the 




Mellanby  Centre  for  Bone  Research  at  the  University  of  Sheffield  has  long  standing 
expertise  in  histomorphometric  analysis  and  within  the  centre,  osteoblasts  are 
commonly identified by their distinct morphological features on TRAP or H&E stained 
sections (Corey et al., 2003; Deleu et al., 2009; Heath et al., 2009; Chantry et al., 2010; 
Mohanty  et  al.,  2010).  I  therefore  received  detailed  training  by  experienced  staff 
members of  the Mellanby Centre. Figure 3.9 gives an overview over criteria used for 







Figure 3.919Guide for identification of osteoblasts and osteoclasts 
Images  depict  TRAP  stained  sections  taken  from  paraffin  embedded  mouse  hind  legs. 




3.4.3.2 Identification of bone area used for osteoblast and osteoclast analysis 
In  order  to  assess  bone  cell  numbers  reproducibly,  analysis  of  osteoclasts  and 
osteoblasts on trabecular bone from tumour free (naïve) animals sacrificed at day 10, 
15, 19, 24 and 33 post start of the experiment (Chapter 4) was initially carried out by 








osteoclast  ratio  (Ob/Oc)  obtained  from  naïve  samples  using  the  pre‐defined  area 
compared  to  the entire  trabecular bone did not  show a  significant difference at  any 
time  point  (Fig.  3.10B),  indicating  that  bone  cells  in  a  naïve  setting  are  evenly 
distributed  along  trabecular  bone  surfaces. More detailed  analysis  of  osteoblast  and 
osteoclast  numbers  per mm  trabecular  bone  surface  by  both methods  showed  that 




When  I  later  assessed  bone  cell  numbers  in  tumour  bearing  samples  it was  noticed 
that  the  tumour  and  surrounding  bone  were  often  located  outside  the  pre‐defined 
section due to highly variable location of the tumour within the metaphysis. Since one 
of  the  aims  of  Chapter  4  was  to  assess  the  tumour‐induced  changes  on  the 








Figure 3.1020Comparison of analysis of a predefined area of trabecular bone 
compared to all trabecular bone surfaces in samples from naïve mice 
A)  Schematic  overview  of  the  analysed  areas  in  a  predefined  area  (3x3  squares  of 
250μmx250μm, 125μm away from the growth plate and 250μm away from cortical surfaces) 
and  the whole  trabecular  bone  area  (all  trabecular  bone  surfaces were  scored  except  bone 
closer  to  the  growth  plate  than  125µm).  B)  Quantitative  analysis  of  Ob/Oc  ratio,  C)  Ob 










Figure 3.1121Comparison of trabecular bone areas in naïve and tumour bearing 
mice 
A) Predefined area  (3x3  squares of 250μmx250μm, 125μm away  from  the growth plate and 
250μm away  from  cortical  surfaces)  in  a  naïve  situation  and  examples  of MDA‐MB‐231‐GFP 
tumour bearing bones. B) Inclusion of all trabecular bone surfaces in naïve and tumour bearing 
mice  represents  the  entire  area  of  bone  in  contact  and  not  in  contact  with  tumour.  C) 




3.4.3.3 Investigation of predilection of tumour growth between tibia and femur 
I furthermore assessed whether the model used in the present study had a preference 
for  a  specific  site  within  the  long  bone.  The  size  of  the  tumour  colonies  in  tibia  or 
femur  did  not  differ  in  bones  taken  10  or  33  days  after  intracardiac  tumour  cell 
injection  (Chapter  4),  suggesting  that  both  sites were  equally  susceptible  to  tumour 
growth (Fig. 3.12A). Furthermore, assessment in trabecular bone cell number in tibias 
and  femurs  showed  no  significant  difference  when  comparing  the  two  sites  (Fig. 
3.12B).  It was therefore decided to use the entire trabeculum in both the femur and 
tibia for the entire thesis, increasing sample size considerably. 







Figure 3.1222Distribution of tumour colonies and bone cell numbers in tibia and 
femur 
A) Tumour area was scored in H&E stained sections in tibias and femurs of animals sacrificed 







3.5 Discussion  





followed  by  microenvironment‐dependent  proliferation  and  finally  independent 
tumour growth. Many  in vivo models are able  to reproduce parts of  these processes 
but  at  present,  there  is  no  single model  of  breast  cancer metastases  that  is  able  to 
mimic  the  entire  human  disease  process.  Despite  this,  the  preclinical  models  are 
irreplaceable for studies aiming to unravel the steps involved in induction of metastatic 
tumour growth and progression as well  as  the mechanisms of  action and efficacy of 
therapies.  Spontaneous  tumour models  such  as  the  PyMT mouse model  involve  the 
development  of  spontaneous  mammary  tumours  and  have  been  shown  to  lead  to 
secondary  tumour  growth  at  skeletal  and  visceral  sites.  However,  spontaneous 
preclinical systems as well as the 4T1 model (syngeneic mouse model where 4T1 cells 
are  injected  into  mammy  fat  pads  which  will  develop  secondary  disease  at  sites 
including bone) may require the removal of the primary tumour, bone metastases are 
infrequent and experiments are lengthy (several months). In the present study a model 
of  bone  metastases  was  required,  with  the  possibility  to  detect  osseous  tumour 
growth as well as having a reasonable time frame between tumour cell  injection and 
the end stage of the disease (approximately 4 weeks). 
Initial  experiments  were  therefore  carried  out  using  the  B02  model,  in  which  the 
cancer cells are  introduced  into  the circulation via  the  lateral  tail artery and osseous 
tumour  growth  can  be  detected  approximately  15  days  post  cell  implantation 
(Peyruchaud et al., 2001). When reproducing the protocol used in a published study by 








Another  possibility  for  the  inability  of  some  cell  batches  to  form  osseous  tumours 
could be a change in gene expression possibly taking place during in vitro culturing. A 
study  carried out by Garcia  et  al.  (2008)  compared  the  in  vitro  transcriptome of  the 
bone seeking B02 cells to the parental MDA‐MB‐231 cells. The group showed that B02 
cells  had  114  upregulated  and  247  downregulated  genes  compared  to  the  parental 
cells  line,  underlining  the  changes  acquired  during  in  vivo  passaging.  Although  gene 
expression analysis of  the B02 cell batches used  in  the present PhD  thesis may have 
helped  to  explain  the  inability  of  some  cell  batches  to  form  tumours,  this  was  not 
within the scope of this PhD project and was therefore not performed. 
Despite  having  successfully  optimised  the  B02  model,  I  have  carried  out  all  in  vivo 
experiments presented in this PhD thesis using the intracardiac model (MDA‐MB‐231‐
GFP  cells  injected  i.c.).  Disadvantages  of  both models  are  that  the  high  cell  number 
injected  into  the  vasculature  does  not  reflect  the  metastatic  process;  the  models 
therefore  only  allow  investigation  of  the  later  steps  of metastasis. Moreover,  young 
mice (around 6 weeks of age) are commonly used in the described models Peyruchaud 
et  al.,  2001;  Garcia  et  al.,  2008;  Ottewell  et  al.,  2008a).  At  this  age,  active  bone 
turnover  takes place  in  the metaphyses of  the  long bones, which  is  the main  site of 
tumour  growth  in  this  model.  The  active  bone  remodelling  and  blood  flow 
characteristics  in  these  areas  could  possibly  determine  the  sites  as  preferential  for 
experimental  tumour  cell  homing.  Homing  of  cancer  cells  to metastatic  niches  is  an 
area  of  active  research  and  the  presence  of  metastatic  niches  has  been  suggested, 
including the vascular and the osteoblastic niche. A recent report showed that HSPCs 
(hematopoietic  stem/progenitor  cells)  homed  preferentially  to  the  metaphsyseal 
region  post  injection  and  it  was  proposed  that  the  cells  are  localised  within  an 
endosteal  niche.  The  niche was  further  characterised  as  being  in  close  proximity  to 
trabecular bone and the associated vasculature (Ellis et al., 2011). It may therefore be 
possible  that  the  endothelium,  as well  as  other  cells within  the  trabeculum,  express 
specific  molecules  involved  in  tumour  cell  adhesion,  supporting  the  initial  steps  of 
tumour  cell  homing  to  bone.  The  requirement  of  young  animals may  be  due  to  an 
increased repertoire in the factors present in a metastatic niche.  
There  is  strong evidence that cells of  the  tumour microenvironment,  including  tissue 
specific  cells,  stromal  cells,  vasculature  and  immune  cells,  play  an  important  role  in 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tumour  growth.  One  aim  of  my  PhD  thesis  was  to  determine  the  effect  of  tumour 
growth in bone following therapeutic targeting of the bone microenvironment. In the 
first in vivo experiments using the intracardiac route (Chapter 4), the presence of small 
tumour  colonies  (GFP  areas  <1mm  in  diameter) was  frequent.  The  analysis  of  these 
colonies  required a specific  series of  steps  (comprehensive GFP  imaging, embedding, 
sectioning  and  examination  of  H&E  test  slides)  to  detect  the  tumour  cells  on 
subsequent histological sections. Moreover, it was determined that the initiating steps 
of  tumour  growth  in  bone  (<10  days  post  tumour  cell  injection)  were  difficult  to 
investigate without a specific marker for tumour cell identification. GFP (MDA‐MB‐231‐
GFP and B02), β‐galactosidase (B02 only) and cytokeratin staining were therefore used 
to  investigate  their  specificity and  reliability  in detecting  tumour  cells on histological 
bone  sections. While β‐Gal was  found  to  detect  tumour  cells  reliably  problems with 
the  detection  of  single  cells  can  arise  because  of  the  endogenous  β‐Gal  expression 
found  in bone  (Kopp et al., 2007).  It  is possible  that  the GFP and β‐Gal expression  is 








One  aim  of  this  thesis  was  to  investigate  the  effects  of  different  tumour  sizes  and 
therapy on bone  cells  and  thus a method  for  comprehensive analysis of  these areas 
was required. The preferred method was found to include the analysis of all trabecular 
bone  surfaces  in  tibias  and  fermurs  due  to  the  high  variability  in  tumour  location 
within the metaphysis. Furthermore, very  limited published data are available on the 
quantification of osteoblasts  in solid tumour bearing bones and the analysis methods 
in  the  few  studies  assessing  changes  in  osteoblasts  have  used  different  techniques 
(Corey et al., 2003; Phadke et al., 2006). Table 3.2 gives an insight into the variability 
and  lack  of  consistency  between  published  studies  in  the  same  field,  making 





in multiple myeloma  bearing  animals  and  I  have  successfully  optimised  the  existing 
criteria for use in osseous breast cancer growth in nude mice. 
In summary, although the optimisation of the B02 model was successful after multiple 
















Bone metastasis  is  a  common  complication  of  advanced  breast  cancer  and  remains 
incurable. Improvement of therapies relies on increased understanding of the cellular 
and  molecular  mechanisms  underlying  bone  metastasis  formation.  However,  the 
majority of preclinical  studies have  focused on end‐stage disease and  little  is  known 
about the events taking place following initial colonisation of bone. 
I  performed  a  longitudinal  study with  5  time  points  to  characterise  osseous  tumour 
progression  and  the  effects  on  bone  integrity  following  intracardiac  inoculation  of 
MDA‐MB‐231‐GFP  breast  cancer  cells  in  immunocompromised mice.  Comprehensive 




trabecular  bone  volume  was  apparent  from  day  19  onwards.  Compared  to  that  of 
naïve control animals, areas of bone in direct contact with the tumour had significantly 
reduced osteoblast but increased osteoclast numbers. Conversely, in areas away from 
the  tumour,  numbers  of  osteoblasts  were  increased  and  osteoclast  levels  remained 
comparable  to  those  of  naïve  mice.  Analysis  of  systemic  changes  in  serum  bone 
turnover markers (PINP, CTX), RANKL, sclerostin, IL‐1, IL‐6, KC (murine IL‐8) and MCP‐1 
levels were  in  line with  the observation  that changes  to  the bone microenvironment 
where spatially confined to the tumour bearing bone. This is the first longitudinal study 
















most studies have  focused on end stage disease, with only  little  information on how 
and when  small  but  established  breast  cancer  colonies  induce  changes  in  bone  cell 
number  and distribution,  ultimately  leading  to  overt  bone destruction.  For  example, 
Clohisy  et  al.  (1996)  reported  that  intrafemoral  injection  of  MDA‐MB‐231  human 
breast  cancer cells  into balb/c nu/nu mice  resulted  in osteolytic bone disease, and a 
significant  increase  in osteoclast number, compared to sham‐injected femurs after 7‐
10 weeks. 
It  is  currently  not  possible  to  predict  which  patients  will  relapse  after  their  initial 
treatment  and  subsequently  develop  bone metastases.  Due  to  the  lack  of  biological 
markers that can be applied in routine diagnosis, bone metastases are detected once 
the tumour is established. Although there are effective therapies available to treat the 
resulting  cancer‐induced  bone  disease,  it  is  currently  not  possible  to  prevent  the 
development of bone metastases. The standard approved therapy for tumour‐induced 
osteolysis  is  zoledronic  acid,  a  nitrogen‐containing  bisphosphonate  (NBP).  The  drug 
acts  by  reducing  osteoclast  activity  via  inhibition  of  the  mevalonate  pathway  thus 





is not  sufficient  to eradicate  tumour growth  in bone  in models of multiple myeloma 









colleagues  (Phadke  et  al.,  2006),  showing  that  the  presence  of  cancer  cells  in  bone 
results  in  reduced  overall  numbers  of  both  osteoblasts  and  osteoclasts  4  weeks 
following  intracardiac tumour cell  implantation, but not at earlier time points. To my 
knowledge,  no  comprehensive  histological  analysis  has  been  carried  out  charting 
changes  in  osteoblast  and  osteoclast  numbers  associated  with  breast  tumour 
progression  in  bone.  I  have  performed  a  detailed  study  of  the  spatial  and  temporal 
changes  of  both  tumour  cells  and  bone  cells,  including  time  points  prior  to  the 
appearance  of  osteolytic  bone  disease.  The  development  of  human  breast  cancer 
growth  and  the  resulting  cancer‐induced  bone  disease  from  early  (day  10  and  15), 
intermediate (day 19 and 24) to late (day 28‐33) stage disease was characterised and 
changes  in  bone  cell  numbers  were  determined  in  detail.  The  new  information 
presented in this chapter gives insight into the early interactions between tumour cells 





In  order  to  investigate  the  longitudinal  tumour‐induced  changes  on  the  bone‐
microenvironment and the bone matrix, the following research questions were asked: 
• Can  MDA‐MB‐231‐GFP  growth  in  the  hind  legs  of  mice  be  characterised 
regarding location and viability of the tumour tissue? At which time point can 
the first tumour foci be readily detected and analysed in bone?  
• At which point does  the osseous  tumour cause measurable bone disease and 



















In  order  to  generate  bone  tumours,  MDA‐MB‐231‐GFP  cells  (1x105)  were  injected 
directly  into  the  left  heart  ventricle  of  6‐week‐old  female  balb/c  nu/nu mice  under 
general  anaesthesia  (56.5mg/kg  ketamine,  5.5mg/kg  xylazine,  in H2O).  Animals were 
randomly  grouped  into  each  of  the  5  sequential  time  points  (n=12  +  5  naïve/time 
point)  covering  early  (day  10  and  15),  intermediate  (day  19  and  24)  and  late  stage 
disease (end of protocol (EOP) including days 28‐33). The range of days in the last time 
point  was  due  to  Project  License  regulations  stipulating  sacrifice  at  first  signs  of 
morbidity  (Fig. 4.1A). Only animals with detectable bone  tumours were entered  into 
subsequent analysis. On the day of sacrifice, food supply was removed for 6 hours and 
blood was  collected  by  intracardiac  puncture  under  deep  non‐recovery  anaesthesia. 
Serum  was  stored  at  ‐80˚C  and  hind  legs  were  fixed  in  4%  PFA  for  72  hours  and 
scanned  by  μCT.  Subsequently,  the  bones  were  decalcified  before  embedding  in 
paraffin wax. 
In the subcutaneous tumour study, MDA‐MB‐231‐GFP cells (5x105) were injected into 
the right  flank of  female balb/c nude mice  (6 weeks). Tumour bearing mice  (n=3 per 
time point) and naïve mice (n=2 per time point) were sacrificed on days comparable to 
the  bone  experiment  including  days  15,  24  and  33  post  tumour  cell  injection  (Fig. 
4.1B). On day of sacrifice, hind legs were fixed in 10% buffered formalin for subsequent 












Following  s.c.  injection  of  5×105  MDA‐MB‐231‐GFP  tumour  cells  on  day  0,  animals 





was  carried  out  using  a  Leica  BMRB  upright  microscope  with  a  4x  objective  and 
Osteomeasure  software.  Tumour  area  (expressed  as %  intraosseous  tumour  area  of 
metaphyseal  bone  area)  was measured  by  drawing  around  the  inner  surface  of  the 
bone marrow  cavity  in  the metaphysis  (defined  as  a maximum of  4x4  fields  of  view 
from the top of the growth plate towards the diaphysis) as well as the tumour area in 
this region. 2‐3 non‐serial histological sections per sample were scored.  
For  measurement  of  subcutaneous  MDA‐MB‐231  tumours,  the  diameter  was 






To  allow  quantification  of  Ob  (osteoblast)  and Oc  (osteoclast)  numbers  in  the  same 
sample,  both  cell  types  were  scored  on  Tartrate‐resistant  acid  phosphatase  stained 
(TRAP,  osteoclast  specific)  sections.  The  number  of  TRAP  positive  osteoclasts  per 
millimetre trabecular bone surface was scored using a Leica RMRB upright microscope 






















murine  bone  remodelling  markers  CTX  and  PINP  were  measured  as  well  as  human 
sclerostin and mouse RANKL levels. Details on suppliers and methods can be found in 
the  general  Materials  and  Methods  section  2.2.1.6.  Serum  was  also  used  for  CBA 
analysis of murine IL‐1α, IL‐1β, IL‐6, KC (IL‐8) and MCP‐1. The CBA protocol was carried 





Prism 7900HT Sequence Detection System and FAM  labelled probes  (species  specific 
TaqMan® assays, page 50).  
4.4.6 Statistical analysis 







I  performed  a  comprehensive  study  of  breast  tumour  growth  in  bone  investigating 
tumour  cell‐bone  cell  interactions  from  early  (day  10‐15  following  tumour  cell 
injection)  to  intermediate  (day  19  and  24)  and  end‐stage  disease  (day  28‐33=EOP, 
n=12 mice per time point). All time points included 5 naïve mice in order to compare 
tumour  bearing  to  non‐tumour  bearing  bone  and  to  be  able  to  distinguish  between 
tumour‐induced and age‐related changes to  the skeleton. A range of  techniques was 
used to assess bone integrity, tumour area, bone‐tumour cell interactions, and serum 
markers  of  bone  turnover  and  cytokines  at  each  time  point.  In  addition  to 
characterising the effects on osteoclasts,  I  focused on the analysis of osteoblasts due 
to the  lack of  information regarding their role  in breast cancer‐induced bone disease 
from in vivo studies. The subcutaneous in vivo experiment was set up in order to assess 
the  effects  of  peripheral  tumours  on  systemic  bone  turnover.  In  addition,  the  study 
allowed comparison between changes in systemic cytokine levels and gene expression 
in animals with tumour growth at different sites (in vitro compared to in vivo, including 









4.5.1.1 Characterisation of osseous tumour burden  
MDA‐MB‐231‐GFP cell growth in  long bones was  identified by GFP imaging on day of 
sacrifice  (Fig.  4.3A)  and  examples  of  tumour  foci  in  bone  are  depicted  on  images  of 
Goldner’s  trichrome  stained  sections  (Fig.  4.3B). When  analysing  the  distribution  of 






Quantification  of  tumour  area  in  the  metaphysis  was  performed  on  histological 
sections of tibias and femurs in which tumour growth had been confirmed by GFP. In 
specimens  taken  from  day  10  to  EOP,  the  percentage  of  the  bone  marrow  cavity 
occupied  by  tumour  tissue  increased  steadily  with  time  (Fig.  4.5A).  In  order  to 
investigate  tumour  viability  at  each  point  I  performed  Ki67  immunohistochemistry, 
which allows the quantification of actively proliferating cells (Fig. 4.5B). The number of 
Ki67 positive cells remained near constant throughout the different stages of tumour 






Figure 4.325Imaging of longitudinal breast tumour growth in bone 
A)  In vivo GFP  imaging of skin and muscle stripped hind  legs confirmed tumour growth  in all 






















24  n=9,  EOP  n=6.  A  minimum  of  2  non‐serial  sections  per  sample  was  analysed.  B) 
Quantification of Ki67 positive (proliferating) tumour cells. A minimum of 2 non‐serial sections 
were analysed per sample. Kruskal‐Wallis and Dunn’s post‐test, ns=not significant. C) Example 






4.5.1.2 Development of osteolytic bone disease 
While  it  is  well  known  that  breast  cancer  metastases  to  bone  are  the  cause  of 
osteolytic  bone  disease,  it  may  be  important  to  identify  the  exact  stage  at  which 
cancer  cells  initiate  bone  destruction  in  order  to  successfully  treat  and  ultimately 
prevent  it.  When  analysing  μCT  cross  sections  of  hind  legs,  overt  osteolytic  lesions 
were apparent in 100% of tumour bearing mice from day 19 onwards. Example images 
of  μCT  radiographs  and  cross  sections  are  shown  in  Figure  4.6.  The  presence  of 
osteolytic lesions is currently used as a clinical indication for metastatic bone disease. 
However,  tumour  cells  may  lodge  onto  or  close  to  trabecular  bone  surfaces  and 
establish  here  before  affecting  the  cortical  bone  area.  In  order  to  analyse  the more 
detailed  effect  of  longitudinal  breast  cancer  growth  on  trabecular  bone  destruction, 
μCT analysis of trabecular bone in the proximal femur and distal tibia was performed. 
MDA‐MB‐231‐GFP  tumour  cell  growth  reduced  trabecular  bone  volume  (bone 
volume/tissue volume, % BV/TV) from day 19 onwards compared to the bone volume 
in naïve mice, with a significant reduction on day 24 (5.51% vs. 11.67%, p<0.001) and 
at  EOP  (3.41%  vs.  12.1%,  p<0.001.,  Fig.  4.7).  The  data  indicate  that  smaller  tumour 










bearing  (opposite)  legs compared  to naïve mice at any  time point. Together  the μCT 



























































































































































































































































































































































































































































































































































































4.5.1.3 Bone cell distribution changes with increasing tumour burden 
After  having  established  the  time  frame  in  which  tumour  cells  induce  a  detectable 
reduction in trabecular bone volume I next carried out comprehensive analysis of the 




osteoclasts  in  trabecular  bone  from  breast  cancer  bearing  compared  to  naïve mice. 
Interestingly,  the  total  number of  resorbing  cells  increased  from day  19 onwards,  in 
line  with  the  reduction  in  trabecular  bone  volume  detected  by  μCT.  Osteoclast 
numbers  were  significantly  higher  than  in  naïve  controls  on  day  19  (5.8  vs.  4.98, 
p<0.05) and on day 24 (4.48 vs. 6.02, p<0.01, Fig. 4.8A). When analysing the effects of 
the  tumour  on  the  total  number  of  osteoblasts,  the  most  profound  changes  were 
shown  to  be  taking  place  before  trabecular  bone  destruction  was  apparent,  with  a 
significant  increase  in  total  osteoblast  numbers  per  mm  bone  surface  compared  to 
non‐tumour  bearing  mice  on  day  15  (13.48  vs.  7.39,  p<0.001,  Fig.  4.8B).  At  earlier 
stages of disease (10 days post tumour inoculation) there was no significant difference 

















showed  that  the  cell  populations were maintained  at  a  constant  level  (ranging  from 
1.38  to  1.61)  throughout  the  duration  of  the  experiment.  In  early  stages  the Ob/Oc 
ratio of tumour bearing animals was higher compared to naïve mice with a significant 
increase on day 15 (2.96 vs. 1.38, p<0.001, Fig. 4.8C). As expected, corresponding with 
the  onset  of  osteolytic  bone  disease  the  Ob/Oc  ratio  dropped  at  the  end  of  the 
protocol  below  that  of  naïve  mice  (0.51  vs.  1.47,  p<0.01),  mainly  driven  by  a 
substantial reduction in osteoblast numbers. 
Taken  together,  the  results  show  that breast  tumour  foci  in bone have a  substantial 
effect  on  total  osteoblast  numbers  15  days  after  tumour  cell  injection,  before  the 
entire osteoclast population on trabecular bone increases and osteolytic bone disease 
is detected by μCT.  
4.5.1.4 Analysis of serum bone remodelling markers PINP and CTX 






to  tumour  bearing  animals  no  difference was  detected.  The  data  do  not  reflect  the 
elevated  Ob  numbers  found  at  day  15  or  the  sharp  reduction  at  the  end  of  the 
protocol.  In  addition,  I  performed  quantitative  analysis  on  CTX  (carboxy‐terminal 
collagen crosslinks) serum levels, a marker for bone resorption, on a subset of samples 
from  the  study.  Although  overt  formation  of  osteolytic  lesions  and  reduction  of 
trabecular bone volume could be detected at the later stages of this study, I could not 
observe  any  changes  in  CTX  levels  (Fig.  4.9B),  leading  to  exclusion  of  the  assay  for 
further samples in the study.  
The data therefore suggest that systemic measurements of serum markers may not be 
sensitive  enough  to  detect  local  (in  the  tumour  affected bone)  changes  of  bone  cell 
activity  or,  that  in  the  case  of  PINP  the  osteoblasts  are  inactive.  A  better 









n=9  day  15,  n=8  day  19,  n=10  day  24  and  n=6  EOP.  Five  naïve  mice  per  time  point  were 







4.5.1.5 Osteoblast and osteoclast numbers change according to their proximity to the 
tumour  
As  the μCT  analysis  indicated  that  the  tumour  initiated  local  (in  the  tumour  bearing 
bone)  bone  destruction;  I  further  investigated  whether  or  not  the  changes  in 
osteoblast  and  osteoclast  numbers  were  dependent  on  direct  cancer  cell‐bone  cell 
contact. To do this, two location‐dependent categories of bone cells in tumour bearing 
bones  were  scored:  Category  1)  osteoclasts  or  osteoblasts  in  direct  contact  with 
tumour cells, and category 2) osteoclasts or osteoblasts not in direct contact with the 
tumour  (Fig.  4.2).  Quantification  of  osteoclast  numbers  in  these  two  categories 
revealed a  clear differential  effect of  the  tumour depending on  the proximity  to  the 
cancer cells. Osteoclast numbers in direct contact with tumour cells (category 1) where 







Intriguingly,  analysis  showed  that  the  presence  of  tumour  colonies  had  the  exact 
opposite effect on the two location dependent categories of bone forming osteoblasts. 




4.10B).  From day  10  onwards  a  reduction  in  osteoblast  numbers  of  category  2) was 









Figure  4.1032The  proximity  to  tumour  cells  determines  changes  in  osteoblast  and 
osteoclast numbers 
Quantitative results for location dependent A) osteoclast and B) osteoblast numbers in tumour 















4.5.2.1 Investigation of changes in serum RANKL and sclerostin levels 
Osteoclastogenesis and activity is greatly regulated through the RANK, RANKL and OPG 
pathway.  The  increase  in  osteoclast  numbers  detected  at  day  19 may  therefore  be 
connected to the earlier increase in osteoblast numbers on day 15. The activity of the 
bone  forming  cells  was  therefore  investigated  by  serum  RANKL  measurements,  an 



















importance  of  the Wnt‐pathway  on  osteoblast  differentiation  I  aimed  to  investigate 
the  serum  levels  of  the  Wnt‐inhibitor  sclerostin,  a  molecule  known  to  inhibit 
osteoblast formation. Mendoza‐Villanueva et al. (2011) have shown that MDA‐MB‐231 
cells  produce  sclerostin  in  vitro  leading  to  inhibition of  osteoblast  differentiation. As 
the  changes  in  bone  cell  numbers  were  induced  by  the  presence  of  tumour  cells,  I 
measured  tumour  cell‐derived  sclerostin  levels  in mouse  serum  by  ELISA  specific  to 
















The  systemic measurement  in murine RANKL  and human  sclerostin  levels  show  that 
concentrations of these molecules do not change in the circulation of tumour bearing 
vs. naïve mice. The data therefore suggest that cell‐cell contact and local changes (in 
the  tumour  bearing  bone)  to  the  microenvironment  are  more  important  for  the 
changes  seen  in  bone  cell  numbers.  The  results  agree  with  the  μCT  and 
histomorphometry  data  showing  that  the  tumour  has  no  effect  on,  for  example  the 
opposite, tumour‐free leg.  
4.5.2.2 Investigation of tumour-induced changes on host cytokine levels (species specific) 
Several  cytokines were  shown  to  be  involved  in  the  induction  of  osteoclastogenesis 
and activity  including the osteoblast and stromal cell derived murine cytokines  IL‐1α, 
IL‐1β,  IL‐6,  KC  (mouse  IL‐8)  and  MCP‐1.  In  order  to  investigate  if  the  increase  in 
osteoblast numbers at day 15 and 19 was linked to an increase in osteoclast activating 
cytokines released by the host stroma, serum levels were analysed by cytometric bead 
array. Measurements of  IL‐1α and  IL‐1β were below detection  level  (below 10pg/ml) 
and showed no difference between naïve and  tumour bearing bones  (Fig. 4.14A and 
B).  Although  the  detection  of  IL‐6  was  too  low  to  draw  meaningful  conclusions, 
tumour‐bearing  animals  appeared  to  express  more  IL‐6  compared  to  naïve  animals 
from day 19 onwards (Fig. 4.14C). No significant changes between tumour bearing and 












Figure  4.1436Measurement  of  host  serum  cytokine  levels  by  CBA  in  animals  with 
osseous tumour growth 












than  small  osteoclasts  (<5  nuclei)  (Trebec  et  al.,  2007).  Since  the  quantification  of 
nuclei on histological sections is difficult, I compared mean osteoclast area (measured 
in mm2) of tumour bearing mice to the cell size of naïve animals. Two time points were 
chosen  for  analysis,  day  15  and  19,  due  to  the  first  detectable  changes  in  bone  cell 
numbers and μCT results on these days.  In  line with  the decrease  in trabecular bone 




direct  contact with  cancer  cells.  This  revealed  that  the  increase  in  osteoclast  size  in 
tumour bearing mice was due  to  large osteoclasts  in direct  contact with  the  tumour 
cells (Fig. 4.15B). Osteoclasts in contact with tumour had a mean size of 3.3x10‐4mm2 
compared  to  those  distal  to  the  tumour with  1.3x10‐4mm2  on  day  15  (p<0.001)  and 
3.3x10‐4mm2 compared  to 1.5x10‐4mm2 on day 19  (p<0.001).  The TRAP positive  cells 
away from the tumour were shown to be of a similar size as in naïve animals. The data 










animals  differentiating  between  Ocs  in  direct  contact  with  tumour  cells  and  NOT  in  direct 
contact with  the  tumour. Mann‐Whitney  test  for  each  time  point  separately,  *  p<0.05,  *** 
p<0.001.  C)  Example  images  of  TRAP  sections  for  1)  naïve mice,  2)  not  in  contact  and  3)  in 
contact with  tumour  (20x objective, * Oc  (red), B=bone, BM=bone marrow, T=tumour,  scale 
bar=50µm. 
 
4.5.3.2 Analysis of tumour gene expression (species specific analysis to human genes) 
The complexity of the tumour and the surrounding microenvironment is partly shown 
in the analysis so far described in this chapter. In order to further decipher the effects 
tumour  cells  may  have  on  the  microenvironment,  I  have  assessed  changes  in  gene 
expression of a number of bone‐related genes of MDA‐MB‐231‐GFP cells grown in vitro 
and  in  vivo  at  a  subcutaneous  site  (Fig.  4.1B)  and  of  tumours  growing  in  bone  post 
intracardiac  injection  (sacrificed  23  days  post  tumour  cell  injection).  The  aim  of  the 
gene  expression  analysis  was  to  assess  whether  the  tumour  produces  bone  related 
molecules,  possibly  explaining  the  tumour‐induced  changes  in  bone  cells.  Species 
specificity  of  the  used  TaqMan®  assays  to  human  genes  only  has  previously  been 
assessed  in  the  laboratory  (page  50).  Genes  of  interest  were  the  inhibitors  of 
osteoblast  differentiation DKK1, DKK2  and  SFRP1;  the RANKL decoy‐receptor OPG  (a 
negative  regulator  of  bone  resorption);  the  osteoclast  enhancing  proteins  RANKL, 
RANK and GMCSF as well as the tumour suppressor DKK3 (Table 4.1). When assessing 
the gene expression pattern of subcutaneous tumours taken on different time points 
post  tumour  cell  injection  including  day  15,  23  and  33  no  significant  changes  were 
detected (Table 4.2). SFRP2, SDF1 and CXCR4 were not detectable at any investigated 























Gene  ∆CT day 15  ∆CT day 23  ∆CT EOP (day 33)  P value 
DKK1  7.66 ± 0.16   7.94 ± 0.11  8.00 ± 0.14  0.3340 
DKK2  13.69 ± 0.41  13.96 ± 0.53  14.95 ± 0.69  0.3119 
DKK3  19.97± 0.24  19.54 ± 0.76  19.78 ± 0.74  0.8501 
SFRP1  15.75± 0.56  16.21 ± 0.91  16.12 ± 1.21  0.9147 
OPG  7.39± 0.46  6.79 ± 0.13  7.26 ± 0.34  0.5940 
RANK  11.25± 0.35  11.65 ± 0.11  11.33 ± 0.08  0.5597 
GMCSF  6.55± 0.16  6.69 ± 0.24  6.57 ± 0.53  0.9710 
Table 4.26Gene expression of bone related genes in subcutaneous tumours 






Next,  MDA‐MB‐231‐GFP  cells  grown  in  vitro  as  well  as  osseous  and  subcutaneous 
tumours  were  analysed  for  changes  in  gene  expression  to  assess  whether  the  site‐
specific  environment  alters  tumour  gene  expression.  Analysis  of  DKK2  and  RANK 
showed no significant change when comparing the in vitro to the in vivo samples (Fig. 
4.16).  Furthermore,  OPG  and  GMCSF  were  significantly  increased  in  both  the 
subcutaneous  and  the osseous  tumour  samples  compared  to  cell  culture  conditions. 
However,  no differences were  found between  the  two  in  vivo  sites. When analysing 
the  Wnt‐pathway  antagonists  DKK1  and  SFRP1,  a  significant  increase  in  gene 
expression  relative  to  GapdH  was  detected  in  bone  compared  to  subcutaneous 












real  time  PCR  analysis  was  performed  using  TaqMan®  assays.  Data  are  expressed  as  the 
relative  expression of  the  gene of  interest  to GapdH  (2^‐(ΔΔCT) with ΔΔCT=ΔCTin  vivo  –  ΔCTin 
vitro). Mean±SEM, one way ANOVA and Tuckey post test, * = vs.  in vitro, ^ = vs. s.c., ND = not 




significant  changes  to  bone  related  gene  expression  patterns  of  MDA‐MB‐231‐GFP 
cells.  Importantly,  the  site‐specific  increase  in  gene  expression  of  the  osteoblast 
inhibitors DKK1 and SFRP1 and osteoclast activator RANKL  in bone  tumours  (day 23) 







It  is  well  established  that  breast  tumour  growth  in  bone  severely  affects  bone 
remodelling; however, it is unclear whether the same tumour cells are able to induce 
changes  to  the  bone when  located  at  a  peripheral  site.  I  therefore  investigated  the 
effects  of  subcutaneous MDA‐MB‐231  tumour  growth  on  bone  integrity  and  serum 
cytokine  levels.  The  sizes of  the  subcutaneous  tumours used  in  this experiment  (day 
23‐33) were comparable to the ones found in bone at EOP.  
4.5.4.1 Bone integrity is not affected by peripheral breast tumour colonies  




Analysis  of  the  proximal  tibia  and  distal  femur  by  μCT  showed  that  trabecular  bone 
volume per tissue volume, trabecular number and thickness were all unchanged when 
comparing  bones  from  tumour  bearing mice  to  those  of  age matched  naïve  control 
mice  (Fig.  4.17B‐D).  The  data  strongly  suggest  that  the  presence  of  a  tumour  at  a 








A) Subcutaneous MDA‐MB‐231‐GFP  tumours were measured by  calliper. Analysis of  left  and 





4.5.4.2 Effects of peripheral breast tumour growth on serum host cytokine levels (species 













The data  suggest  that  subcutaneous  tumour  growth does  reduce  the  serum  level  of 
MCP‐1 compared to  tumour‐free mice significantly but has  little effect on other pro‐















with  different  stages  of  bone  metastasis,  investigating  the  temporal  and  spatial 
relationship  between  breast  cancer  cells,  osteoblasts  and  osteoclasts  in  the  bone 
microenvironment.  The  increase  in  tumour burden  from day  10 until  day  28‐33 was 
accompanied by a statistically significant decrease in trabecular bone volume from day 




cancer‐induced bone destruction  is a  localised process mainly affecting  trabeculae  in 
direct contact or in close proximity (in the tumour bearing bone) to the tumour colony. 
This  is  in agreement with a study undertaken by Clohisy et al.  (1996b), where breast 
cancer‐induced  bone  disease  was  shown  to  form  focal  lesions  rather  than  systemic 
bone disease.  
Detailed  analysis  of  total  osteoclast  numbers  (regardless  of  their  proximity  to  the 
tumour) showed a significant increase from day 19 onwards compared to tumour‐free 
bones,  the  same  time  point  at  which  trabecular  bone  was  reduced  and  osteolytic 
lesions were detected in 100% of tumour bearing mice. Analysis of earlier time points 
(day  10  and  15)  revealed  that  there  was  no  change  in  total  osteoclast  numbers, 
suggesting that small tumour colonies have no significant effect on the total number of 
osteoclasts. Clohisy et al. (1996a) have investigated the changes in osteoclast numbers 
after  intrafemural  injection  of  the  osteosarcoma  cell  line  2472  into  C3H/He  mice, 
showing that osteoclast numbers increased from 6 to 9 days post tumour cell injection 
compared  to  sham  injected  bones. However,  osteoclast  numbers  dropped  at  a  later 




In  contrast  to  the  current  perception  of  breast  cancer‐induced  bone  disease,  the 











cancer  cell  line  MCF‐7  with  mouse  marrow  cells  is  only  capable  of  inducing 
osteoclastogenesis when osteoblasts were  present  (Thomas  et  al.,  1999).  Although  I 
could  detect major  changes  in  the  numbers  and  ratios  of  bone  cells  during  tumour 
progression,  the bone forming or  resorbing activity of  these cells  is ultimately key to 
determining  the downstream biological  effect. Measurements of PINP  indicated  that 





Since  breast  cancer  colonies  in  bone  had  a  significant  effect  on  total  bone  cell 
numbers,  I  next  investigated  if  direct  contact  between  bone  and  tumour  cells  was 
required  to  initiate  these  changes.  In  this  respect  it  is  noteworthy  that  the  spatial 






the focal  induction of osteolytic bone disease.  In published studies this  local tumour‐
effect  is  not  taken  into  consideration  and  only  the  overall  number  of  osteoclasts  is 
investigated (Phadke et al., 2006; Chantry et al., 2010). Based on the present results it 
may  therefore  be  important  to  distinguish  between  the  proximity  of  bone  cells  to 
tumour cells, especially in the increasingly relevant studies of early metastatic events. 




osteoblast  numbers  present  in  bone  away  from  the  tumour.  The  tumour  therefore 
appears  to  have  a  localised  effect  but  also  modifies  more  distal  areas  of  the  same 
tumour  bearing  bone,  indicating  the  involvement  of  soluble  as  well  as  surface 
molecules. However, it is not clear if these changes occurred due to tumour‐mediated 
factors  or  if  they  are  initiated  as  a  downstream  effect  of  the  local  cancer‐induced 
changes  in bone  turnover.  The differential  expression of  anti‐osteoblastic molecules, 
including  DKK‐1  and  noggin,  by  osteolytic  but  not  osteoblastic  cancer  cell  lines  has 
been reported by Schwaninger et al. (2007) indicating that tumour cells can also affect 
osteoblasts directly, thus enhancing the bone destructive nature of the tumour.   
I  further  aimed  to  assess  this  question  by  analysing  selected  soluble  murine  and 
human  molecules  as  well  as  more  local  effects  of  the  tumour  on  the 
microenvironment.  When  aiming  to  investigate  whether  soluble  factors  (RANKL, 
sclerostin)  on  a  systemic  level  could  be  responsible  for  the  changes  in  bone  cell 
number, the data was in agreement with the μCT data showing that the tumour has a 
localised,  not  a  systemic  effect.  In  vitro  studies  have  investigated  the  molecular 
pathways  involved  in  cancer  cell‐bone  cell  interactions  by  measuring  effects  on 
secreted  molecules.  Kinder  et  al.  (2008)  assessed  whether  osteoblasts  produce  a 
specific  range  of  osteoclast  activating  cytokines  after  stimulation with MDA‐MB‐231 
breast cancer cells. When osteoblast cultures were treated with conditioned medium 
taken from MDA‐MB‐231 cells or when co‐cultured with the breast cancer cell line, an 
inflammatory  stress  response  of  the  osteoblasts  was  detected.  MDA‐MB‐231  cells 
induced an  increased expression of osteoblastic  IL‐6,  IL‐8 and MCP‐1, molecules  that 
have  been  previously  shown  to  activate  osteoclasts.  I  have  therefore  analysed  the 
effect  of  osseous  tumour  growth  on  the murine  cytokines  IL‐1α,  IL‐1β,  IL‐6,  KC  and 
MCP‐1, but no statistically significant differences were found. 
Since none of the above discussed soluble factors appeared to be responsible for the 




from  the  tumour,  suggesting  direct  effects  of  the  tumour  on  the  osteoclasts.  In 
159 
 
addition,  gene  expression  levels  of  bone  related  genes  were  analysed  in  osseous 
tumours, which were  compared  to  subcutaneous  and  in  vitro  samples.  The elevated 
DKK1 and SFRP1  levels  in  the osseous  tumour samples could explain  the decrease  in 
osteoblast number and  the associated  increase  in osteolytic bone disease at day 23. 
The data support a recent finding by Secondini et al. (2011) who reported a reduction 
in  bone  formation  as  well  as  resorption  after  intraosseous  implantation  of  the 
osteolytic prostate cancer cell line PC3. Interestingly, the anti‐osteoblastic effect could 
be inhibited when noggin‐silenced cells were used. SFRP1 is a soluble antagonist of the 
Wnt pathway and has  recently been associated with reduced bone  formation  in vivo 
(Yao  et  al.,  2010). MDA‐MB‐231‐GFP  cells  growing  in  bone may  therefore  have  the 
ability to further deregulate normal bone remodelling processes. In addition, the sharp 
upregulation  of  tumour  RANKL  could  explain  the  local  effect  on  osteoclast  numbers 
but should be investigated in more detail.  







435  cells were  used,  the  precise  origin  of which  has  been  the  subject  of  conflicting 





were  unchanged  2 weeks  post  cancer  cell  injection  compared  to  day  0,  but  no  age‐
matched  naïve  animals  were  used  for  comparison.  In  line  with  my  study,  further 
growth of  the  tumour up  to 4 weeks  reduced Ob numbers dramatically  (p<0.001 vs. 






to  affect  bone  turnover.  Taken  together,  the  data  obtained  from  the  subcutaneous 
tumour study supported the results obtained from the bone study suggesting that only 




on osteoblasts  and osteoclasts  takes place prior  to  the  formation of overt osteolytic 
bone disease, and that the extent of these depend on the degree of contact between 
bone  and  tumour  cells.  In  support  of  this  was  the  finding  that  bone  integrity  was 
unaffected  by  tumour  growth  in  the  opposite  leg  or  at  a  peripheral  site.  Our  data 
therefore  suggest  that  the  effects  on  bone  cells  are  of  a  localised  nature  and  that 













to  the  standard  anti‐cancer  therapy.  In  vitro  and  in  vivo  studies  have  reported 
synergistic  anti‐tumour  effects  after  administration  of  the  chemotherapeutic  agent 
doxorubicin followed 24 hours later by the bisphosphonate zoledronic acid. However, 
the  effects  of  the  sequence‐  and  schedule‐dependent  combination  treatment 




24 hours  later  by  zoledronic  acid,  in  a mouse model  of  breast  cancer metastases  to 
bone. Tumour size and bone integrity were investigated at two separate time points, 
15 and 23 days after tumour cell injection. Direct effects on the tumour were assessed 
by  quantification  of  apoptotic  and  proliferating  cells  and  changes  in  expression  of 
genes  implicated  in  apoptosis,  proliferation  and  bone  turnover.  Effects  on  the  bone 




single  agents  and  PBS  control.  The  combination  treatment  induced  an  increase  in 
apoptotic  tumour  cells  as  well  as  substantial  changes  in  osteoblast  and  osteoclast 









Metastatic  breast  cancer  is  currently  incurable  and  patients  with  diagnosed  bone 
metastases  often  only  receive  palliative  treatment  like  radiation  therapy  and 
bisphosphonates  (BPs).  In  addition  to  their  well‐established  anti‐resorptive  activities 




affect  every  cell  type  through  the  inhibition  of  the  ubiquitous mevalonate  pathway 
ultimately leading to apoptosis. Several in vitro (Neville‐Webbe et al., 2002) and in vivo 
(Brown et al., 2009) studies have shown beneficial effects of BPs alone or in addition to 
standard  therapy,  of  a  variety  of  tumours  in  and  outside  bone.  A  comprehensive 
comparison of  the  bone  studies  suggests  that  improved outcome  could  be obtained 
with an earlier BP treatment schedule than that currently in place for metastatic bone 
disease  (Brown  et  al.,  2009).  The  results  from  Chapter  4  are  in  line  with  this 
observation,  showing  that  even  small  tumour  colonies  induce major  changes  to  the 
microenvironment  before  overt  osteolysis  is  detected.  Early  intervention  may 
therefore  be  necessary  to  inhibit  homing  and  growth  of  the  tumour  cells  at  the 
metastatic site. 
The  clinical  relevance  of  bisphosphonates  as  anti‐cancer  agents  has  been  subject  to 




the  majority  of  reports  observing  anti‐tumour  effects  and  few  reporting  either  no 
effect or increased cancer cell growth. Despite the inconsistent reports of the benefits 








several  in  vivo  studies have  investigated  the  activity  of  the  sequence‐  and  schedule‐
dependent  treatment of  doxorubicin  followed 24 hours  later with  zoledronic  acid. A 
dosing regimen of weekly injections for a total of 6 weeks induced significant reduction 
in s.c. MDA‐MB‐436 xenografts (Ottewell et al., 2008b; Ottewell et al., 2010), osseous 
breast  tumours  (Ottewell  et  al.,  2009)  and  inhibited  spontaneous  development  of 
mouse mammary  tumours  (Ottewell  et  al.,  2011). However,  the  clinical  relevance of 
these  studies  is  debatable  since  patients  currently  receive  zoledronic  acid  only  once 
every 3‐4 weeks compared  to  the 6 weekly doses and agents are given on  the same 




overview  of  the  previously  performed  studies  using  the  sequence‐  and  schedule‐



































































        n.a.  n.a. 
Table  5.17Overview of  in  vivo  studies  using  combination  therapy with  doxorubicin 
followed by zoledronic acid 
The  table  summarises  the  effects  of  combination  therapy  compared  to  vehicle  control  on 
tumour (size, proliferation, apoptosis) and bone (bone volume, osteoclast (Oc) and osteoblast 
(Ob)  number  on  trabecular  bone)  for  each  study.  Note  the  lack  of  investigation  into  the 
indirect treatment effects on bone cell (n.a=not analysed).  
 
The  here  presented  study  investigated  whether  early  administration  of  a  single, 
clinically  achievable  dose  of  zoledronic  acid  in  combination  with  doxorubicin  is 
sufficient to reduce breast tumour growth inside and outside the bone marrow cavity 
of  immunocompromised mice.  Treatment‐induced  effects  on  tumour  and  bone  cells 
were analysed in detail. To do this, the experiment was terminated at day 15 and 23, 







5.3 Aims  
The main aims of the here presented chapter were as follows: 




(osteoblasts  and  osteoclasts)  and/or  is  the  tumour  affected  (apoptosis, 
proliferation) at the assessed time points? 
• Are  systemic  changes  in  pro‐inflammatory  cytokine  levels  affected  by  the 
treatment and are these connected to any changes in tumour growth and bone 
cell numbers? 
• Can  tumour  colonies  in  bones  of  treated  mice  be  used  for  gene  expression 










To  assess  the  effects  of  treatment  on  bone  cell  numbers  in  a  non‐tumour  bearing 
environment,  animals  that  had  not  developed  tumours  following  injection with  B02 
cells  (Chapter  3)  were  used.  A  total  number  of  24  non‐tumour  bearing  animals 
(n=3/treatment  group)  that  had  received  1)  PBS,  2)  doxorubicin  (2mg/kg  i.v.),  3) 
zoledronic  acid  (100μg/kg  s.c.)  and  4)  doxorubicin  followed  24  hours  later  with 
zoledronic acid at day 2 were sacrificed on day 10 or 15. Hind legs were collected and 
processed for histology. An overview of the experiment outline is shown in Figure 5.1. 















n=10  per  treatment  group  on  day  23. MDA‐MB‐231‐GFP  cells  (1x105)  were  injected 
directly  into  the  left  heart  ventricle  of  6‐week‐old  female  balb/c  nu/nu mice  under 
general anaesthesia. Animals were randomly grouped into 4 treatment groups: 1) PBS, 
2)  doxorubicin  (2mg/kg  i.v.),  3)  zoledronic  acid  (100μg/kg  s.c.)  and  4)  doxorubicin 
followed  24  hours  later  with  zoledronic  acid.  Treatment  was  initiated  2  days  post 
tumour  cell  injection  (Fig.  5.2).  Food was  removed  on  day  of  sacrifice  for  at  least  6 
hours  and  blood  was  collected  under  deep  non‐recovery  anaesthesia.  For  mice 
sacrificed on day 15, hind legs were scanned by μCT and then processed for histology. 
On day 23, right hind legs were processed as above while bone marrow and tumours 




Figure  5.242Study  protocol  of  experiments  assessing  treatment‐effects  on  tumour 
bearing bones 



































PBS  8  6  7  7  7  7  3  8 
Dox  6  6  5  5  5  6  3  6 
Zol  8  6  8  8  8  7  3  8 



























PBS  7  3  7  6  7  6  7  7 
Dox  5  3  5  3  3  3  5  5 
Zol  5  3  5  5  5  5  5  5 













serial  sections per  tumour sample were stained  for BrdU (day 15), Ki67  (day 23) and 
caspase‐3 (day 15 and 23). The number of DAB positive cells per mm2 tumour area was 
scored using a Leica BMRB upright microscope and Osteomeasure software with a 10x 
objective.  Intra‐  and  extraosseous  tumour  areas  were  scored  separately.  Note  that 












Core  Facility,  University  of  Sheffield  and  to  the manufacturer’s  instructions  and  the 
assay was shown to be species specific for detection of mouse cytokines.  
5.4.5 Gene expression analysis by qRT‐PCR 
The  TaqMan®  PreAmp  Cells‐to‐CTTM  Kit  (Applied  Biosystems)  was  used  for  sample 
preparation prior to qRT‐PCR analysis on individual gene products using the ABI Prism 
7900HT  Sequence  Detection  System  and  FAM  labelled  probes  (species  specific 




Prism GraphPad  (Version 5.0a) was used  for all  statistical analysis. Analysis was by  t‐
test or one‐way ANOVA followed by Tuckey post‐test. The applied test is  indicated in 





The present  study  investigated  the effect of  a  clinically  relevant dose of doxorubicin 
administered  24  hours  before  zoledronic  acid  on  breast  tumour  growth  in  bone.  In 
addition  to  the  assessment  of  tumour  size  and  bone  integrity,  the  effects  of  the 

















tumour  cell  injection  significantly  increased  trabecular  bone  volume  at  both 
investigated time points when compared to PBS or single agents (zol 29.24% and dox 
then zol 22.43% vs. PBS 8.4%, both p<0.001 on day 15;  zol 28.09% and dox  then zol 
32.39% vs.  PBS 6.1%, both p<0.001 on day 23,  Fig.  5.4A).  It was  furthermore  shown 
that  doxorubicin  did  not  reduce  trabecular  bone  volume  when  compared  to  PBS 



























Previous  in  vivo  studies  have  shown  that  doxorubicin  followed  24  hours  later  by 
zoledronic acid induced a significant reduction of tumour growth at various sites (Table 
5.1). However, the majority of studies used a repeated dosing regimen with a total of 6 
doses.  As  shown  in  Figure  5.6,  a  single,  early  dose  of  combination  treatment  was 
sufficient to effectively reduce bone associated tumour growth on day 15 compared to 
mice  treated with PBS or  zol alone  (PBS 0.16mm2 vs. dox  then zol 0.03mm2, p<0.05, 
Fig. 5.6A) and this was, importantly, also maintained on day 23 (PBS 0.97mm2 vs. dox 
then  zol  0.17mm2,  p<0.001,  Fig.  5.6A),  while  single  agents  had  no  effect.  The 
combination  treatment  was  the  only  therapeutic  strategy  used  in  this  study  that 
induced  a  sustained  anti‐tumour  effect.  Doxorubicin  alone  inhibited  total  tumour 
growth  transiently  (day  15,  PBS  0.16mm2  vs.  dox  0.04mm2,  p<0.05,  Fig.  5.6A),  but  a 
single dose of the chemotherapeutic agent was not sufficient to affect later stages of 
tumour  progression  (day  23).  Differential  analysis  of  intra‐  vs.  extraosseous  tumour 




PBS.  It  is  important  to  mention  that  the  tumours  in  the  combination  group  were 
separate tumour foci growing either inside or outside the bone marrow cavity,  in the 
absence of osteolytic  lesions, possibly suggesting that tumour growth was redirected 




Taken  together,  the  data  suggest  that  administration  of  combination  treatment 







Analysis  of  tumour  area  (mm2)  was  performed  on  a  minimum  of  2  non‐serial  sections  per 
















































































































































































































































Figure 5.848Schematic  illustrations of approximate tumour  foci distribution  in mice 
receiving combination treatment 
Schematic overview of tumour location in dox then zol treated mice on A) day 15 and B) day 
23. Grey ellipses  represent  tumour  foci detected outside  the bone marrow cavity and white 
circles  represent  intraosseous  tumour  colonies.  Note  that  the  figure  only  shows  the 






In  vivo  studies  investigating  combination  therapy  have  so  far  focussed  on  the 
treatment effect on human tumour cells (Table 5.1). The indirect anti‐cancer effects of 
the  schedule,  like  treatment‐induced  cellular  alterations  in  the  bone 
microenvironment,  have  been  studied  less  extensively.  In  addition,  it  is  unclear  to 
which  degree  the  combination  treatment  affects  a  tumour‐free  bone 
microenvironment.  The present  study  therefore aimed  to determine  the effects of  a 




Non‐tumour  bearing  animals  administered  with  PBS,  dox  or  zol  alone  or  the 




bearing).  Similar  effects  were  seen  in  tumour  bearing  bones  where  zoledronic  acid 









5.4A). When  investigating  the  later  time  point  (day  23)  osteoclast  numbers  of mice 








Figure  5.949Treatment  effects  on  osteoblasts  and  osteoclasts  in  a  non‐tumour 
bearing and a tumour bearing setting 







The  %  of  trabecular  bone  surface  in  contact  with  osteoclasts  may  be  a  better 




this  discrepancy  may  be  due  to  the  zoledronic  acid‐induced  changes  in  osteoclast 
activity  rather  than  number.  Furthermore,  the  presence  of  large,  multinucleated 
osteoclasts  was  noted  when  analysing  the  zol  only  and  combination  treated  mice. 
Determination  of  osteoclast  area  in  the  total  osteoclast  population  showed  that 
zoledronic acid treated animals had significantly larger osteoclasts (measured in mm2) 
compared to  those of PBS control animals  (PBS 1.9x10‐4mm2 vs. 3.3x10‐4mm2 on day 
15,  p<0.001  and  PBS  2.3x10‐4mm2  vs.  3.7x10‐4mm2  on  day  23,  p<0.01,  Fig.  5.10B). 
Location  dependent  analysis  distinguishing  between  osteoclasts  in  contact  or  not  in 
contact  with  tumour  cells  revealed  that  this  effect  was  independent  of  osteoclast‐
tumour cell contact. Significantly  larger osteoclasts  in contact with tumour cells were 
detected following zol  treatment on day 15  (4.2x10‐4mm2) compared to control mice 
(2.9x10‐4mm2,  p<0.001)  and  on  day  23  (3.8x10‐4mm2  vs.  2.7x10‐4mm2,  p<0.01,  Fig. 
5.10C).  Furthermore,  increased  osteoclast  area  was  found  in  cells  away  from  the 
tumour  in  the  zol  group  versus  PBS  treated  mice  (day  15:  2.9x10‐4mm2  vs.  control 
at 1.6x10‐4mm2  and  on  day  23  with  2.6x10‐4mm2  vs.  control  at  1.6x10‐4mm2,  both 




cells  in  contact with  the  tumour can be attributed  to  the  low sample number  in  the 
combination  group  at  day  23.  Collectively  the  data  indicate  an  initial  effect  of 
zoledronic  acid  on  osteoclast  activity  connected  with  morphological  changes  rather 
than  a decrease  in osteoclast  viability.  Example  images of  TRAP  stained  sections  are 
shown in Figure 5.11.  
Taken  together,  the  data  show  that  the  bone  targeting  bisphosphonate  has  a 
substantial effect on bone cell numbers independent of the presence of malignant cells 








osteoclast  surface  in  contact 
with  trabecular  bone  and 
osteoclast size 
A)  Analysis  of  the  percentage  of 
trabecular bone surface in contact 
with osteoclasts. B) Measurement 
of  osteoclast  size  (expressed  as 
mean  area  in  mm2)  for  the  total 
osteoclast  population  and  for  C) 
osteoclasts  in  contact  with 
tumour  cells  and  D)  osteoclasts 
not  in  contact  with  tumour  cells. 
Data  are  shown  as mean  ±  SEM, 
One way ANOVA and Tuckey post 
test. * is p<0.05, ** is p<0.01, *** 
is  p<0.001  compared  to 














Although  the  detected  changes  in  bone  cell  numbers  following  treatment  give 
information on a cellular level, the data are not sufficient to conclude changes in bone 
remodelling activity. CTX and PINP ELISAs were therefore used to measure active bone 
resorption  and  formation,  respectively,  in  serum  from  animals  in  each  treatment 
group. Surprisingly, mice treated with zol alone had increased CTX levels on both day 
15 and day 23 (Fig. 5.12A), although variability in the zol treated samples was high and 
no  statistical  significance was  detected.  The  CTX  data  can  therefore  not  explain  the 
discrepancy between the increased trabecular bone volume (μCT) and the unchanged 
osteoclast numbers on day 15. When investigating the treatment effects on systemic 
PINP  concentrations,  significantly  reduced  levels  were  detected  in  zol  only  vs.  PBS 
treated mice  on  day  15  (zol  22.8ng/ml  vs.  PBS  42.17ng/ml,  p<0.05,  Fig.  5.12B).  This 
effect was, however, only transient since bone formation was restored on day 23. No 
change  in  osteoblast  activity was  seen  after  administration  of  combination  therapy. 
Doxorubicin  did  not  alter  CTX  or  PINP  levels  at  either  time  point,  indicating  that  a 
single dose does not affect bone  turnover.  The data  for  zol only  treated mice are  in 
agreement with  the histomorphometric quantification of osteoblast numbers on day 
15 showing a drug‐induced reduction in Ob number.  
In  summary  the  data  suggest  that  PINP,  but  not  CTX,  may  be  used  as  a  marker  of 



















was  due  to  treatment‐induced  changes  in  apoptosis  and/or  proliferation,  caspase‐3, 
Ki67  and  BrdU  immunohistochemistry  were  performed.  Quantification  of  active 




analysis of  intra‐ and extraosseous  tumour areas showed that  the  increase  in overall 
tumour  cell  death  in  the  combination  group was  due  to  an  increase  in  apoptosis  in 
tumours  growing  outside  the  bone  marrow  cavity  on  day  15.  The  data  are  in 
agreement with the observed decrease in extraosseous tumour area on this day (Fig. 
5.6B).  In  addition,  doxorubicin  mono‐therapy  increased  the  number  of  apoptotic 
tumour  cells  in  the  intra‐  but  not  the  extraosseous  tumour  foci  (Table  5.3),  again 
mirroring  the  effects  on  tumour  size  on  day  15  (Fig.  5.6B  and  C).  No  change  in  the 


















































The  table  shows  mean  values  and  standard  deviation  (SD)  of  caspase‐3  positive  tumour 





be  detected  at  any  of  the  two  time  points  investigated  (Fig.  5.16  and  Fig.  5.17).  In 
addition, analysis of actively proliferating tumour cells in areas in or outside the bone 






















































day  15  in  form  of  significantly  increased  apoptotic  cell  numbers  as  indicated  by 
detection of active caspase‐3, suggesting that a single dose of combination therapy is 






























Figure  5.1656Quantification  of  treatment‐induced  changes  in  tumour  cell 
proliferation on day 15 
Histological  sections  were  stained  for  BrdU  to  detect  proliferation.  A)  At  least  2  non‐serial 
sections per sample were analysed (10x objective). B) Representative images of BrdU staining 
(10x objective,  scale bar=100μm, T=tumour, B=bone, BM=bone marrow, dotted  line=tumour 





Figure  5.1757Quantification  of  treatment‐induced  changes  in  tumour  cell 
proliferation on day 23 









In  order  to  investigate  if  the  molecular  changes  induced  by  administration  of  early 
treatment could be assessed in more detail, I performed gene expression studies using 
qRT‐PCR on bone tumour samples collected at day 23. Initial experiments using the Tri‐
reagent method  showed  insufficient  RNA  product  for  qRT‐PCR  analysis.  Thus  a  pre‐
amplification  step  was  performed  prior  to  qRT‐PCR  analysis.  The  efficiency  and 
unbiased amplification of a selected gene (ß‐actin) compared to GapdH was tested on 
in  vitro  and  in  vivo  samples  prior  to  use  of  the  study material.  Ottewell  et  al.  have 
previously  published  significant  changes  in  gene  expression  of  genes  involved  in 
tumour cell apoptosis and proliferation post combination treatment with doxorubicin 
followed  by  zoledronic  acid  in models  of  subcutaneous  (Ottewell  et  al.,  2008b)  and 
intraosseous  Ottewell  et  al.,  2009)  tumour  growth.  Genes  analysed  in  this  study 
included  the  cell  cycle  related  genes  cyclinD1,  cyclinD3,  p21  and  p53  as well  as  the 
apoptosis related genes BCL2, BAX, CRADD and FADD. Gene expression analysis in the 
present  study  reflected  the  results  on  apoptosis  and  proliferation  determined  by 
immunohistochemistry,  with  no  significant  changes  detected  at  day  23  (Fig.  5.13  to 
5.17).  Not  all  genes  were  detectable  post  amplification.  BCL2  and  CRADD,  both 
involved  in apoptosis, were shown to be unchanged when compared  to PBS control. 
Gene products known to be involved in proliferation, including P21 and CyclinD1, were 
also  found  to  be  not  significantly  different  following  treatment  when  compared  to 




to  peripheral  tumours.  Only  two  genes,  SFRP1  and OPG were  detectable  even  after 
pre‐amplification  of  the  samples,  emphasising  that  analysis  of  bone  tumours  by  this 
method is challenging due to the limited amount of material available. Pooling of the 
samples  was  not  carried  out  due  to  the  small  n  numbers.  SFRP1  and  OPG  gene 
expression was  significantly  increased  in  zol  only  and  combination  treatment  groups 















Figure  5.1959Species  specific  (human)  quantitative  real  time  PCR  of  bone  related 
genes 
qRT–PCR  analysis  was  performed  on  osseous  tumours  collected  23  days  post  tumour  cell 







treatment  at  an  early  time  point  does  not  have  significant  effects  on  tumour  cells 
death  and  growth  21  days  post  administration.  However,  treatment  did  affect  bone 
related  genes  significantly  emphasising  the  treatment‐induced  effects  on  the  bone 




Several cytokines  including  IL‐1 and  IL‐6 have been proposed to be pro‐tumourigenic 
and  part  of  the  vicious  cycle  driving  metastatic  bone  disease  but  investigation  of 
cytokine changes post combination treatment has not been performed previously.  In 




University  of  Sheffield)  but  was  found  to  be  not  sensitive  enough  for  serum 
measurements.  Thus,  it  was  investigated  whether  the  cytometric  bead  array  was 
suitable. 
On day 15 serum concentrations of mouse  IL‐1α and  IL‐1β were below the detection 
limit  of  10pg/ml  in  all  treatment  groups. However,  significantly  lower  levels  of  IL‐1β 
were detected when comparing doxorubicin  to  zoledronic acid  treated animals  (5.54 
pg/ml vs. 8.26 pg/ml, p<0.05, Fig. 5.20B). Furthermore, analysis of  IL‐6, KC  (IL‐8) and 
MCP‐1  revealed  lower  levels  in  dox  treated mice  compared  to  the  other  treatment 
groups and PBS control animals although no significantly different concentrations were 
reached  (Fig.  5.20C‐E).  Analysis  of  cytokine  levels  on  day  23  revealed  a  different 









In  summary,  the  data  show  that  the  osteoclast  enhancing  cytokines  IL‐6  and  KC  are 

























The present  study  is  the  first  to  show  that  a  single  administration of  sequential  dox 
then  zol  at  an  early  time  point  (day  2  following  tumour  cell  injection)  induced 
sustained  inhibition  of  osseous  tumour  growth  as  well  as  improved  bone  integrity 
compared to single treatments and vehicle control. 
Treatment studies in xenograft models of bone metastases often neglect the impact of 
the  therapeutic  agents  on  the  host.  In  order  to  fully  understand  the  effects  of  the 
drugs  under  investigation,  the  treatment‐induced  changes  on  the  host‐
microenvironment in addition to the tumour xenograft need to be taken into account. 





However,  the  data  cannot  decipher  if  the  effect  on  osteoblast  numbers  is  due  to  a 
direct drug‐induced  inhibition of osteoblast development or  if  it  is  taking place via a 
downstream effect of inhibition of the osteoclast.  
Next, the effects of therapy were analysed in a tumour bearing setting. μCT analysis on 
tumour  bearing  bones  showed  significant  bone  protection  after  zol  alone  or 
combination  treatment  compared  to  PBS  control  on  day  15  and  23,  confirming  the 
anti‐resorptive  activity  of  the  bisphosphonate.  Despite  this,  the  effect  on  bone  cell 
numbers  in  a  tumour‐bearing  environment  was  not  as  prominent  compared  to  the 
non‐tumour bearing bones, possibly underlining the strong influence the tumour cells 
have on the metastatic site. No reduction  in osteoclast number was detected on day 
15  although  μCT  analysis  clearly  showed  a  dramatic  increase  in  bone  volume.  In 
agreement  with  Ottewell’s  study  of  dox  then  zol  treatment  (6  week  regimen)  on 
intratibial MDA‐MB‐436 tumours (Ottewell et al., 2009) was the analysis of the day 23 







long‐term  alendronate  treatment  in  an  osteoporotic  setting  (Jain  and  Weinstein, 
2009).  The  authors  concluded  that  aminobisphosphonates  effectively  inhibited 
osteoclast  activity  and  prolonged  the  lifespan  of  the  cells  ultimately  leading  to  an 
increase  in  cell  size  due  to  continuous  fusion  of  the  osteoclast  with  mononuclear 
precursors.  In  addition,  apoptosis  was  detected  in  about  30%  of  the  “giant”  cells 
(Weinstein  et  al.,  2009).  The  data  therefore  suggest  that  the  bisphosphonate 
decreases  osteoclast  activity  and  changes  cell  morphology  before  reducing  viability. 
CTX analysis did, however, not confirm this although the interpretation of the CTX data 
is  difficult  due  to  high  variation  in  sample  values  in  the  zol  and  combination  group. 
Furthermore, it may be too late to measure a detectable change in CTX levels in mice 
at the relatively late time point (day 15 and 23) post zoledronic acid administration.  
Similar  to  the  results  observed  in  the  tumour‐free  bones,  albeit  less  extensive,  was 
that  the  main  bone  cell  affected  by  zoledronic  acid  was  the  osteoblast  with  major 
reductions in cell number and activity (PINP) detectable on day 15 and 23 compared to 
PBS  control.  Zoledronic  acid  treatment  may  therefore  effectively  counteract  the 
tumour‐induced  changes  in  both  osteoblast  and  osteoclast  numbers  as  seen  in  PBS 
controls and in the longitudinal study described in Chapter 4. Noticeably, the effects on 
the  bone microenvironment  were  due  to  the  presence  of  zoledronic  acid  since  dox 
only treatment had no effect on bone cell numbers and combination treatment did not 
result  in  a  synergistic  effect.  The  role  of  the  osteoblast  in  the  initiation  of  osseous 
breast  cancer  cell  growth  is not well  established and  there  is  currently no published 
data  looking  into  the  effects  of  an  osteoblast‐deficient  bone  microenvironment  on 
breast tumour growth  in bone (this  is currently an area of active research within our 
unit).  Although  the  literature  is  frequently  questioning  the  in  vivo  effect  of 
bisphosphonate treatment on cells other than osteoclasts (Roelofs et al., 2009; Brown 
et  al.,  2011),  the data  shown  in  this  study  suggest  that  a  single,  clinically  achievable 
dose of zoledronic acid may affect osteoblasts or other cell types directly or indirectly. 
Evidence that bisphosphonates can be internalised by osteoblasts in vivo was reported 
by  Idris  et  al.  (2008).  The  group  investigated  the  uptake  of  alendronate  into  bone 
forming cells in mice after a single dose of 0.1mg/kg alendronate was injected 24 hours 
prior  to  sacrifice.  Ex  vivo  analysis  of  isolated  mouse  calvarial  osteoblasts  showed 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detectable  levels  of  unprenylated  Rap1A,  indicating  uptake  of  the  drug  in  this  short 
period of time and subsequent inhibition of the mevalonate pathway.  
Taken together, the data shown here suggest indirect anti‐tumour effects of zoledronic 
acid, most  likely  taking place via  impairment of  the  tumour‐driven alterations  to  the 
bone  microenvironment.  However,  this  effect  is  not  sufficient  to  reduce  tumour 
growth  on  its  own,  since  the  group  receiving  zol  only  did  not  show  a  reduction  in 
tumour size at any time point compared to PBS. The detected reduction in osteoclasts 
and  osteoblasts  post  zoledronic  acid  treatment  could,  however,  render  the 
intraosseous bone microenvironment unfavourable for metastatic tumour cell growth, 
redirecting  it  to  other metastatic  sites  such  as  the  periosteal  surface  as  seen  in  the 
combination  group.  In  fact,  there  is  preclinical  evidence  that  bisphosphonate 
treatment exhibits stronger anti‐tumour effects  in the bone marrow cavity compared 
to  the extraosseous bone‐associated  soft  tissue when given alone or  in  combination 
with  cytotoxic  agents  (Brown  and  Holen,  2009).  Studies  investigating  the  effects  of 
bisphosphonates  as  a  single  agent  have  reported  either  no  effect  on  extraosseous 
tumour  growth  post  pamidronate  or  olpadronate  treatment  (van  der  Pluijm  et  al., 
2005) or increased bone‐associated soft tissue tumours after risedronate (Sasaki et al., 
1995)  or  YH529  (a  third  generation  bisphosphonate)  administration  (Sasaki  et  al., 
1998).  Collectively  the  data  from  these  studies  suggest  that  the  bisphosphonate‐
induced inhibition of bone remodelling may lead to redirection of the tumour growth 
to  the  extraosseous  site.  As  described  by  Ottewell  et  al.  (2008a),  the  use  of 
combination therapy (doxorubicin given 24 hours post zoledronic acid) only increased 
the  anti‐tumour effect on  the  intraosseous MDA‐MB‐231/B02  tumour  areas but had 
no  effect  on  the  extraosseous  parts.  The  present  data  are  in  agreement with  these 
reports  showing  that  a  single  dose  of  combination  treatment  effectively  reduced 
tumour growth inside the bone marrow cavity with only one out of six animals having 
detectable  intraosseous  tumours  on  day  23,  but  treatment  did  not  eliminate 







settled  in  the bone marrow cavity disseminated  to other sites.  In addition,  there are 




cancer  effects  on  the  tumour  showed  that  only  the  combination  group  exhibited 
significant differences  in  tumour cell apoptosis on day 15, mirroring  the  reduction  in 
tumour area detected on the same day. No changes in active tumour cell proliferation 
were detected at either time point. While the results of tumour cell death agree with 
previously  published  preclinical  studies  using  dox  then  zol,  the  proliferation  data  do 
not (Ottewell et al., 2008a; Ottewell et al., 2008b; Ottewell et al., 2010; Ottewell et al., 
2009). In addition, apoptosis and proliferation candidate genes that were significantly 
altered  in  a  study  by  Ottewell  et  al.  (2009)  were  unchanged  after  a  single  dose  of 




effect  of  combination  therapy  detectable  24  hours  post  treatment.  It  is  therefore 
possible  that  the  here  observed  increase  in  tumour  cell  death,  which  was  evident 
many days post completion of  treatment,  is due to an  indirect anti‐tumour effect on 
the microenvironment rather than on the tumour cells directly.  
Although the  increased anti‐tumour effect of combination treatment  inside the bone 




stromal  cells  reduced  interleukin‐6  levels  as  well  as  interleukin‐1  stimulated 
production of MMP‐1 (Derenne et al., 1999). These cytokines, as well as IL‐8 and MCP‐
1,  have  been  shown  to  play  a  role  in  bone  metastasis  and  are  therefore  worth 
investigating  as  a  possible  mediator  of  the  increased  anti‐tumour  activity  of 
combination treatment. The serum concentrations of IL‐1α, IL‐1β, IL‐6, KC (mouse IL‐8) 





unlikely  that  the  increase  in  IL‐6  detected  in  this  study  is  due  to  a  similar  reaction. 
Firstly,  the acute phase response has been characterised as a transient complication, 




likely  that  the  changes  in  IL‐6  and  KC  seen  on  day  23  are  due  to  changes  in  bone 
marrow stromal cells, osteoblasts or other cytokine producing cells. Since the levels in 
the  combination  treatment  group  were  lowest  for  all  investigated  cytokines,  it  is 
possible  that  the combination of a chemotherapeutic and a bisphosphonate  is partly 
responsible for the protection of the bone microenvironment from tumour growth. It 
may be  that, on a more  local  level,  the  reduction  in  inflammatory  cytokines  is more 
prominent  inside  the  bone  marrow  cavity,  possibly  contributing  to  the  increased 
efficacy of the combination treatment at the intraosseous site.  
This is the first study to report that early administration of a single, clinically achievable 
dose  of  combination  treatment  is  effective  in  significantly  reducing  breast  tumour 
growth and improving bone integrity compared to single agents or control. Despite the 











Nitrogen‐containing‐bisphosphonates  (NBPs)  are  known  to  rapidly  bind  to  the  bone 
matrix where the drugs exert their bone‐sparing activity. In addition to the effects on 
bone  resorption,  indirect  and  direct  anti‐tumour  effects  have  been  reported  in  vitro 
and  in  vivo. However,  it  remains unclear which  cell  types apart  from osteoclasts  are 
capable of internalising NBPs in vivo and especially the question whether tumour cells 
take  up  bisphosphonates  is  of  great  interest.  This  chapter  assessed  whether 
subcutaneous  human  breast  tumour  xenografts  and  host  soft  tissues  are  able  to 
internalise the fluorescently labelled NBP, AF647‐RIS.   
5x105 MDA‐G8  (MDA‐MB‐436‐GFP)  cells were  subcutaneously  injected  into  the  right 
flank of 8‐week old female balb/c nude mice and allowed to develop into tumours over 
4‐5  weeks.  400μg/kg  AF647‐RIS,  AF647  or  PBS  was  injected  s.c.  24  hours  prior  to 
sacrifice. Non‐invasive imaging of drug distribution was monitored every 2 minutes for 
20 minutes and then at 2 and 24 hours post  injection using an  IVIS®  imaging system. 
Cells  of  the  peritoneal  cavity,  tumour,  bone marrow,  spleen,  liver,  lung,  kidney  and 
forelimbs were collected for analysis by confocal microscopy and flow cytometry.  
Optical  imaging  demonstrated  the  rapid  uptake  of  AF647‐RIS  into  the  skeleton  2‐20 
minutes  after  injection,  whilst  uptake  of  AF647‐RIS  into  tumour  tissue,  cells  of  the 
peritoneal  cavity  and  bone  surfaces was  visualised  by  confocal microscopy  24  hours 
after  injection.  Flow  cytometric  analysis  showed detectable AF647‐RIS  uptake  in  cell 
suspensions  of  the  subcutaneous  tumour  and  the  peritoneum  but  no  significant 
change was seen in bone marrow samples. A proportion of GFP‐positive tumour cells 
appeared to be AF647‐RIS‐positive suggesting uptake of the drug by tumour cells. 
This  study demonstrates  that  cells within  s.c. breast  tumour xenografts and of other 
non‐osseous tissues are capable of internalising AF647‐RIS 24 hours following a single 







of  bone  remodelling,  indirect  and  direct  anti‐tumour  effects  have  been  reported 
(Neville‐Webbe et al., 2002). In vitro studies have shown that NBPs are internalised by 
the highly endocytic osteoclasts (Coxon et al., 2008) as well as a variety of cells types 




unprenylated  Rap1A  and  the  reversal  through  the  downstream  product  GGOH 
(geranylgeranylgeraniol) is therefore commonly used as a surrogate marker for cellular 
NBP  uptake  in  vitro.  However,  the  determination  of  cell  or  tissue  specific 
bisphosphonate distribution and uptake in vivo is more difficult to investigate, which is 
partly  due  to  the  drugs’  rapid  clearance  from  the  circulation  to  the  skeleton.  For 




pits  of  active  osteoclasts  (Sato  et  al.,  1991),  a  level  high  enough  to  have  potential 
cytotoxic effects. However, the concentration of BPs outside the sealed resorption pit 
remains to be established.  
Studies  investigating  the  biodistribution  of  NBPs  in  vivo  have  focused  on  different 
tissues  and  cell  types.  Osteoclasts  have  been  commonly  investigated  by 
histomorphometry in in vivo studies using bisphosphonates and the effects on the cells 
are often expressed in changes in cell number or osteoclast surface/mm bone surface. 
Direct  measurement  of  BP  uptake  and  inhibition  of  the  mevalonate  pathway  on  a 
cellular level is difficult in vivo and often require isolation of the cell types of interest or 
use of  labelled bisphosphonates. The  injection of 0.4mg/kg [3H]  labelled alendronate 
into  newborn  rats  was  shown  to  cause  intracellular  accumulation  of  the 
bisphosphonate  in  osteoclasts,  but  no  other  cell  type  in  the  bone  marrow,  when 




is  unclear  if  the  maximum  concentration  of  free  bisphosphonate  would  reach 
sufficiently  high  levels  to  affect  any  other  cell  type  than  the  actively  resorbing 
osteoclast. Monkkonen et al. (1990) showed that administration of a single dose of the 
14C‐labelled  bisphosphonates  clodronate,  etidronate  and  amidronate  resulted  in 
accumulation  in  the skeleton and the kidney, with amidronate also detectable  in  the 
liver  and  spleen  for  up  to  6  months  post  injection.  In  a  more  recent  study  it  was 
furthermore  shown  that  bisphosphonates  are  readily  internalised  into  peritoneal 
macrophages  in vivo  (Monkkonen et al., 2007). There is evidence of bisphosphonates 




bone  residing  cancer  cells  may  be  exposed  to  a  potentially  cytotoxic  drug  level, 
compared  to  peripheral  tumours.  A  key  outstanding  question  is  therefore  whether 
drug levels outside bone can reach cytotoxic concentrations.  
Several studies investigating in vivo bisphosphonate distribution have been carried out 
using  radiolabelled  bisphosphonates,  but  currently  there  is  no  commercial  access  to 
most  of  these  compounds.  The  recent  development  of  fluorescently  labelled 
bisphosphonates  has  allowed  further  investigation  of  the  drugs  biodistribution.  The 
fluorescent  tag allows  the application of more sensitive  imaging  techniques  than  the 
commonly  used  detection  of  unprenylated  Rap1A.  A  downside  of  a  fluorescently 
tagged bisphosphonates in comparison to Rap1A detection is that no measure of drug 
activity  is possible. A  few studies using bisphosphonates  labelled with  fluorochromes 
have  been  published  including  IRDye78‐pamidronate  (Zaheer  et  al.,  2001),  FAM‐RIS 
(carboxyfluorescein‐risedronate),  AF647‐RIS  (Alexa  Fluor  647‐risedronate)  (Roelofs  et 
al., 2009), and the commercially available pamidronate analogues Osteosense680 and 
Osteosense750 (Kozloff et al., 2007). The compound used for this study, a risedronate 
analogue  conjugated  to  the  near  infrared  fluorochrome  AF647  (AF647‐RIS,  kindly 
provided by Professor M Rogers, University of Aberdeen, UK) has recently been shown 
to inhibit the accumulation of hydroxyapatite crystals in vitro (Roelofs et al., 2009). In 





To my  knowledge,  no  study  has  been  published  investigating  the  cellular  uptake  of 
NBPs into peripheral breast tumours at a clinically relevant dose. The work described 
in  this  chapter  investigated  the  in  vivo  distribution  of  the  fluorescently  labelled 
bisphosphonate  AF647‐RIS  following  a  single  administration  of  the  compound  in 
subcutaneous  tumour‐bearing mice. Soft  tissues  including  tumour,  liver,  lung,  kidney 
as well  as  bone marrow  cells,  cells  of  the  peritoneal  cavity  and  bone  samples were 
assessed for AF647‐RIS uptake by non‐invasive imaging, confocal microscopy and flow 
cytometry.  




• Can  AF647‐RIS  localisation  on  a  cellular  level  be  assessed  ex‐vivo  by  flow 
cytometry and microscopy? 












balb/c  nude  mice  and  were  allowed  to  develop  into  tumours  for  4‐5  weeks 
(approximately  8mm  in diameter).  400μg/kg AF647‐RIS,  400μg/kg AF647 or  PBS was 
injected  s.c.  24  hours  before  sacrifice  (Fig.  6.1).  AF647‐RIS  was  kindly  provided  by 
Professor  M  Rogers,  University  of  Aberdeen,  UK.  The  compound  has  a  molecular 






MDA‐MB‐436‐GFP  (MDA‐G8) cells were  injected s.c.  into  the  right  flank of nude balb/c mice 
and  left  to  grow  for  approximately  30  days.  Twenty‐four  hours  before  sacrifice,  100μl  PBS, 






and  kidney  were  collected.  Because  cells  of  the  peritoneal  cavity  were  previously 
shown to internalise BPs  in vivo (Monkkonen et al., 2007), these cells were used as a 
positive  control  for  cellular  bisphosphonate  uptake.  Tissues  were  processed  for  the 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different  analysis methods  including microscopy  and  flow  cytometry  as  described  in 
Materials  and Methods  (Chapter 2). Because only  limited amounts of  the drug were 
available  (sufficient  for  5  animals),  not  all  techniques  were  performed  on  all 



























minutes  for  20  minutes  and  then  at  2  and  24  hours  post  injection  using  an  IVIS® 
imaging  system. PBS or AF647  injected  tumour‐bearing control mice were  imaged at 




Soft  tissues  and  cells  of  the  bone  marrow  and  the  peritoneal  cavity  were  used  for 
preparation of single cell suspensions. Samples from vehicle treated mice were used as 











of  AF647‐RIS was  assessed  in  bone,  cells  of  the  peritoneal  cavity  and  subcutaneous 
tumour  tissue.  In  some  experiments,  soft  tissues  and  cytospins  of  cell  suspensions 
were visualised. Excitation of AF647 was performed using a 633nm laser and band pass 
filter BP 650‐710 IR. Second harmonic generation was used to visualise bone (900nm, 











The  uptake  of  amino‐bisphosphonates  into  the  skeleton  is  one  of  the most  studied 
areas of  the drugs biodistribution. The non‐invasive  imaging system  IVIS® allows  real 
time  in  vivo  imaging  of  fluorescent  markers  and  was  therefore  used  to  assess  the 
location of AF647‐RIS at 2‐20 minutes; 2 hours and 24 hours post  injection. Negative 
controls  were  either  vehicle  control  (PBS)  or  the  fluorescent  tag  AF647.  Imaging  of 
mice for a duration of 20 minutes (images were taken every 2 minutes) after injection 
of the compounds showed that AF647‐RIS was visible at site of injection and appeared 













Mice  were  either  injected  subcutaneously  with  PBS,  AF647  (400μg/kg,  red)  or  AF647‐RIS 





















the  tumour,  liver,  lungs,  spleen  and  kidney were  removed  and  placed  into  a  6‐well 





The  skeletal  distribution  of  AF647‐RIS  was  detected  at  similar  time  points  in  two 
further experiments as well as the detection of the drug in the soft tissues as described 
here. Together the data indicate that AF647‐RIS is rapidly localised to the skeleton but 
that  some soft  tissues,  including  the  tumour, also  take up  the drug when  imaged 24 






























































































































































































































Soft  tissues  (subcutaneous  tumour,  kidney,  liver,  lung  and  spleen)  of  PBS  or  AF647‐RIS 
(400μg/kg)  injected  mice  were  placed  into  a  6‐well  plate  and  imaged  using  Living  Image 
software  24  hours  post  injection  of  the  compound.  Regions  of  interest  (ROI)  were  defined 







the  skeleton but  is  also detectable  in  soft  tissues  such as  the  subcutaneous  tumour. 
However,  analysis  of  the  drug  distribution on  a whole  tissue  level  only  gives  limited 
information  on  the  percentage  and  type  of  cells  that may  have  taken  up  the  drug. 
Samples  from  two  experiments  have  therefore  been  analysed  by  flow  cytometry. 
Tumour tissue, bone marrow and cells of the peritoneal cavity were prepared as single 
cell suspensions and run on a MoFlow® flow cytometer to detect AF647 in all samples 
as well  as GFP  in  the  tumour  cell  suspension.  The use  of  the GFP  expressing  cancer 
cells allowed direct quantification of tumour cells (GFP positive) that have taken up the 
bisphosphonate.  Samples  from 2 mice per  treatment group were  split  in half  before 
processing, resulting in a replicate of n=4/tissue for PBS control and AF647‐RIS injected 
mice. Details on gating are described in the respective Figure legends. Analysis of the 
cells  of  the  peritoneal  cavity  showed  a  significant  increase  in  AF647  detection  with 
26.73% AF647 positive cells in the AF647‐RIS mice compared to a background level of 
1.10%  in  the  PBS  control  animals  (Fig.  6.8C,  p<0.0003).  Furthermore,  the  analysis  of 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bone  marrow  samples  revealed  no  significant  difference  in  AF647  fluorescence 









the  gate  R1  (to  exclude  cell  debris  and  because  the  main  cell  population  appeared  to  be 
present within this area). B) Overlay histogram of cells in gate R1 of PBS control and AF647‐RIS 







the  AF647‐RIS  group.  Samples  were  divided  into  two  prior  to  processing  resulting  in  n=4 
samples/group.  Cell  suspensions were  then  analysed  by  flow  cytometry  for  the  presence  of 
AF647. A) Example of a  light scatter dot plot depicting the total cell population. No gate was 









The  solid  tumour  tissue  was  dissociated  enzymatically  as  well  as  manually  prior  to 
acquisition on the flow cytometer. A gate (R1) was therefore set according to  in vitro 
MDA‐G8 cells  to exclude cell debris  (Fig. 6.10A). For  the analysis of  tumour samples, 
the  percentage  of  GFP  positive  tumour  cells  was  determined  showing  similar 
percentages in both groups (p<0.9448, Fig. 6.10B). Next, the same cell population (R1) 
was  analysed  for  AF647  to  assess  the  total  number  of  AF647‐RIS  positive  cells.  PBS 
control  animals  had  a  low  background  of  2.34%  in  the  AF647  channel  while  the 
percentage  increased  significantly  in  the  AF647‐RIS  injected  mice  up  to  9.96%  (Fig. 




bisphosphonate  (AF647‐RIS)  was  internalised  by  subcutaneously  growing  MDA‐G8 












mice  in  the AF647‐RIS group. Samples were divided  into  two prior  to processing  resulting  in 
n=4 samples/group. Cell suspensions were then analysed by flow cytometry for the presence 
of  AF647  and  GFP.  A)  Example  of  light  scatter  dot  plots  depicting  the  total  cell  population 
derived from subcutaneous tumours. Gate R1 was set according to  in vitro MDA‐G8 samples. 
B) Example histograms of GFP positive cells in gate R1 for a PBS and AF647‐RIS sample. Mean 




















Confocal microscopy was used to  further confirm the  internalisation of  the drug  into 
the different soft tissues and the skeleton. Firstly the front legs of PBS and AF647‐RIS 
injected mice were imaged using a 633nm laser to visualise AF647 and a multiphoton 
laser  set  at  900nm  to  visualise  bone  collagen  by  second  harmonic  generation.  As 
expected,  AF647‐RIS  was  clearly  visible  along  bone  surfaces  in  the  bisphosphonate 
injected mice but not in the vehicle treated animals (Fig. 6.11). Next, cytospins of the 
cells  collected  from  the  peritoneal  cavity  and  bone  marrow  cell  suspensions  were 



















(Chameleon)  at  900nm  to  visualise  bone  (white,  second  harming  generation=sgh)  and  third 









































(Fig.  6.14)  while  the  tumours  from  PBS  treated  mice  were  negative  for  the  AF647 
signal. Because  imaging of a  tumour piece did not allow discrimination between GFP 
positive tumour cells and other cells within the tumour (due to high background from 






F4/80  staining  was  performed  using  a  pacific  blue‐labelled  antibody.  Staining  was, 
however,  not  specific  enough  to  draw  any  conclusions  and was  therefore  not  taken 
forward. 
Together  the  data  indicate  that  AF647‐RIS  is  internalised  by  cells  residing  in  the 







Tumours  that were  excised  from  AF647‐RIS  or  PBS  treated mice were  snap  frozen  in  liquid 
nitrogen,  embedded  in OCT  and  then  visualised  by microscopy.  A  633nm  laser was  used  to 
detect  AF647  (red)  and  transmitted  light  to  visualise  the  tumour.  Images  depict  tile  scans 


















Due  to  the  high  affinity  for  bone  and  rapid  clearance  the  main  target  of 
bisphosphonates  are  bone  cells.  However,  many  groups  have  reported  anti‐tumour 
effects  of  the  agents, with  some  showing  effects  on  extraskeletal  tumours,  but  it  is 
unclear whether  these are of direct or  indirect nature.  I  have  therefore  investigated 
the  skeletal  and  soft  tissue  distribution  of  the  AF647  tagged  risedronate  analogue 








minutes  onwards.  The  bisphosphonate  appeared  to  be  visible  in  skeletal  structures 
rather than soft tissues suggesting that the signal of the drug in the circulation is too 
low  to  be  detected with  the  used  settings  and only  accumulation  at  skeletal  sites  is 
visible. This may explain why the AF647 tag was only visible at site of  injection when 
given on its own, supporting the conclusion that any signal in AF647‐RIS treated mice is 
not by  free  label.  In agreement with other published studies  in  tumour‐free animals, 
AF647‐RIS  was  detected  in  the  liver,  kidney  and  lung  but  not  in  the  spleen  after 
sacrifice of the animals. Most importantly, the drug was also detected in subcutaneous 
tumours  24  hours  post  injection.  Roelfos  et  al.  (2009)  investigated  the  uptake  of 
AF647‐RIS into tibia and femur as well as the soft tissues liver, kidney and spleen of 3‐





the data presented here showing detection of AF647‐RIS  in  liver kidney and  lung but 
not  the  spleen  and  that  of  Roelofs  et  al.  could  be  due  to  limitations  of  the  imaging 




(1992)  that  a high dose of  alendronate  (30mg/kg)  is  present  in  the  liver,  spleen and 
kidney of young rats  for a  longer period of  time compared to the 1mg/kg dose, with 
approximately  25%  of  drug  being  present  in  the  non‐calcified  tissues  48  hours  post 
30mg/kg alendronate administration.  
I  further  analysed  cells  isolated  from  peritoneal  cavity  and  bone  marrow  by  flow 
cytometry, which  showed a  significantly higher percentage of AF647 positive  cells  in 
samples  taken  from  the  peritoneal  cavity,  but  not  in  bone  marrow  cells,  when 
compared  to  control.  Due  to  the  very  limited  amount  of  drug  available  in  this  pilot 
study  I  was  not  able  to  further  identify  the  cells  detected  to  be  AF647  positive, 
although  other  groups  have  identified  bisphosphonate  internalising  cells 
predominantly  to be of  the macrophage  lineage. Roelofs et  al.  (2009) have assessed 
the uptake of bisphosphonates into osteoclasts  in vivo after injection of a single dose 
of  FAM‐RIS  and AF647‐RIS  (day  1  post  injection)  by  imaging  either  bone  sections  or 
isolated  osteoclasts  by microscopy.  The  results  demonstrated  intracellular  uptake  of 
the  drugs  into  osteoclasts  in  vivo  and  the  activity  of  FAM‐RIS  was  confirmed  by  an 
increase  in  unprenylated  Rap1A.  Investigation  of  BP  uptake  into  rabbit  and  human 
bone marrow  cells  in  vitro  showed  that  AF647‐RIS  was  readily  internalised  after  24 
hours.  Further  immunofluorescence  staining  showed  detection  of  the  drug 
predominantly  in CD14 positive monocytes. The  intracellular uptake and  inhibition of 





in  vivo  accumulation  of  NBP‐induced  IPP  and  ApppI  could  confirm  the  presence  of 








cancer  cells  per  se  since  it  is  possible  that  the  drug  is  bound  to  the  tumour  cell 
membrane  or  that  other  AF647  positive  cell  types  are  attached  to  the  cancer  cells. 
When assessing whole tumour tissue by microscopy only  localised staining for AF647 
was detectable, which  is  in agreement with a study carried out by Shay et al.  (2011) 
showing that only parts of a peripheral tumour were positive for AF647. In contrast to 
the  present  data  showing  clear  internalisation  of  the  drug  into GFP  positive  tumour 
cells, Shay et al. did not find any GFP positive tumour cells that had internalised AF647‐
RIS  but  could  show  that  a  population  of  myeloid  cells  (CD11b+F4/80+ 
monocytes/macrophages  and  Gr1+CD11b+  myeloid‐suppressor  cells)  were  AF647 
positive.  The  discrepancy  between  the  studies  could  be  due  to  the  use  of  different 
mouse models. Shay et al. used the syngeneic 4T1 mouse model, which was found to 





acid  in male  rat  soft  tissues  and  the  skeleton.  It  was  shown  that  there was  a  slow, 
albeit  low release of 14C‐labelled zoledronic acid from bone with  levels  in soft tissues 
and plasma being below 0.4nmol/g, 96 hours after the last dose was given (0.15mg/kg, 
16x on consecutive days). The authors concluded that the detection of zoledronic acid 
(up to 240 days after  the  last  injection)  in plasma and non‐calcified tissues reflects a 
slow release of the drug from the skeleton, rather than systemic clearance. In addition, 
Roelofs  and  colleagues  have  suggested  that  the  endocytic  activity  of  cells  in  vivo  is 
more relevant to the internalisation of bisphosphonates than the location within bone 
(Roelofs et al., 2009). Whether these systemic low concentrations of bisphosphonates 
released  from  the  bone  are  sufficient  to  exert  biological  effects  remains  to  be 
established.  But  as  the  anti‐resorptive  effect  wears  off  after  3‐4 weeks  (even when 




(2009)  investigated whether  zoledronic  acid  is  internalised  into  intratibial MDA‐MB‐
231 
 
436‐GFP  tumours  in  vivo.  Treatment  commenced  one  week  after  tumour  cell 
implantation  for a  total of  six weeks with PBS, doxorubicin  (2mg/kg),  zoledronic acid 
(100μg/kg)  or  doxorubicin  followed  24  hours  later  by  zoledronic  acid  (once  weekly 
administration) and were sacrificed 24 hours after the last treatment. It was shown by 
western blot analysis  that unprenylated Rap1A was only detectable  in  tumours  from 
animals  treated  with  the  chemotherapeutic  agent  (doxorubicin)  24  hours  prior  to 
zoledronic acid, but not in animals treated with zoledronic acid alone. The data suggest 
that  zoledronic  acid  concentrations  are  not  sufficient  to  significantly  affect  the 
mevalonate pathway  in peripheral tumour cells when administered alone or that the 
method  was  not  sensitive  enough  to  detect  low  levels  of  unprenylated  Rap1A.  In 
addition,  the  frequent  dosing  regimen  results  in  a  relatively  high‐accumulated 
zoledronic  acid  concentration,  not  mimicking  the  clinical  situation  of  a  single  dose 
every 3‐4 weeks. 
Taken  together  the  data  presented  in  this  chapter  show  that  the  bisphosphonate 
AF647‐RIS  is  internalised  by  a  small  proportion  of  GFP  positive  tumour  cells  at  a 
subcutaneous  site.  The  findings  suggest  that  the bisphosphonate does  reach  tumour 









Advanced  breast  cancer  is  associated  with  a  high  mortality  rate  and  approximately 
70%  of  patients  will  develop  secondary  disease  with  a  high  prevalence  of  bone 
associated  tumour  growth.  Currently,  the  metastatic  tumour  spread  cannot  be 
effectively impeded due to lack of effective treatment regimens. Predictive markers for 
metastatic disease are not available and patients with bone metastases will therefore 
often  present  with  symptomatic  disease  caused  by  already  established  osseous 
lesions.  Previous  preclinical work  has  contributed  greatly  to  the  detection  of  factors 
involved  in  the  vicious  cycle;  and most  studies have mimicked  the  clinical  setting by 
investigating end stage disease with overt bone destruction. It has become clear that 
investigation  of  earlier  stages,  prior  to  bone  destruction,  is  required  for  the 








Work  presented  in  this  thesis  has  utilised  a  number  of  novel  in  vivo  studies  and 
analysis  methodologies  to  help  determine  bone  cell‐tumour  cell  interactions  during 
disease progression and the effects of early combination treatment.  Initially, analysis 
methodologies to investigate the tumour as well as the bone microenvironment, as for 
example  differential  analyses  of  histological  sections  or  the  use  of  multiphoton 
microscopy  for  detection  of  tumour  cells  in  bone,  were  assessed.  While  the  latter 
method has the benefit of high resolution and detection of even single tumour cells in 
the  bone  compartment,  it  is  not  feasible  to  investigate  the  surrounding  bone  cells. 
Histology  and  bone  histomorphometry  therefore  remain  invaluable  tools  for 
identification of the complex cellular interactions within bone and other tissues. New 
imaging  techniques  are  continuously  emerging  and  will,  in  combination  with  other 
methods, help to elucidate the early stages of tumour cell colonisation and growth in 




activated  fluorescent  probes  such  as  Prosense®680  (Weissleder  et  al.,  1999)  or 
photoswitchable  fluorescent  proteins  (PsmOrange)  (Subach  et  al.,  2011)  will 
furthermore add important information to standard methods. Especially the increased 
ability  to  visualise  small  numbers  of  tumour  cells  at  great  tissue  depths  will  be 
beneficial. A downside of relying on histology alone is that only snapshots of the in vivo 
situation are available and extrapolation of  three‐dimensional  interactions  from two‐
dimensional images is required. The identification of single tumour cells on histological 
sections was proven to be difficult (Chapter 3). Detection of disseminated tumour cells 
in  the  bone  marrow  would  greatly  benefit  from  identification  through  a  specific 
marker; however the expression levels of human tumour cell‐associated antigens like 
GFP, beta‐galactosidase, luciferase, cytokeratin and EpCAM may vary greatly in vivo. A 
recent  study  reported  that  antibodies  to  the  human  HLA  antigen,  which  is  highly 
expressed by human cancer cell lines, allow detection of disseminated tumour cells in 
the murine bone marrow  (Shiozawa et al.,  2011).  The application of  this antibody  in 
breast cancer metastases to bone is currently under investigation in our unit and could 
add significant value to future studies. 
Chapter  4  describes  the  first  longitudinal  in  vivo  study  reporting  the  detailed  spatial 
and temporal relationship between bone and breast cancer cells and revealed that the 
dynamic  between  these  cell  types  is  more  complex  than  previously  described.  The 
study provided strong evidence that differential analysis of osteoblasts and osteoclasts 
is required to decipher the tumour‐induced changes in detail. The spatial proximity of 
bone  cells  to  the  tumour  is  currently  not  taken  into  account  in  many  studies 
investigating  the  tumour bearing bone microenvironment. Osteoblast  numbers were 
drastically altered  in the presence of  the tumour, strongly suggesting a major role of 
this  cell  type  in  metastatic  breast  tumour  development.  This  data  supports  current 
reports  identifying  the  osteoblast  as  a  crucial  factor  of  tumour  cell  homing  and 
progression  in bone. For example,  in vitro  analyses using a 3‐dimensional osteogenic 
tissue model grown from the murine MC3T3‐E1 pre‐osteoblast cell line showed direct 
interactions  between  osteoblasts  and  MDA‐MB‐231  cells  (Dhurjati  et  al.,  2008). 
Interestingly, immature culture conditions were found to be more beneficial to cancer 
cell colonisation while mature osteoblast cultures were required for tumour formation. 
An  in  vivo  study  furthermore  reported  that  intratibial  co‐injection  of  the  pre‐
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osteoblastic  MC3T3‐E1  cell  line  and  MDA‐MB‐231  cells  induced  significantly  higher 
tumour  burden  compared  to  athymic  mice  injected  with  the  cancer  cells  alone 
(Bodenstine et al., 2011).  In addition, the recently published study by Shiozawa et al. 
(2011), showed that prostate cancer cells home specifically to the HSC niche, in which 
the  osteoblast  is  an  important  component,  and  that  niche  expansion  (PTH 
administration) or  reduction  (SDF‐1  inhibitors  like AMD3100) enhanced or decreased 
tumour  cell  numbers  in  the  bone marrow,  respectively. While most  recent  research 
has  focused  on  the  osteoblast‐tumour  cell  interactions  at  the  homing  stage  of 
metastatic  disease,  the  intermediate  stages  of  tumour  growth  like  the  escape  from 
quiescence  and  the  switch  from  microenvironment‐dependent  to  ‐independent 
tumour  growth  are  equally  important  areas  of  interest.  The  data  from  this  thesis 
furthermore add to the understanding of these processes by showing that osteoblasts, 
in  addition  to  osteoclasts,  may  also  be  relevant  during  the  transition  of  micro‐  to 
macro‐metastatic growth. This is in agreement with a study investigating bone biopsies 
of  breast  cancer  patients  (Vukmirovic‐Popovic  et  al.,  2002).  Comprehensive  analysis 
showed  increased  osteoclast  and  osteoblast  numbers  on  biopsies  with  small  to 
medium cancer  colonies  (bone marrow  cavity  covered  to  7.5% or  24.4% by  tumour) 




model  and  human  biopsies  and  that  total  tumour  burden  in  the  biopsy  cannot  be 
assessed  due  to  the  relatively  small  area  available  for  investigation.  In  addition, 
osteoclast and osteoblast distribution may vary depending on location within the bone 
(Chapter  3).  Published  information  on  early  stage  breast  cancer  and  the  related 
changes to the bone microenvironment is largely limited to the report of Phadke et al. 
(2006),  who  reported  tumour  progression‐dependent  reduction  of  osteoclast  and 
osteoblast  numbers  four  weeks  after  tumour  cell  implantation.  The  decrease  in 
osteoblast  number  was  shown  to  be  associated  with  an  increase  in  osteoblast 
apoptosis. In the present study osteoblast numbers were also reduced at later stages 





The present work  is  furthermore  the  first  to comprehensively assess  in vivo whether 
the changes in bone cell numbers were of a local or systemic nature. The lack of bone 
loss  in  the  opposite  non‐tumour  bearing  leg  strongly  suggested  the  involvement  of 
local  interactions  (within  the  affected  bone  compartment), which was  supported  by 
the  unaffected  serum marker  concentrations  in  tumour  bearing  compared  to  naive 
animals.  In  addition,  the  analysis  of  tumour  gene  expression  indicated  that  bone 
related  genes,  such  as  the  osteoblast  inhibitors  DKK1  and  SFRP‐1  as  well  as  the 
osteoclast  stimulating  RANKL  and  GMCSF,  were  upregulated  in  tumours  growing  in 
bone compared to the same cells grown  in vitro or as subcutaneous tumours. Thus a 
direct  effect  on  the  surrounding  cells  is  likely  but  requires  further  investigation.  The 
present  study  therefore  strongly  suggests  that  tumour  cells  influence  bone  cells 
through direct cell‐cell contact as well as via secretion of factors to affect more distal 
cells.  Tumour‐induced  angiogenesis,  which  is  strongly  associated  with  both  the 
osteoclast  and  the  osteoblast  (Parfitt,  2000)  could  also  be  investigated  in  future 
studies.  Little  is  known  about  tumour  angiogenesis  in  bone  due  to  lack  of  suitable 
analysis methodologies, however the association of blood vessels with the HSC niche 
emphasises  the  need  to  explore  the  dynamics  between  the  endothelium,  bone  and 
tumour  cells  in  more  detail  (Roche  et  al.,  2012).  The  possible  application  of  new 
techniques like the three‐dimensional perfusion model (allowing 3‐D reconstruction of 
the vasculature, visualisation and quantification of vessels) in metastatic bone disease 
may give  further  insight  into  the  spatial  and  temporal  relationship between  tumour, 
bone and blood vessels. 
The data  from  the  longitudinal  study  indicate  that early  treatment  regimens may be 
more  beneficial  than  those  currently  in  clinical  practice.  This  has  been  shown 
previously  in  preclinical  treatment  studies  (Brown  and  Holen,  2009),  although  the 
association with the detected changes in bone cells is novel to the present study. The 
rise  in  total  osteoblast  numbers  that  is  taking  place  before  the  onset  of  bone 
degradation and its associated increase in total osteoclast numbers (Chapter 4) may be 
the  turning  point  in  the  highly  complex  initiation  process  of  microenvironment 





later  by  zoledronic  acid  has  previously  been  shown  to  be  effective  in  reduction  of 
subcutaneous (Ottewell et al., 2008b; Ottewell et al., 2010), advanced bone (Ottewell 
et  al.,  2008a;  Ottewell  et  al.,  2009)  and  spontaneous  mammary  fat  pad  tumours 
(Ottewell  et  al.,  2011).  The  synergistic  anti‐tumour effect  is  suggested  to be exerted 
through  alterations  in  apoptotic  and  cell  cycle  gene  pathways  as  well  as  through 
increased bisphosphonate uptake after doxorubicin treatment (Ottewell et al., 2009). 
However,  the  effects  of  the  treatment  on  the  bone  microenvironment  were  not 
investigated in detail.  




was  inhibited  but  not  eliminated.  The  site  dependent  reduction  of  MDA‐MB‐231 
growth indicates an indirect anti‐cancer effect through the bone microenvironment. In 
fact,  a  single  dose  of  zoledronic  acid,  alone  or  in  combination  with  dox,  caused  a 
dramatic  change  in  osteoblast  numbers  on  day  15.  While  the  effects  of 
bisphosphonates  on  osteoclasts  are  well  established,  the  findings  of  reduced 
osteoblast numbers are the first reported after administration of a single dose in vivo. 
Currently  few  data  are  published  investigating  the  effects  of  bisphosphonates  on 
osteoblasts.  In  a  recent  study,  primary  rat  osteoblast  numbers  growing  on 
bisphosphonate‐coated bone slices were significantly reduced compared to untreated 
control,  suggesting  active  cellular  internalisation  (Cornish  et  al.,  2011).  Furthermore, 
an in vivo study undertaken by Pozzi et al. (2009) investigated the effects of zol (weekly 
for  three weeks)  on  C57BL6 mice.  The  group  detected  a  decrease  in  osteoblast  and 
osteoclast numbers by histomorphometric analyses, which were reflected in decreased 
serum  measurements  of  osteocalcin  (bone  formation  marker)  and  TRAP5b  (bone 
resorption  marker).  The  inhibitory  effect  of  zol  (10µM,  twice/week)  on  osteoblast 
viability and activity was confirmed in vitro showing that inhibition was only detectable 
after 7 days of culture. The delayed effect of zol on osteoblasts  in vivo  in the present 
study  is  in  agreement  with  these  data  suggesting  that  the  low  endocytic  activity  of 




increased  activity  at  low  doses,  depending  on  the  exposed  concentration  in  vitro 
(Corrado et al., 2010). First  in vivo evidence that zoledronic acid‐induced reduction of 




research  in  our  unit  is  investigating  the  effects  of  osteoblast  deficiency  on  osseous 
breast  tumour  growth  in  vivo.  A  single  dose  of  zoledronic  acid  with  or  without 
doxorubicin  was  also  shown  to  reduce  osteoclast  activity  and  increase  cell  size  but 
numbers  were  unchanged  until  twenty‐one  days  after  treatment.  The  data  are  in 
agreement with  a  recent  case  study  report  by  Jain  and Weinstein  (2009)  suggesting 
that primarily osteoclast activity is inhibited by BP treatment.  
In order to decipher the microenvironment‐dependent and  independent anti‐tumour 
mechanisms  in more detail,  a  selection of  genes  involved  in  apoptosis  and  cell  cycle 
regulation were analysed by quantitative real time PCR. The genes had previously been 
shown  to be  altered  in  advanced bone  tumours  after  combination  therapy with dox 
then zol  (Ottewell et al., 2009). Analysis of  the  small  tumour colonies  in  the present 
study was  problematic  even  after  pre‐amplification.  The  successfully  assessed  genes 
confirmed  the  immunohistochemistry  data  showing  lack  of  direct  effects  on  the 
tumour at the later time point (day 23). This suggests  immediate cytotoxic activity of 
the combination therapy since I investigated tumour tissue 21 days after completion of 
treatment  compared  to  24  hours  in  the  study  by  Ottewell  et  al.  (2009).  Also,  gene 
signatures  and  response  to  treatment  may  differ  between  the  two  cell  lines  used 
(MDA‐MB‐231 vs. MDA‐MB‐436). 
The present study is the first to show that a single dose of early combination treatment 
induced  almost  complete  elimination  of  intraosseous  tumour  growth  (in  6  out  of  7 
mice)  and  that  single  agents  had  no  effect  on  overall  tumour  burden.  Despite  this, 
small,  separate  extraosseous  tumours were  detected  along  the  periosteum of  these 
mice. The findings indicate that alterations to the bone microenvironment may cause a 
diversion  of  cells  to  other  sites.  This  could  also  occur  at  extra‐skeletal  organs  and 
although  at  the  time  not  possible,  could  now  easily  be  investigated  with  the  new 





reporting  similar  bone  restricted  anti‐tumour  effects  of  bisphosphonate  treatment 
alone (Sasaki et al., 1995, van der Pluijm et al., 2005) or in combination with cytotoxic 
drugs (van Beek et al., 2009). 
The  predictive  significance  of  preclinical  treatment  studies  is  not  always  clear  since 
drugs  often  fail  or  cause  differential  effects  in  clinical  studies  compared  to  those 
demonstrated using in vivo models. An example is the recent AZURE trial (Coleman et 
al.,  2011),  which  was  partly  based  on  the  promising  preclinical  data  from  the 
sequence‐ and schedule‐dependent combination studies with doxorubicin followed by 
zoledronic  acid  (Neville‐Webbe  et  al.,  2005;  Ottewell  et  al.,  2008a;  Ottewell  et  al., 
2008b; Ottewell et al., 2010).  Importantly, AZURE as well as  the ABCSG‐12  (Gnant et 
al.,  2009)  and  the  NSABP‐34  (Paterson  et  al.,  2011)  trial  reported  the  relevance  of 
reproductive  hormone  levels  for  the  observed  anti‐tumour  effects,  with  post‐
menopausal women benefiting from the addition of zoledronic acid.  Importantly, the 
hormone receptor status was  reported  to be of no significance  for disease outcome. 
The  AZURE  trial  furthermore  indicated  that  inhibition  of  the  vicious  cycle  may  also 
carry  the  risk  of  relocating  the  metastatic  processes  to  areas  outside  bone,  an 
observation  that  was  also  made  in  the  present  preclinical  study.  Early  treatment 
(adjuvant)  of  breast  cancer  patients  should  therefore  be  assessed  with  caution  and 
further  preclinical  research  is  required  to  investigate  the  treatment  effects  on  bone 
remodelling and tumour growth in more detail. While these important data were not 
yet  available  during  my  PhD,  the  interactions  between  reproductive  hormones  and 
treatment of osseous cancer is currently investigated in our unit.  
Although  bisphosphonates  are  frequently  used  in  preclinical  and  clinical  studies  the 
biodistribution, half‐life and tissue concentrations of BPs are difficult to measure and 
the effects of the drugs on non‐osseous tissues in vivo are not well understood. This is 
mainly due  to difficulties  in detection of  the drug with  the main  two methods being 
detection  of  unprenylated  Rap1A  by  western  blot  and  the  use  of  radiolabelled 
compounds.  The  recent development of  fluorescently  tagged  risedronate  (Roelofs et 
al.,  2009)  has,  however,  increased  the  sensitivity  of  detection  greatly.  A  pilot  study 
performed  in  this  thesis  is  the  first  to  show  that  peripheral  MDA‐MB‐436  tumours 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actively  internalise  fluorescently  labelled  risedronate  (AF647‐RIS).  The  near‐infrared 
tag allows  imaging with a good signal  to noise  ratio and  thus analyses by  IVIS®,  flow 
cytometry and microscopy was successfully performed. Benzaid et al. (2011) were the 
first  to  report  IPP  and  ApppI  detection  in  T47D  subcutaneous  tumours  twenty‐four 
hours  after  treatment  with  IL‐2  +  zoledronic  acid  +  PBMC  (peripheral  blood 
mononuclear  cells).  The  group  concluded  that  the  IPP  and  ApppI  accumulation  was 
due  to  inhibition  of  the  mevalonate  pathway  in  T47D  cells  rather  than  tumour‐
associated  cells  like macrophages,  since  phosphoantigens were  undetectable  in  B02 




acid  treatment.  Animals  were  treated  either  once  or  thrice  with  zoledronic  acid 
(8μg/mouse)  and were  culled  24,  48  or  72  hours  after  the  last  injection. While  the 
work  arising  from  my  thesis  strongly  complements  these  two  studies  in  favour  of 
active bisphosphonate uptake into peripheral tumour cells  in vivo, a study by Shay et 
al. (2011) did not. In this study, the 4T1 murine breast cancer model was used to assess 
AF647‐RIS  distribution  in  vivo.  AF647‐RIS  uptake  was  detected  in  a  proportion  of 
tumour‐associated macrophages 24 hours after  injection of  the drug but not  in GFP‐
tagged cancer cells.  In conclusion,  the  few studies  investigating the  internalisation of 
bisphosphonates  into  peripheral  tumours  in  vivo  have  reported  controversial  data. 
However,  the use of  different  tumour models  suggests  great  variation  in  the  in  vivo 
distribution  of  the  compounds.  Whether  these  data  are  applicable  to  the  clinical 




for  bone‐associated  diseases  and  the  interactions  between  the  bone 
microenvironment and the tumour cells  in bone have been the research focus of the 
last  year.  The  present  thesis  has  contributed  to  this  field  of  knowledge  in  several 
aspects as has been described above. The importance of the microenvironment in the 
development  of  new  treatment  targets  has  recently  been  exemplified  by  the 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development  of  denosumab,  a  human  anti‐RANKL  antibody  with  superior  anti‐
resorptive activity (delayed first on study SRE in breast cancer) compared to zoledronic 
acid  (Stopeck  et  al.,  2010).  The  underlying  mechanisms  of  treatment‐induced 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